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ABSTRACT 
Thyroglobulin (Tg) is a major autoantigen in autoimmune thyroiditis, a T-een-
mediated, organ-specific autoimmune disorder. Immunization with Tg or some 
Tg peptides can activate thyroiditogenic T cells and cause experimental 
autoimmune thyroiditis (EAT) in mice. Most of the identified pathogenic Tg 
peptides have been characterized as cryptic epitopes due to their insufficient 
presentation following processing of Tg in vivo and in vitro. The main goal of 
this study was to examine whether modification of Tg processing could enhance 
generation of cryptic T-cell epitopes. Two physiologically relevant parameters 
that could modify Tg processing were tested: the first was the formation of 
immune complexes (IC) of Tg with Tg-specific Abs; and the other was the 
increased iodination of Tg. 
It is shown that generation of the non-dominant pathogenic Tg epitope (2549-
2560), containing thyroxine (T4) at position 2553 (T4(2553)), is augmented in APC 
that internalize ICs of Tg with selected Tg-specific IgG mAbs. The enhancing 
effects of certain mAbs on the generation of T4(2553) is FeR-dependent, but FeR-
mediated internalization of Tg is not sufficient for generation of T4(2553). The 
data rather suggest a mAb effect on Tg processing within APC. Interestingly, one 
of Tg-specific mAbs, 55H8, suppressed the generation of T4(2553) following 
processing Tg-mAb ICs. The suppressive role of 55H8 on activation of T4(2553)-
specific T -cells was further investigated. It was found that 55H8 can bind to the 
I 
T4(2553) peptide within Ak MHC and prevent recognition of the peptide by 
T4(2553)-specific T-cells. These two studies indicate that Tg-specific Abs may 
regulate the course of AT by enhancing or suppressing activation of Tg-reactive 
pathogenic T-cells. It was shown that highly iodinated thyroglobulin (1-Tg) 
exhibits higher immunopathogenicity than normal Tg in mice. Processing of 1-Tg 
in LNC in vivo, or in macrophages and dendritic cells, but not B cells, in vitro, 
promoted presentation of the cryptic pathogenic Tg peptide (2495-2511) to T 
cells. This study demonstrates that generation of non-iodinated, cryptic but 
pathogenic determinants during processing of 1-Tg, may contribute to the 
development of AT. In conclusion, the studies describe general mechanisms as to 
how autoantibodies may regulate process of T-cell-mediated autoimmune 
diseases and how environmental factors such as excess iodine may trigger 
autoimmune responses. 
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CHAPTERl 
INTRODUCTION 
1.1. Autoimmune thyroiditis 
1.1.1. Autoimmune Hashimoto's thyroiditis 
The human autoimmune thyroid diseases (AITD) include Hashimoto's 
thyroiditis (HT) and Graves' disease (GD). HT, also named autoimmune 
thyroiditis (AT) or lymphocytic thyroiditis (LT), is generally present in either a 
goitrous form (classic HT) or a non-goitrous form (atrophic thyroiditis) (Davies, 
1994). Thyroid destruction occurs progressively over months to years during the 
course of HT. Although the levels of the thyroidal hormones, triiodothyronine 
(T3) and thyroxine (T4), may be within the normal range for some HT patients, 
the serum thyroid stimulating hormone (TSH) level can be elevated, indicating a 
sub-clinical thyroid failure (Vlase and Davies, 1999). GD can be divided into two 
types. One is the classical hyperthyroid GD, which is characterized by a 
decreased level of serum TSH and some degree of thyrotoxicosis - a clinical 
syndrome of hyperthyroidism resulting from increased serum T3 and T4 
concentrations. Another is the euthyroidal GD with a normal TSH level and no 
thyrotoxicosis (Davies, 1994). The following paragraphs will discuss the 
immunopathology and the immunogenetics of HT. 
The immunopathology of HT is highlighted with lymphocytic infiltration of the 
thyroid gland and production of autoantibodies (auto-Abs) against thyroidal 
autoantigens (auto-Ags). Lymphocytic infiltration ranges from mild focal to 
extensive. Focal thyroidal lymphocytic infiltration is found very frequently at 
autopsy, occurring in 40% of women and 20% of men (Okayasu et al., 1993). 
Diffuse lymphocytic infiltration occurs commonly in HT patients and causes 
various degrees of goiter. The infiltrating cells include plasma cells, macrophages 
and T-cells (Bigazzi and Rose, 1985). Formation of germinal centers and fibrosis 
can be seen in some thyroid glands from HT patients. Both CD4 and CDS 
positive T -cells are found among the infiltrating cells (Bigazzi and Rose, 1985). 
Two major thyroidal auto-Ags are thyroglobulin (Tg) and thyroid peroxidase 
(TPO). Auto-Abs against Tg and TPO occur in most HT patients (Weetman and 
McGregor, 1984). Serum anti-Tg and anti-TPO Abs have long been recognized as 
important indicators for HT diagnosis, but the presence of anti-Tg and anti-TPO 
auto-Abs does not necessarily indicate occurrence of HT. A study estimated that 
about 5-10% of healthy people have auto-Abs against thyroidal Ags (Bigazzi, 
1993). The prevalence of anti-Tg and anti-TPO auto-Abs in normal populations 
seems to vary with age. A study conducted in the UK showed that 10.6% of 
healthy women aged 18-24 w ere positive for anti-Tg auto-Abs, but the frequency 
increased to 30.3% among women aged 55-64. Similarly, the frequency of anti-
TPO auto-Abs increased with age increases, and the respective frequency for the 
two groups of women was 14.9% versus 24.2% (Prentice et al., 1990). HT patients 
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without anti-Tg or anti-TPO auto-Abs are rare. Depending on the methods used 
for detection of the serum auto-Abs, the frequency of auto-Ab positive HT 
patients can vary from 60% to 100% (Bigazzi, 1993). Using a sensitive 
radioimmunoassay, circulating auto-Abs against Tg and TPO were detected in 
86-100% of patients with HT (Bigazzi and Rose, 1985). It is not clear whether or 
how these auto-Abs mediate the pathogenesis of HT, but such a high frequency 
of auto-Abs in HT patients clearly demonstrates a strong association between the 
anti-Tg/TPO auto-Abs and development of HT. (Burek and Bresler, 1990). 
HT has a multi-factorial etiology, involving both genetic and environmental 
factors (Burek and Bresler, 1990). Clustering of HT in families is frequently 
observed, and concordance of HT between twins is significantly higher than 
between non-twin siblings, suggesting the importance of genetic predisposition 
in development of HT (Weetman and McGregor, 1984). Most of the genetic 
association and linkage analyses focus on human leukocyte antigen (HLA) genes, 
and have initially shown some degree of association between HT and specific 
HLA alleles (Weetman and McGregor, 1984). In some studies, HLA-DR3 is 
shown to associate with HT (Stenszky et al., 1987; Tandon et al., 1991). Other 
studies have shown a high risk of development of HT among the HLA-DRS gene 
carriers (Farid, 1987; Weissel et al., 1980). HLA-DR4 gene has also shown a strong 
association with goitrous HT in Canadian people with a relative risk index of 5 
(Thompson and Farid, 1985). However, one study has demonstrated that HLA 
class II polymorphism contributed little to the development of HT (Jenkins et al., 
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1992). Since the results of the genetic association of HT with HLA alleles are not 
consistent in different studies, it is possible that the HLA genes may not be a 
major contributor to HT susceptibility (Roman et al., 1992). The variable results 
in different studies may reflect different ethnicities, case ascertainment, study 
methodologies and/or environmental influences (Weetman and McGregor, 
1994). 
Given the weak association of HLA genes with HT, other genes may regulate the 
susceptibility to HT, such as the gerrnline genes coding the T-cell receptor (TcR) 
a- and 13- chains. Several studies have examined the association between TcR Vl3-
genes and HT development. One study showed a significant association of HT 
with TcR 13-chain genes (Ito et al., 1989), but this association could not be 
confirmed in another study (Mangklabruks et al., 1991). The influence of 
immunoglobulin (Ig) genes on the development of HT is unclear, as few studies 
conducted showed conflicting results (Weetman and McGregor, 1994). Women 
are at 5-10 fold higher risk than men to develop HT, with a peak incidence 
between 50-60 years age (Vanderpump et al., 1995), suggesting that sex 
hormones may play a critical role in HT. Iodine is considered the most important 
environmental factor in HT induction (Rose et al., 1997). Either iodine deficiency 
or iodine excess may cause thyroid disorders (Woeber, 1991). 
1.1.2. Animal models for AT 
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1.1.2.1. Induced experimental autoimmune thyroiditis 
In 1956, Witebsky and Rose performed a pioneering study. They successfully 
induced experimental autoimmune thyroiditis (EAT), which showed similar 
immunopathology as HT, in rabbits by immunization with rabbit thyroid gland 
homogenate emulsified in complete Freund's adjuvant (CFA) (Witebsky and 
Rose, 1956). Following this protocol, EAT has been established in various animal 
species such as dog and guinea pig (Terplan et al., 1960), rat (Jones and Raitt, 
1961), monkey (Kite et al., 1966) and mouse (Rose et al., 1971). Both homologous 
and heterologous Tg preparations have been used as immunogens to induce EAT 
in mice (Romball and Weigle, 1984). Generally, heterologous Tg preparations are 
more immunogenic but less thyroiditogenic than self Tg as detected by 
proliferation of draining lymph node cells (LNC) and thyroid histology. This 
suggests that certain unique epitopes within the homologous Tg molecule may 
be more thyroiditogenic than those shared between self Tg and the heterologous 
Tgs (Kong and Lewis, 1990). 
EAT has also been induced in some strains of mice by immunization with Tg 
peptides emulsified in CFA (Carayanniotis and Rao, 1997), or TPO protein and 
its peptides (Kotani et al., 1990; Kotani et al., 1992). A strong adjuvant such as 
lipopolysaccharide (LPS) or CFA is required for inducing an immune response 
against the thyroidal Ags and their peptides. However, Balasa et al. successfully 
induced mouse EAT using Tg conjugated to a monoclonal antibody (mAb) 
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specific for mouse class II MHC molecules as Ag, without addition of a adjuvant 
(Balasa and Carayanniotis, 1993). Other approaches can also induce EAT in 
animal models. Braley-Mullen et al. established an EAT mouse model by 
adoptively transferring Tg-primed and activated splenocytes into normal 
syngeneic recipients (Braley-Mullen et al., 1985). Purified Tg-specific T-cells or T-
cell clones have been reported to induce EAT in syngeneic mouse recipients 
(Okayasu, 1985; Romball and Weigle, 1987), supporting the view that EAT is T-
cell mediated autoimmune disease. Thymectomy plus total body sublethal 
irradiation of young mice can trigger autoimmune response against their thyroid 
glands (Penhale et al., 1973), but it is not known whether the autoimmune 
response is restricted only to the thyroid glands. 
Quite commonly, EAT is induced in mice immunized with purified mouse Tg 
emulsified in CPA. Through the use of this model, some questions related to 
immunopathology and immunoregulation of autoimmune thyroiditis have been 
extensively addressed (Kong, 1999). To examine the association of major 
histocompatability complex molecules (MHC) with EAT induction, Rose's group 
immunized 33 different mouse strains of 11 different MHC haplotypes with 
thyroid extracts emulsified in CF A. The susceptibility of the mouse strains was 
classified based on the incidence and severity of thyroidal lymphocytic 
infiltration. Mice carrying H-25 ' k, and q MHC haplotypes are the most susceptible 
to EAT induction, strains with H-2a, m, r, and P MHC haplotypes have 
intermediate susceptibility, and mice with H-2b, d, g, i, and v MHC haplotypes are 
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resistant to EAT induction (Vladutiu and Rose, 1971b). To examine the 
association of HLA genes with EAT induction in animal models, Kong et al. 
introduced the HT-associated HLA gene DR3 into the EAT-resistant mouse 
strain B10.M, and found that over 40% of the DR3-transgenic B10.M mice 
developed severe EAT following immunization with Tg (Kong et al., 1996). 
The roles of Th1 /Th2 cells and their secreting cytokines such as IFN-y and IL-4 
on induction of EAT have also been addressed in the adoptive transfer EAT 
model described above (Stull et al., 1992). It is generally accepted that organ-
specific T-cell-mediated autoimmune diseases such as EAT and experimental 
autoimmune encephalomyelitis (EAE) are induced by Ag-specific Th1 cells, and 
induction of a Th2 response may ameliorate the diseases (O'Garra et al., 1997; 
Pearson and McDevitt, 1999). Interestingly, Tg-primed T-cells from mice lacking 
the IFN-y gene could induce EAT in recipient mice (Tang et al., 1998b), 
suggesting that Tg-specific effector T-cells can cause thyroid destruction without 
IFN-y secretion. In addition, disruption of the IL-4 gene in Tg-primed effector T-
cells did not exacerbate EAT in recipient mice (Tang et al., 1998a), indicating IL-4 
is not essential for development of EAT. Culturing Tg-primed lymphocytes with 
IL-4 before adoptive transfer did not benefit the recipients in respect of thyroid 
destruction albeit a decrease of anti-Tg Ab production was observed in the 
recipients. In contrast, culturing Tg-primed lymphocytes with IL-10 significantly 
decreased their thyroiditogenicity and prevented development of EAT in 
recipient mice {Mignon-Godefroy and Charreire, 1995}. Furthermore, IL-12 can 
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promote generation of thyroiditogenic T-cells in vitro that, subsequently, 
adoptively transfer EAT to recipient mice {Braley-Mullen and Bickel}. 
1.1.2.2. Animal models for spontaneous autoimmune thyroiditis 
Spontaneous autoimmune thyroiditis (SAT) is characterized by spontaneous 
development of thyroidal lymphocytic infiltration, production of anti-thyroid 
auto-Abs and cell-mediated destruction of thyroidal tissue. These immuno-
pathological changes closely resemble those in HT. Several animal models of 
SAT have been established. The most extensively studied model is the Obese 
strain (OS) chicken, which develops SAT during the first few weeks of life (Wick 
et al., 1971). The disease is characterized with severe mononuclear cell 
infiltration, formation of germinal centers in thyroid glands and development of 
auto-Abs against Tg, T3 and T4. The autoimmune thyroidal destruction leads to 
hypothyroidism and n ecessitates a hormone-replacement treatment of the 
younger chickens for successful breeding and propagation of the strain (Wick et 
al., 1989). Increase iodine uptake exacerbates the thyroid destruction in OS 
chickens (Bagchi et al., 1985). 
The Bio Breeding/ Worchester (BB/W) rat was originally used to study 
spontaneous induction of insulin-dependent diabetes mellitus (IDDM), but some 
of the rats have also been found to develop hypothyroidism and SAT at 60 to 120 
days of age (Allen et al., 1986). The incidence of development of spontaneous 
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IDDM and SAT in the BB/W rat is very high. Up to 59% of rats with IDDM also 
have lymphocytic infiltration in thyroid glands (Sternthal et al., 1981). SAT has 
also been reported in the Buffalo rat. Over 26% of old Buffalo rats show high 
titers of anti-thyroid auto-Abs and mononuclear cell infiltration in thyroid 
glands, and neonatal thymectomy increases the incidence (Noble et al., 1976). 
SAT has also been found in non-obese diabetes (NOD) mice, a well-established 
model for spontaneous IDDM. The incidence of SAT in these diabetes-prone 
mice ranges from 67 to 90% (Bernard et al., 1992). It is possible that common 
mechanisms of organ-specific autoimmune destruction rna y exist between SAT 
and IDDM in the NOD mice. 
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1.1.3. Autoimmune responses against Tg 
1.1.3.1. Mapping T -cell epitopes in Tg 
The Tg molecule is a 660 KD homodimeric glycoprotein, which is stored in the 
thyroid follicular lumen and comprises over 75% of the dry weight of thyroid 
gland (Rayner et al., 1993). Cloning and sequencing of the eDNA of Tg from 
AKR/J mice indicated a primary sequence of 2746 amino acid (a.a.) residues, 
preceded by a 20 a.a. signal peptide (Kim et al., 1998). Tg is unique in its content 
of iodinated tyrosine residues. Normal human Tg varies widely in iodine content 
from 0.1% to 1.1% (Taurog, 1996). The main function of Tg is to act as the thyroid 
prohormone. The thyroid hormones, thyroxine and triiodothyronine, are 
synthesized following thyroid peroxidase-catalyzed modification or iodination of 
the tyrosine residues within Tg (Rayner et al., 1993). 
Thyroid peroxidase (TPO) and Tg are the two major autoantigens in AT 
(Weetman 1994). TPO peptides 100-119, 420-434, 625-644, and 882-901 are the 
most common sites recognized by TPO T-cellline, indicating that they may be 
immunogenic epitopes in AT {Fisfalen 1995}. One T-cell epitope of TPO 118-131 
has been identified as pathogenic in EAT and shares part of its sequence with Tg, 
providing an evidence of epitope spreading {Hoshioka 1993}. Our study focuses 
on examining the autoimmune responses against Tg by using the Tg-indued EAT 
mouse model. Since Tg has a large molecular size and extensive modifications 
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such as glycosylation and iodination, the task of mapping pathogenic epitopes in 
Tg is extremely challenging. Diverse strategies have been used for this purpose. 
Champion et al. found that poorly iodinated Tg failed to elicit EAT in mice and 
could not activate Tg-specific T-cell hybridomas (Champion et al., 1987). This 
observation raised the possibility that dominant pathogenic Tg epitopes might be 
iodinated. T -cell epitope mapping efforts led to the identification of a 
thyroiditogenic T4-containing Tg epitope, T4(2553), which contains a thyroxine 
molecule at position 2553 (Champion et al., 1991; Hutchings et al., 1992). The 
T4(2553)-reactive T -cell hybridomas were originally created by fusion of the Tg-
primed LNC with thymoma cells (Rayner et al., 1987). This study emphasized 
the role of the hormonogenic sites in the pathogenicity of Tg. 
Other approaches have been taken by several labs to map Tg epitopes. Using 
trypsinized Tg fragments, Texier et al. identified a 40mer Tg peptide (1672-1711) 
that could stimulate the cytolytic activity of Tg-primed CTL and induce EAT in 
CBA mice following immunization with the peptide (Texier et al., 1992). Based 
on the hypothesis that Tg may share similar epitopes with TPO, Hoshioka et al. 
identified a 14mer Tg peptide (2730-43) as an immunodominant epitope, which 
could stimulate proliferation of Tg-primed LNC. However, the 14mer peptide 
failed to induce EAT following immunization of animals with the peptide and 
adjuvant (Hoshioka et al., 1993). A different approach has been taken by 
Carayanniotis' group. The rat Tg sequence was screened for sites that were likely 
to contain T-cell epitopes based on the "AMPHI" and "tetramer motif" computer 
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algorithms (Rothbard and Taylor, 1988; Taylor, 1994). The predicted Tg sites 
were synthesized as 12-18 mer peptides, and then, used to challenge EAT-
susceptible mice for induction of EAT. Following this strategy, two Tg peptides, 
2495-2511 and 2694-2711, were identified as pathogenic determinants 
(Carayanniotis et al., 1994; Chronopoulou and Carayanniotis, 1992). However, 
both peptides were characterized as non-dominant T -cell epitopes, since in vitro, 
they could not stimulate Tg-primed LNC to proliferate, and in vivo, they could 
not prime T-cells able to recognize intact Tg in a subsequent proliferation assay 
in vitro (Carayanniotis and Rao, 1997). 
1.1.3.2. Anti-Tg auto-Abs 
Tg-specific Abs were first reported in HT patients in 1958 (Roitt and Doniach, 
1958). The frequency of anti-Tg auto-Abs in healthy women varies depending on 
the method used for Ab measurement: from 5-10% by haemagglutination and 
ELISA to 15-20% by RIA, while the frequency in men is 10-fold lower than in 
women (Beever et al., 1989) (Vanderpump et al., 1995). Tg-specific Abs have been 
found in the majority of patients with HT, and their occurrence in HT patients is 
commonly associated with anti-TPO auto-Abs (Nordyke et al., 1993). It is 
currently not clear whether or how anti-Tg auto-Abs are involved in the 
pathogenesis of HT, or whether they are non-pathogenic Abs generated 
secondary t:o the T-cell infiltration and tissue damage in the thyroid gland. Tg-
specific Abs cannot fix complement, but may play a role in antibody-dependent 
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cell-mediated cytotoxicity (ADCC) (Weetman et al., 1989). Both healthy people 
and AT patients may carry anti-Tg Abs in their circulation. It seems that some of 
the anti-Tg auto-Ab clones may be harmless and others may be pathogenic and 
related to the development of HT (Tomer, 1997). 
Various approaches have been taken to identify the specificity of anti-Tg auto-
Abs. Enzyme-digested fragments of Tg molecules have been used in epitope 
mapping (Male et al., 1985), but this approach can only identify linear, not 
conformational epitopes. In order to overcome this, cross-inhibition studies have 
been performed by using panels of anti-Tg mAbs (Piechaczyk et al., 1987; Ruf et 
al., 1983). These studies suggest that most disease-associated anti-Tg auto-Abs 
may be restricted in their epitopic specificity, in other words, they are 
oligoclonal, while the natural anti-Tg auto-Abs in healthy people may be 
polyclonal (Dietrich et al., 1991). In addition, Dong et al. reported that the 
binding sites of pathogenic anti-Tg Abs were clustered on certain regions within 
Tg, but the epitopes of the natural anti-Tg Abs were spread randomly within Tg 
(Dong et al., 1989). Recently, Prentice et al. has also demonstrated that the Tg 
epitopes recognized by Tg-specific Abs from AT patients are different from those 
recognized by Abs from healthy individuals (Prentice et al., 1995). Similarly, 
Tomer suggested that the oligoclonal anti-Tg auto-Abs of HT patients have 
different specificity from the polyclonal anti-Tg auto-Abs of healthy people, and 
might participate in the initiation of HT (Tomer, 1997). 
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To examine the direct thyroiditogenicity of Tg-specific Abs, several workers 
attempted to elicit EAT by passive transfer of sera. Successful induction of EAT 
by transferring sera from Tg-immunized animals to syngeneic recipients has 
been reported in different animal models (Nakamura and Weigle, 1969; Polley et 
al., 1981; Tomazic and Rose, 1975; Vladutiu and Rose, 1971a). Also, mice injected 
with the hybridoma cells secreting anti-Tg mAb developed thyroid lesions 
quickly (Yokochi et al., 1991). However, there are other conflicting studies that 
show that Abs or Tg-immuned serum cannot directly induce EAT (Inoue et al., 
1993). The reason(s) for these discrepancies remains unkown. The mechanism 
underlying Ab-mediated pathogenesis is also unknown. It has been proposed 
that Abs that bind to Tg may enhance Tg internalization and epitope 
presentation on Ag presenting cells (APC), and thus, to activate auto-reactive T-
cells specific to Tg peptides (Mcintosh and Weetman, 1997). This hypothesis 
provides a mechanism to bridge Ab-mediated pathogenesis with T-cell-mediated 
thyroidal destruction. 
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1.2. The role of iodine in autoimmune thyroiditis 
1.2.1. Iodine metabolism and thyroid hormone synthesis 
Iodine is a trace element necessary for thyroid hormone synthesis. T4 and T3 are 
formed following an intramolecular coupling of two iodotyrosyl residues in Tg 
(Woeber, 1991). Hormone synthesis can be divided into the following steps: 
active transport of iodide; iodination of tyrosyl residues of Tg; coupling of 
iodotyrosine molecules within Tg to form T4 and T3; proteolysis of Tg to release 
iodotyrosine and iodothyronines, and secretion of iodothyronines; deiodination 
of iodotyrosines and rescue of iodide (Taurog, 1996). These processes are 
discussed in the next few paragraphs. 
Iodine transport and iodination of Tg molecules 
Iodine is actively transported into the thyroid follicle cells against both a 
chemical and electrical gradient (Wolff, 1964). The iodine transport across the 
plasma membrane of the follicle cells is dependent on cellular ATP, and the Na+-
K + ATPase may be involved in this process (Wolff, 1964). Binding of 
phospholipids to iodine can make the iodine soluble, and thus, a membrane 
carrier has been suggested to mediate the iodine transportation (Weiss et al., 
1984). The most important regulator for iodine transportation is thyroid 
stimulating hormone (TSH), which enhances iodine uptake by the follicular cells 
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(Halmi et al., 1960). Iodination of Tg is a post-translational modification that 
occurs after the maturation of Tg molecules. It takes place at the cell-colloid 
interface close to the apical membrane of the thyroid follicular cells and requires 
the presence of four elements, TPO, H20 2, iodide and Tg (Taurog, 1996). The 
reaction of iodination is catalyzed by TPO, which is excreted together with Tg to 
the apical membrane by the thyroid follicular cells. TPO within the intracellular 
exocytotic vesicles is not functional because of the lack of accessibility to H20 2, 
which is a necessary component for TPO activity and is present only near the 
apical membrane of the follicular cells (Taurog, 1996). This site-restricted activity 
of TPO minimizes non-specific iodination of the intracellular protein molecules. 
Formation of thyroid hormones 
TPO contains two binding sites, one for iodine binding and the other for tyrosine 
binding (Woeber, 1991). The tyrosine oxidation reaction catalyzed by TPO yields 
some free radicals and iodotyrosines, monoiodotyrosine (MIT) and 
diiodotyrosine (DIT). In addition to catalyzing the iodination of tyrosine 
residues, TPO is also able to catalyze intracellular coupling of two iodotyrosyl 
residues to form T4 and T3 within the Tg molecule. Formation of DIT and MIT 
may facilitate a coupling event (Deme et al., 1975). Generally, several conserved 
sites within Tg are used for hormone synthesis such as tyrosine residues at 
position 5, 2553, 2567 etc (Dunn and Dunn, 1999). However, many other sites 
have also been described as tyrosyl donors or recipients for hormone synthesis 
(Marriq et al., 1989; Ohmiya et al., 1990). The primary sequence and the native 
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structure of Tg molecule may play a major role in selecting which tyrosine 
residues are used for hormonogenesis (Maurizis et al., 1981). The mature Tg 
molecules containing T4 or T3 are stored in the follicular lumen for future use. 
Proteolysis of Tg molecules and release of hormones 
To release thyroid hormone, the mature hormone-containing Tg molecules 
within the follicular lumen must be endocytosed by the surrounding follicular 
cells and further digested in the cells to free the T4 and T3 molecules. The 
follicular cells take up the stored Tg molecules either through fluid phase 
pinocytosis or a receptor-mediated specific uptake (Consiglio et al., 1981). 
Following endocytosis, the endocytotic vesicles fuse with lysosomes, where Tg 
molecules meet the proteases. The lysosomal enzymes play a major role in the 
intrathyroidal degradation of Tg. Some proteolytic enzymes such as cathepsins 
are crucial for generation of T4 and T3 hormones (Dunn et al., 1991). Once 
released from Tg, the T4 and T3 hormones rapidly leave the follicular cells and 
enter the circulation by crossing the basal membrane of the cells. TSH stimulates 
Tg endocytosis and hormone release (Dunn, 1996). Most of the released 
iodotyrosine residues following Tg degradation are deiodinated within the 
follicular cells, and the iodide is recycled for iodination of new Tg molecules. 
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1.2.2. The relationship between iodine excess and Hashimoto's thyroiditis 
The minimum daily iodine requirement is about 50 11g (Woeber, 1991). The 
thyroid gland can defend a short-term wide fluctuation in iodine supply to retain 
a constant secretion of the thyroid hormones. However, chronic iodine excess or 
deficiency may lead to some thyroid dysfunction and possibly thyroid disease 
(Rose et al., 1997). Total daily urine iodine less than 25 J-tg may be considered as 
iodine deficiency (Woeber, 1991). The most common pathologic consequence of 
iodine deficiency is endemic goiter. A more severe deficiency may cause endemic 
cretinism in fetal life and childhood. Although environmental iodine deficiency 
continues to be a major public health problem in some developing countries, it is 
mostly eradicated in Europe and North America due to the iodization program 
that adds additional iodine into salt or oil (Brush, 1952; Hetzel and Dunn, 1989). 
The program significantly prevented endemic goiter in iodine-deficient areas and 
communities (Pharoah and Connolly, 1987), and was beneficial as a therapy for 
the patients with spontaneous hyperthyroidism (Azizi, 1985). However, a 
converse problem, iodine excess, arose due to the abuse of iodized products and 
iodine-containing drugs (Oddie et al., 1970; Woeber, 1991). In 1980, the 
recommended daily allowance (RDA) for iodine intake was 150 J-tg in the US, but 
many Americans are ingesting over 1 mg of iodine per day (Barsano, 1981). A 
survey in 1970 showed that the average iodine intake by Americans varied from 
240 J-tg to 740 11g (Oddie et al., 1970). 
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At least two different types of iodine excess can cause dysfunction of the thyroid 
gland. One is a persistent long period of exposure to a moderately increased 
iodine level such as that resulting from the abuse of iodized salt or oil. Another is 
a short-term exposure to a large dose of iodine contained in certain drugs. 
Increased iodine uptake by iodine-deficient people resulted in a direct toxic effect 
on the thyroid function and subsequent thyroiditis (Mahmoud et al., 1986). The 
incidence of HT grew in some previously iodine-deficient areas after the 
Chernobyl explosion, perhaps due to the increased environmental iodine 
isotopes (Vermiglio et al., 1999). In 1971, Braverman and his colleagues examined 
the effect of excess iodine on euthyroid HT patients. Four out of seven patients 
developed severe hypothyroidism, suggesting a strong relation between excess 
iodine and HT (Braverman et al., 1971). A causative role of excess iodine on the 
development of HT was suggested based on both clinical and epidemiological 
observations (Kahaly et al., 1998; Konno et al., 1994; Vono et al., 1996). Some 
clinical diagnostic or therapeutic protocols may cause excessive iodine intake by 
patients. One example is amiodarone, an iodine-rich drug used frequently in the 
treatment of Cardiac arrhythmias and Angina pectoris. It is clear that long periods 
of taking amiodarone can induce anti-thyroid Abs and cause HT (Martino et al., 
1984; Monteiro et al., 1986). However, a short-term exposure to a large dose of 
iodine may not be as dangerous as long-term exposure to a moderate dose of 
iodine, and it ordinarily does not lead to d ysfunction of thyroid glands. 
Radioiodine-containing reagents used for clinical diagnosis and therapy may 
also cause HT, but the mechanism may be different from non-radioactive iodine 
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excess. It has been shown that radioactive iodine may cause a direct injury of 
thyroid tissue (Fisher and Oddie, 1969; Oddie et al., 1968). 
1.2.3. Iodine-induced AT in animal models 
In 1969, Evans et al. examined the effect of excess iodine on the development of 
AT in dogs. The dogs were immunized with dog thyroid extract, and some of 
them were simultaneously treated with excess iodine. The results demonstrated 
that dogs treated with excess iodine developed more severe thyroiditis than 
untreated dogs following immunization with the thyroid extract (Evans et al., 
1969). Belshaw et al. confirmed the role of excess iodine on development of AT in 
iodine-deficient dogs treated with thiouracil. Most of the iodine-deficient animals 
developed severe lymphocytic infiltration in the thyroid tissue following 
treatment with excess iodine in the diet (Belshaw et al., 1974). 
In 1985, Bagchi et al. demonstrated a role of excess iodine in induction of AT in 
chickens (Bagchi et al., 1985). Cornell strain (CS) chickens were chosen for the 
study, because the CS chicken is closely related to the OS chicken, which 
developes SAT, whereas the CS chicken does not. During the experiment, the CS 
chickens were treated from the first day of hatching with excess iodine through a 
daily supply of KI-containing water. Sera were taken from the iodine-treated 
chickens at different periods, and the titers of anti-Tg, T3 and T4 Abs were 
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determined. At 10 weeks of age, the chickens were sacrificed for histological 
examination of their thyroid glands. Those chickens that received excess iodine 
had up to 7.3 %lymphocytic infiltration as well as a high incidence of anti-Tg, T3 
and T4 Abs. In contrast, only 1.28 % of chicken with normal iodine intake 
showed thyroid lymphocytic infiltration and a low incidence of Ab response. To 
further address the effect of iodine deficiency in development of AT, they raised 
the OS chickens under an iodine-deficient environment, and found that the 
incidence of presenting anti-Tg, T3 and T4 Abs was significantly decreased in 
these SAT-prone chickens. The data clearly demonstrated that excess diet iodine 
intake increased the incidence of AT in CS chickens. 
Similar results have been found in the BB/W rat SAT model (Allen et al., 1986). 
The diabetic-prone BB/W rat develops SAT without functional hypothyroidism 
between 60 and 120 days of age. To examine the effect of excess iodine in the 
development of SAT in the BB /W rat, young rats less than 30 days of age were 
treated with water containing 0.05% of iodine for 7 - 8 wks. Serum anti-Tg Ab 
and the thyroid glands were examined to estimate the development of SAT. The 
data showed that rats treated with iodine-containing water had a significant 
higher incidence of SAT (77%) than those rats treated with tap water (30%). 
However, hypothyroidism did not occur in these iodine-treated rats as indicated 
by a normal T4, T3 and TSH levels, but occurred only when the young rats were 
hemithyroidectomized prior to iodine treatment (Allen et al., 1987), suggesting 
some other determinants may contribute to the development of hypothyroidism 
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in the iodide-treated BB/W rats. Neonatally thymectomized Buffalo rats have 
also been shown to be susceptibile to excess iodine-induced SAT and 
hypothyroidism (Allen and Braverman, 1990). After treating the thymectomized 
rats with iodine-containing water for 12 weeks, the rats exhibited a significantly 
higher incidence in development of SAT than the non-iodine-treated group (73% 
vs. 31%) as defined by thyroid lymphocytic infiltration. A mouse SAT model, 
NOD-H-2h4, has also been used to examine the effect of excess iodine in the 
development of SAT (Rasooly et al., 1996). After feeding the mice with water 
containing 0.05% iodine for 8 wks, approximately 54% of the female mice and 
70% of the male mice developed thyroid lesions, whereas only 1 out of 20 control 
mice that received plain water developed thyroiditis at the same age. 
1.2.4. Iodination of Tg increases its immunogenicity 
1.2.4.1. Circulating Tg has lower iodine content than intrathyroidal Tg 
The thyroid gland is not an immunologically privileged site, and Tg molecules 
and its fragments circulate continuously in the blood. These circulating Tg 
molecules contain very little or are devoid of iodine, as compared to the stored 
Tg molecules in the thyroid follicles (Ikekubo et al., 1981; Schneider et al., 1983). 
It has been suggested that serum Tg is derived from the leakage of the colloid Tg 
through the lymphatic vessels (Daniel et al., 1967). This suggestion may not be 
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correct, since, otherwise, the circulating Tg would have contained similar iodine 
content as the stored Tg within the colloid. An observation by Chambard et al. 
may help to solve the puzzle of why the circulating Tg has much less iodine than 
the intrathyroidal Tg. They found that Tg synthesized within the follicular cells 
could be secreted through the basolateral membrane directly into the blood 
(Chambard et al., 1987). Since iodination only occurs at the apical membrane as 
described before, the newly synthesized Tg entering into the blood directly 
through the basolateral membrane would not contain any iodine and thyroid 
hormone. A transcellular vesicular transport (transcytosis) of Tg from the lumen 
to the basolateral membrane and into the blood occurring within the thyroid 
follicular cells may count for some of iodine content within the circulating Tg 
(Herzog, 1983). However, the transcytosis must occur at a very low rate since 
most of the endocytosed Tg molecules are degraded within the lysosomes to 
release T3 and T4 hormones. 
Circulating Tg molecules from patients with some thyroidal abnormalities 
contain higher iodine content than that from normal individuals (Druetta et al., 
1999). However, in patients with thyroid tumors, the iodine content of the 
circulating Tg is unchanged although an increased concentration of circulating 
Tg is observed (Schneider et al., 1983). The destruction of the thyroid follicles 
during the course of thyroid disease may result in leakage of the colloid Tg into 
the blood or lymphoid system. TSH stimulation of thyrocytes causes a marked 
increase of the iodine content in circulating Tg to a level similar to that of the 
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intrathyroidal Tg, suggesting that TSH stimulation may facilitate the release of 
iodinated Tg (Schneider et al., 1985). In addition, excess intake of diet iodine 
generally results in an increase of iodine content in Tg extracted from thyroid 
glands (Sundick et al., 1987). 
1.2.4.2. The effects of iodine content on the immunogenicity of Tg 
It has been suggested that iodination of Tg increases its immunogenicity and 
causes an autoimmune response against the iodine-modified Tg (Champion et 
al., 1992; Rose et al., 1997). Highly iodinated Tg molecules (HI-Tg) differ from 
low iodinated Tg (LI-Tg) in their conformational structure (Berg and Eckholm, 
1975) and their susceptibility to thyroidal hydrolytic proteases (Pouchier et al., 
1983; Lamas and Ingbar, 1978), indicating that iodination may alter the 
immunogenic properties of the Tg molecules. 
Sundick et al. examined Ab responses against Tg preparations with different 
iodine content (Sundick et al., 1987). The HI-Tg preparation was obtained from 
thyroid glands of CS chicken fed with iodine rich diet and contained about 60 
iodine atoms per Tg molecule. The LI-Tg preparation was purified from the 
thyroid glands of CS chickens treated with propylthiouracil, an inhibitor of 
iodination, and the iodine level of this LI-Tg preparation was undetectable. To 
compare their immunogenicity, they challenged CS chicken with either HI-Tg or 
LI-Tg. A stronger anti-Tg response was induced after immunization with HI-Tg 
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but not with LI-Tg, suggesting that iodination increases the immunogenicity of 
Tg. Similar results had been obtained in BB/W rats (Ebner et al., 1992). In this 
study, Ll-Tg was obtained from rats fed with 0.5% methimazole, and the 
immunogenicity and thyroiditogenicity of this LI-Tg was compared with that of 
Tg purified from rats fed with normal diets. The BB/W rats rarely develop SAT 
before the age of 75 days. Young rats were immunized with LI-Tg or normal Tg 
emulsified in CFA and sacrificed before the age of 65 days for examination of 
anti-Tg Ab titers and thyroidal lymphocytic infiltration. About 31% of young 
BB/W rats developed EAT after immunization with normal Tg, whereas none of 
the rats developed EAT following immunization with LI-Tg. Also, the titer of 
anti-Tg Abs was higher in the sera from rats immunized with normal Tg vs. that 
in the sera from rats immunized with LI-Tg. 
T-cells play a major role in the development of AT in animal models (Kong, 1999) 
and also possibly in human HT (Weetman. A. P., 1998). It has long been 
suspected that iodine modification may break the T-cell tolerance against Tg to 
initiate autoimmune thyroiditis. Allen et al. compared the relative frequency of 
HI-Tg-specific vs. LI-Tg-specific precursor T-cells in the AT-prone BB/W rats 
(Allen and Thupart 1995). Circulating na'ive T-cells from the young BB/W rats 
were tested for their activation by HI-Tg or LI-Tg in vitro. They found that there 
was no difference in the proliferation of these T-cells against HI-Tg and LI-Tg, 
suggesting that T-cell repertoire contains a similar frequency of precursor T-cells 
specific for HI-Tg and LI-Tg. 
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Using two Tg-specific T-cell hybridoma clones (Champion et al., 1985), 
Champion et al. demonstrated that activation of the T-cell hybridomas required 
the presence of iodine within Tg preparations (Champion et al., 1987). Tg 
purified from mice treated with aminotriazole was not able to stimulate the T-
cell hybridomas to proliferate. In contrast, Tg from normal mice strongly 
activated the hybridoma cells. Immunization of mice with various Tg 
preparations confirmed that Tg devoid of iodine was not thyroiditogenic, but 
normal Tg induced significant EAT. Furthermore, human Tg with variable 
T4/T3 content activated the T-cell hybridomas to various degrees, and the 
activation indices correlated with the hormone content of the Tg preparations 
(Champion et al., 1987). The study suggested that iodinated determinants 
recognized by T -cells may play a central pathogenic role in the induction of EAT. 
The subsequent studies identified the specificity of the T-cell hybridomas to a T4-
containing Tg peptide T4(2553) (Champion et al., 1991), and immunization with 
this peptide can directly induce EAT in susceptible mice (Hutchings et al., 1992). 
T4 was a crucial residue for recognition of the peptide by the T-cell hybridomas, 
since an analog peptide carrying a tyrosine instead of T4 at position 2553 did not 
activate the T-cells (Dawe et al., 1996). To examine whether iodine is important 
for the T4(2553) peptide to be pathogenic, Kong et al. compared the 
immunogenicity of the T4(2553) peptide with its non-iodine analog, T0(2553), 
which has the same peptide backbone as T4(2553) peptide, Tg2549-2560, but no 
iodine atoms on the phenyl-rings of the T4 molecule (Kong et al., 1995). They 
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demonstratE~d that both T4(2553) and T0(2553) peptides are immunogenic and 
suggested that the presence of iodine within T4 is not necessary for the 
thyroiditogenicity of the T4(2553) peptide. 
In human studies, Rasooly et al. first described that iodine was required for 
appropriate recognition of Tg by human T-cells (Rasooly et al., 1998). A minimal 
amount of iodine was necessary for Tg to elicit proliferation of lymphocytes from 
HT patients. However, the study also showed that lymphocytes from healthy 
people or HT patients proliferated against iodinated Tg in a similar fashion. This 
was not expected since the frequency of Tg-reactive T-cells in HT patients should 
have been higher than that in normal individuals. In contrast to Rasooly's 
findings, Shimojo et al. found that the iodine content of Tg did not correlate with 
its activity to stimulate peripheral lymphocytes to proliferate, and also sera from 
AT patients reacted equally well to different Tg preparations regardless of their 
iodine content (Shimojo et al., 1988). The reasons for the discrepancies between 
the two studies remain obscure. 
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1.3. Cryptic T -cell epitopes and autoimmunity 
1.3.1. lmmunodominance and crypticity 
When we immunize a host with a particular protein Ag, the host's T-cell 
response against the Ag usually focuses on a few sites within the protein 
molecule, and the response to other sites of the molecule is relatively 
insignificant. This phenomenon is denoted as immunodominance (Berzofsky, 
1988). Immunodominance was first observed in the immune responses against 
foreign Ags such as hen-egg lysozyme (HEL), hemagglutinin (HA) and allergens. 
It was found that LNC from animals immunized with these foreign Ags only 
proliferated against a few synthetic peptides originating from the protein Ags 
(Finnegan et al., 1986; Hurwitz et al., 1984; Katz et al., 1982; Kurisaki et al., 1986). 
The concept of crypticity was introduced in 1993 by Sercarz, and it means the 
failure of certain potential determinants within a protein Ag to be recognized by 
T-cells following immunization with the protein Ag (Sercarz et al., 1993). T-cell 
epitopes of a protein Ag can be predicted by algorithm-based computation 
programs (Rothbard and Taylor, 1988; Sette et al., 1989b), but the number of 
predicted epitopes is generally much greater than that of the dominant epitopes 
mapped by T-cell proliferation and activation assays (Chronopoulou and 
Carayanniotis, 1992). Some of these predicted epitopes may have the capacity to 
induce significant immunological responses after challenging animals with the 
epitopes themselves, but be unable to be recognized by LNC previously primed 
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with the intact Ag, and thus, they are named as cryptic epitopes. A functional 
definition for immunodominance and crypticity is shown in Table 1.1. 
Table 1.1. A functional definition for dominant and cryptic T-cell epitopes 
In vivo 
immunization 
Intact Ag 
Peptide# I 
Peptide#2 
Peptide#3 
Intact Ag 
+++ 
+++ 
+/-
In vitro LNC proliferation against 
Peptide# I 
+++ 
+++ 
Peptide#2 
+ 
+++ 
Peptide#3 
+++ 
Table 1.1. Definition for immunodominant and cryptic T -cell epitopes. A 
dominant epitope, such as peptide #1, can strongly stimulate LNC primed 
with the intact Ag to proliferate. A cryptic epitope, like peptide #3, can 
induce a strong immune response, but it can neither stimulate the intact 
Ag-primed LNC to proliferate in vitro, nor induce T-cells recognizing the 
intact Ag in vitro. Peptide #2 is characterized as subdominant epitope for 
its intermediate capacity to activate intact-Ag-primed LNC. 
Three parameters play a major role in selecting which peptide within a protein 
Ag acts as the immunodominant target. The first is the peptide affinity of 
binding to the specific MHC. The second is the availability ofT-cells reactive to 
the peptide-MHC complexes (Sercarz et al., 1993). The third is the relative 
efficiency of a peptide to be generated and presented on professional APC such 
as DC and macrophages. Factors that affect the efficiency of Ag processing and 
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presentation will be discussed in following paragraphs, including primary and 
secondary structures of the Ag, MHC hyplotypes and differential Ag processing 
in diverse APC. 
1.3.1.1. Primary and secondary structures of protein Ag affect peptide 
presentation 
The amino acid (a.a.) sequence of a protein Ag is an essential factor that instructs 
Ag processing and generation of MHC-binding peptides. If a peptide sequence 
within the Ag encompasses a MHC-binding motif, the peptide can potentially be 
immunogenic. Amino acid substitutions within the peptide can increase or 
decrease its overall binding affinity to the MHC molecule (Sloan-Lancaster and 
Allen, 1996), (Jardetzky et al., 1990). Altered peptide ligands (APL) with a.a. 
substitutions at various positions can be used to predict the binding motif for a 
given MHC molecule, which then can be used for prediction of the potential 
MHC-binding sequences within a given protein Ag (Buus et al., 1987). However, 
binding to the MHC does not necessarily render a peptide immunogenic, 
because the peptide may not be generated during the digestion of the intact 
protein within APC or not recognized by T-cells (Sette et al., 1989b). 
The a.a. sequence flanking a MHC-binding motif may also be important in 
affecting presentation of the peptide following processing of the protein Ag 
(Kurlander et al., 1999; Latek et al., 2000; Moudgil et al., 1996). The flanking 
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regions may contain critical sites for protein-unfolding and enzymatic digestion. 
Amino acid substitutions at these sites may prevent the enzymatic cutting to 
generate the MHC-binding fragments, or inhibit peptide loading into the MHC-
binding groove. 
The tertiary structure of a protein Ag may also influence the processing of the Ag 
in APC (Glimcher et al., 1983). For example, stabilization of HEL with additional 
intracellular disulphide-bridge-links can render HEL resistant to proteolysis and 
lead to a strong reduction in its immunogenicity (So et al., 1997); Also, 
dimerization of monomeric human chorionic gonadotropin (HCG) can alter the 
tertiary structure of the protein and thus affect presentation ofT-cell epitopes 
during HCG processing (Rouas et al., 1993). 
1.3.1.2. MHC-guided Ag processing and presentation 
Exogenous Ags can be internalized by APC either through non-specific 
endocytosis such as pinocytosis and phagocytosis or by specific receptor-
mediated endocytosis (Watts, 1997). Following internalization, the exogenous 
Ags enter the various stage endosomes where they meet local proteases and 
become partially digested. Digestion is completed in the MHC class II 
compartments (MIIC) which are formed after fusion of the late-stage endosornes 
with the enzyme-rich lysosomes. Within the MIIC compartments, the newly 
synthesized MHC class II molecules are chaperoned with HLA-DM molecules 
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and stabilized with the class II-associated invariant chain peptide (CLIP) derived 
from li chain, and a dynamic peptide exchange occurs for loading an appropriate 
peptide into the MHC-binding groove. Once a kinetic balance is achieved, the 
MHC-peptide complexes are stabilized and dissociate from the HLA-DM 
molecules, and then move to the cell membrane (Wolf and Ploegh, 1995). 
It has been reported that class II MHC molecules can bind some protein 
molecules, like sperm whale myoglobin, without any processing other than an 
extracellular denaturation (Sette et al., 1989a; Streicher et al., 1984), and some T-
cells can directly recognize non-processed protein Ags, e.g. fibrinogen, directly 
presented on APC (Lee et al., 1988). These unusual observations finally found a 
theoretic explanation after unveiling of the crystal structure of MHC class II 
molecule (Fremont et al., 1996). The structural study shows that the peptide-
binding groove of MHC class II molecule has open ends, which may allow MHC 
class II molecule to bind to some large peptide fragments. Based on this property 
of the class II MHC molecule, "MHC-guided Ag processing" was proposed. In 
this view, after encountering the proteases within the endosomes, protein Ags 
are unfolded by destruction of disulfide bonds, and then partially digested to 
generate large protein fragments. Loading of the large protein fragments into the 
MHC peptide-binding groove occurs within MIIC compartments. T-cell 
determinants within the fragments are protected from enzymatic digestion after 
binding to MHC molecules, but the flanking regions are further trimmed by the 
proteases within the MIIC to generate minimal T -cell determinants (Germain, 
32 
1994; Madden, 1995). Generation of an insulin T-cell epitope was monitored in 
vitro by Delovitch's group in order to address the MHC-guided processing (Lang 
et al., 1996). The data showed that binding of a large insulin fragment to lAd 
molecules was essential for presentation of the insulin T -cell epitope, whereas, in 
the absence of the MHC molecules, the insulin fragment degraded without 
generation of the T-cell epitope. 
1.3.1.3. APC diversity and Ag processing 
Different lineages of APC may differ in their processing machinery, such as the 
intracellular proteases and their localization, levels of expression of MHC and 
costimulation molecules, chaperone molecules and sensitivity to environmental 
stimuli such as cytokines and infections (Manca et al., 1998; Vidard et al., 1992). 
Thus, presentation of dominant peptides may vary among the different APC 
populations. Even in the same APC population, peptide presentation may be 
diverse depending on the routes of Ag internalization, the stage of APC 
maturation and the tissue localization (Harding, 1996). 
Dendritic cells (DC) 
DC are considered the most efficient APC population due to their high 
expression of MHC and co-stimulatory molecules, their vigorous rate of 
endocytosis and phagocytosis, and mostly, their capacity to activate naive T -cells 
(Guery and Adorini, 1995). It has been suggested that DCs represent the natural 
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adjuvant forT-cell activation (Cella et al., 1997). DCs are bone-marrow-derived 
monouclear cells, and have very high level of fluid phase pinocytosis, which 
allow them to concentrate large volumes of macromolecules. Also, it has been 
shown that DC localized in non-lymphoid tissues are in an immature stage, and 
characterized with high capacity of Ag capturing and processing, but low 
capacity ofT-cell stimulation (Steinman, 1991). After activation by inflammatory 
mediators, these immature DCs migrate into the draining lymphoid tissues and 
become mature DCs. There, they lose the ability to capture Ag, but gain the 
capacity to stimulate T-cells. Different subclasses of DC have been recently 
identified (Rissoan et al., 1999). It would be interesting to compare their 
properties in Ag processing and presentation. 
In addition, DC express high amounts of the low affinity type II Fc-gamma 
receptor (FcyR) and mannose receptors that allow efficient capture of immune 
complexes and manosylated Ags, respectively (Sallusto et al., 1995). Unlike FcyR, 
which strongly associates with its ligands, mannose receptor dissociates from its 
bound Ag quickly following Ag internalization (Stahl, 1992). Therefore, the 
mannose receptor may only mediate Ag uptake, but the FcyR, like the mig, may 
mediate Ag uptake and also affect Ag processing. 
Macrophages 
Macrophages are active in phagocytosis, and thus, efficient in presentation of 
particular Ags. Similarly to DCs, the Ag-processing capacity of macrophages is 
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affected by their stage of maturation, activation status, localization and 
environmental stimuli (Schneider and Sercarz, 1997). Macrophages may contain 
different subtypes with various capacities in Ag processing since different 
macrophage clones with similar phenotype can differentially process protein Ag 
to generate T -cell epitopes, suggesting that these clones may vary in their 
proteases such as cathepsins (Rodriguez and Diment, 1992; Walker, 1989). 
Similar results have been reported by using c-Myc-transformed macrophage cell 
lines (Trannoy et al., 1993), and demonstrating a great heterogeneity in Ag 
processing and presentation among these transformed macrophage clones. 
Techniques to isolate functionally different macrophage populations are required 
to examine macrophage diversity in Ag processing and presentation. 
B-cells 
Resting small B-cells poorly present protein Ags due to their inefficient Ag 
uptake by fluid phase pinocytosis (Lassila et al., 1988). The resting B-cells do not 
express sufficient amounts of co-stimulatory molecules such as B7 and CD40, 
and thus, cannot activate na'ive T -cells albeit the FcyR- and mig- mediated Ag 
internalization may be effective in these B-cells (Noelle and Snow, 1990). 
Furthermore, the lack of co-stimulation following T-B conjugation may cause T-
cell anergy and induce tolerance (Schwartz, 1997). However, it has been 
suggested that activated B-cells efficiently present soluble protein Ags (Vidard et 
al., 1996; Wagle et al., 1998). B-cell activation requires a primary signal delivered 
following engagement of mig with the specific Ag and co-stimulation signals 
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provided by helper T-cells (Healy and Goodnow, 1998). Cross-linking of BcR or 
LPS stimulation could activate resting B-cells without T -cell help. By using 
activated B-cells as APC, Wagle and Vidard demonstrated that activated B-cells 
were effective in pinocytosis and phagocytosis, and also efficient in presentation 
of sufficient peptide to activate specific T -cells, although the efficiency and 
selective presentation were different from that of macrophages (Vidard et al., 
1996; Wagle et al., 1998). 
Ag presentation in Ag-specific B-cells are different from that in resting B-cells. 
First, mig-mediated Ag internalization is 100-1000-fold more efficient than non-
specific Ag uptake by resting B-cells (Song et al., 1995). Second, binding of a 
protein Ag to mig may partially enhance expression of costimulatory molecules 
forT-cell activation (Grewal and Flavelt 1996; Noelle and Snow, 1991). Third, 
binding of Ag to its specific Ab may alter the Ag processing in B-cells (Simitsek 
et al., 1995). These unique Ag processing properties may characterize Ag-specific 
B-cells as the key APC for the regulation of an immune response. Due to the 
difficulty of isolating large number of na'ive Ag-specific B-cell clones, the study of 
Ag processing pathways in Ag-specific B-cells is hampered. 
1.3.2. Circulating T -cell repertoire is auto-reactive 
1.3.2.1. Positive and negative selection in thymus 
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Positive and negative selection is an active process that occurs in the thymus 
following conjugation of double positive (DP) thymocytes with the thymic APC 
or epithelial cells. Positive selection rescues MHC-restricted thymocytes. 
Negative selection deletes auto-reactive thymocytes (Marrack and Kappler, 
1997). It is the avidity and affinity between the thymocytes and the thymic APC 
that determines the fate of the immature thymocytes, either positively selected to 
become mature and enter the peripheral blood or negatively depleted by 
apoptosis (Sebzda et al., 1999). 
Currently, there are two models explaining thymic selection. The affinity model 
focuses on the single TcR-peptide-MHC interaction. Different peptide-MHC 
complexes may provide different affinities to the TcR. The avidity model focuses 
on the T-cell-APC conjugate, in which the amount of TcR-peptide-MHC 
complexes formed between the T-cell and APC may be crucial for the T-cell's 
fate. These two models agree at the molecular level in that a strong TcR signal 
generated by a high affinity TcR-peptide-MHC interaction and/ or many TcR-
peptide-MHC ligations may result in a negative selection, and a weak TcR 
signaling generated by a low affinity TcR-peptide-MHC interaction and/or few 
TcR-peptide-MHC ligations may lead to a positive selection (Ashton-Rickardt 
and Tonegawa, 1994; Jameson et al., 1995). Without TcR engagement by peptide-
MHC complexes, there will be no signal produced for T -cell survival, and thus, 
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the immature T-cells will die through a default pathway, programmed cell death 
(PCD) (Alam et al., 1996; Sebzda et al., 1994). 
1.3.2.2. Thymic selection mediated by self Ags 
The mature T -cell repertoire is normally shaped by self-protein molecules 
presented on thymic APC. Previously, it was suggested that common auto-Ags 
such as myelin basic protein (MBP), proteolipid protein (PLP), Tg and 
acetylcholine receptor (AchR) etc occurred only outside the thymus, but recent 
evidence supports the view that most of these auto-Ags are expressed 
intrathymically (Anderson et al., 2000; Grima et al., 1992; Heath et al., 1996; 
Pribyl et al., 1993; Wheatley et al., 1992). The medullary epithelium is considered 
to be highly heterogeneous consisting of a diverse array of different cell lineages 
and able to generate a mosaic of peripheral self-proteins (Farr and Rudensky, 
1998). Alternatively, peripheral APC may internalize tissue-specific Ags and then 
circulate into the thymus to mediate central tolerance. In this way, tolerance to 
peripheral, tissue-specific self-proteins is maintained. Since the mature T -cell 
repertoire is being selected by weak interactions between thymocytes and the 
thymic-expressing self-proteins, the mature T-cells may retain their weak 
reactivity to the selecting molecules in the periphery. In fact, it is well accepted 
that the circulating T-cell repertoire is auto-reactive (Gammon et al., 1991; 
Lanzavecchia, 1997). It is possible that this weak interaction that mediates thymic 
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positive selection may also provide signals to maintain the homeostasis of the 
peripheral mature T-cell repertoire (Sant'Angelo et al., 1997). 
1.3.2.3. A novel view of cryptic epitopes of self Ags and thymic selection 
For a given self-protein expressed in the thymus, some T-cell epitopes may 
present dominantly on thymic APC and others may remain cryptic (Fig. 1.1). The 
dominant peptides, expressed at a high density on thymic APC, will provide a 
high avidity to the APC-T-cell conjugates, and may negatively select the T-cells 
with a high affinity to the peptide-MHC complexes, and positively select those T-
cells with a low affinity to the peptide-MHC complexes. In contrast, the 
subdominant and/ or cryptic peptides, expressed at a low density on the thymic 
APC, will provide low avidity to the APC-T-cell conjugates, and thus, may 
positively select high affinity T-cells reactive to the peptide-MHC complexes. 
Those T -cells binding to the subdominant and cryptic epitopes with very low 
affinity are eliminated due to insufficient surviving signals generated from TcR-
peptide-MHC interaction (Miller and Basten, 1996){Fairchild & Wraith 1992 
#1680} (Cibotti et al., 1992). The model shown in Fig. 1.2 demonstrates how auto-
reactive T -cells specific to sub dominant and cryptic pep tides escape from the 
thymic selection. 
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Dominant 
Theoretical number ofT-cell 
epitopes in an Ag 
Cryptic 
Fig. 1.1. Epitope crypticity in Ag presentation. For a given protein Ag 
that may contain many potential MHC binding peptides, a hierarchy of 
peptides may be presented on the APC surface, bound to the MHC 
molecules, following processing of the protein Ag in a single APC cell. 
Som<;~ of the peptides may be presented in high amounts on the APC 
surface and denoted as dominant peptides, and others are presented in 
low amount and denoted as cryptic peptides. Due to the competitive 
mechanism of the peptide presentation and the influences of the factors 
affecting Ag processing, only a few peptides present as dominant 
peptides; most of peptides act as subdominant or cryptic ones. 
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Cryptic epitopes and thymic selection 
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Fig.1.2. Cryptic epitopes and thymic selection. Two parameters determine 
the fate of an immature thymocyte. One is the affinity (Y -axis) between 
the TcR and its reactive peptide-MHC complex. The other is the avidity 
(X -axis) between the T -cell and the peptide-presenting APC, which is 
mostly dominated by the number of the interacting TcR-peptide-MHC 
complexes. These two parameters control the strength of interaction 
between the T-cell and the APC. A minimal threshold (solid curve) of 
interacting strength is required for delivering a signal for T -cell survival. 
When the strength is too high and over a certain threshold (dash curve), 
the apoptotic signals are activated and cause cell death. The first 
phenomenon leads to positive selection and the second leads to negative 
selection. The gap between the two thresholds creates the chance for T-
cell survival. The concentration of a single peptide present on the APC not 
only determines the avidity ofT-cell-APC interaction, but also determines 
the dominance or crypticity of the peptide. A dominant peptide provides a 
high avidity for APC-T -cell conjugates, and a cryptic peptide gives a low 
avidity. Since the dominant peptides with high avidity may easily activate 
the apoptotic signals, T -cells reactive to these peptides are mostly 
negatively selected. Also, because the absolutely cryptic peptides cannot 
provide surviving signals toT-cells, they do not participate in the T-cell 
selection. Thus, the T -cell repertoire is established following interaction of 
TcRs with the dominant, subdominant or some cryptic peptides of the 
thymic-expressing proteins. 
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1.3.3. Generation of cryptic T -cell epitopes by receptor-mediated Ag internalization 
and processing 
Unlike particulate Ags, whose uptake in APC occurs through phagocytosis, 
soluble Ags are mostly captured through surface receptors expressed on the 
APC, especially in B-cells, in which pinocytosis and phagocytosis occurs at a very 
low rate (Lanzavecchia, 1990). The most significant receptors are the Fe receptors 
(FeR) on macrophages or dendritic cells and the membrane Ig (mig) on B-cells. 
Other surface receptors such as complement receptors and mannose receptor 
may play secondary role in Ag internalization by APC (Lanzavecchia, 1990). The 
receptor-mediated Ag internalization may have two different effects on Ag 
processing and presentation. First, the receptors can greatly enhance the amount 
of Ag internalized by APC due to its efficient Ag capture. Second, binding of Ag 
to the surface receptors may affect the processing of the Ag to generate different 
T-cell epitopes by APC (Watts, 1997). 
1.3.3.1. Enhancing Ag uptake via surface receptors on APC 
FcyR 
IgG-binding FeR consist of three families, FcyRI, FcyRII and FcyRIII. The FcyRI 
family has the highest binding affinity for IgG, and is expressed mostly on 
monocytes and macrophages (Ravetch and Kinet, 1991). The FcyRII family is the 
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most widely distributed FeR, including FeR on NK cells, neutrophils, platelets, 
monocytes, macrophages and B-cells. The FcyRII family consists of three 
subtypes, FcyRIIA, FcyRIIB and FcyRIIC. Two isoforms of FcyRIIB have been 
reported with different distributions. FcyRIIB1 is the dominant FeR on 
macrophages, and FcyRIIB2 is expressed only on B-cells (Amigorena et al., 1992). 
Both isoforms have a higher affinity for IgG1 and IgG2b than IgG2a. FcyRIIA and 
FcyRIIC are expressed on monocytes and neutrophils, but not on lymphocytes 
and NK cells. FcyRIIB is the only FcyR restricted to lymphocytes (Ravetch and 
Kinet, 1991). The FcyRIII family is expressed on macrophages. Unlike FcyR on 
NK cells, which mediates ADCC, FcyRIII on macrophages may be the binding 
ligand for immune complexes that trigger macrophage activation (Ravetch and 
Kinet, 1991). Enhanced Ag uptake mediated by FcyR has been observed both in 
macrophages and B-cells (Manca et al., 1988; Perkins and Chain, 1986; 
Stockinger, 1992). Complexing Ag with Ab can increase the capture of Ag-Ab 
conjugates by APC through surface FcyR, and enhance peptide presentation 
(Berget al., 1997). This increased peptide presentation is inhibited in the presence 
of anti-FcyR mAb. 
FcyR-mediated increased Ag uptake may not always boost the immune response 
against the Ag. First, although increased Ag uptake may occur in resting B-cells 
through FcyR-mediated Ag internalization, the inactive B-cells cannot activate 
naive T-cells without engagement of mig and may induce T-cell anergy due to 
the lack of co-stimulation (Schwartz, 1997). Second, in the situation of FcyR-
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mediated Ag internalization by Ag-specific B-cells, the Ag-Ab conjugates can 
cross-link mig with FcyR and initiate a negative signal to inhibit B-cell activation 
(Minskoff et al., 1998). The negative signal delivered by FcyR may enable B-cells 
to regulate the immune response when large amounts of immune complexes (IC) 
are formed. 
mig 
Resting B-cells are not efficient in pinocytosis and have 10-50-fold lower capacity 
to internalize Ags than that of macrophages (Chesnut et al., 1982a; Chesnut et al., 
1982b). Therefore, processing and presentation of non-specific Ags in these B-
cells is very inefficient. However, both na"ive and memory B-cells express certain 
amount of mig, and uptake of specific Ags is 100-1000x more efficient than that 
of non-specific Ags (Lanzavecchia, 1985). Targeting Ag uptake to B-cells was 
achieved by conjugating Ag with Abs specific for B-cell surface molecules such 
as mig, FcyR and MHC class II molecules (Ozaki and Berzofsky, 1987). Snider et 
al. addressed Ag internalization of B-cells by conjugating Ag to non-specific Abs, 
and found that targeting Ag to MHC and mig, but not the B220 B-cell surface 
marker, significantly increased Ag uptake and peptide presentation (Snider and 
Segal, 1987; Snider and Segal, 1989). Interestingly, increased Ag uptake and 
presentation following conjugation of Ag with FcyRII-specific mAb was observed 
only in B-celllymphomas but not in normal B-cells in these studies. 
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1.3.3.2. Altered Ag processing following conjugation of Ag with membrane 
receptors 
It is clear that receptor-mediated Ag uptake and presentation allows T -cells to 
recognize Ags at very low concentrations partially due to the efficient Ag 
internalization (Lanzavecchia, 1990). However, some studies have shown that 
increased Ag internalization cannot exclusively account for the enhanced Ag 
presentation (West et al., 1994), suggesting that some post-endocytic regulatory 
events may be involved in the increased Ag presentation (Amigorena and 
Bonnerot, 1998). Two mechanisms have been proposed to explain how the post-
endocytic events regulate Ag presentation. One is that the surface receptors on 
APC can target Ag into different endocytic compartments depending on the 
signals provided by the receptors (Amigorena and Bonnerot, 1998). The other 
mechanism is that Ag processing can be altered by ligands bound to the Ag, such 
as FcyR and Ig. The ligands bound to Ags can selectively enhance or suppress 
presentation of some epitopes within the Ag, depending on the binding area of 
the ligands within the Ag molecules (Watts, 1997). 
In studies of the role of FeR in Ag processing, Amigorena et al. demonstrated 
that two FeR, FcyRIIb2 and FcyRIII, could differentially mediate Ag processing 
within a B-celllymphoma (Amigorena et al., 1998). The B-cells were transfected 
with different FcRs, and the Ags, HEL and A receptor, were conjugated with their 
specific mAbs. Following processing of the ICs within the B-cells, 4 out of 11 
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epitopes tested were efficiently presented when the B-cells were transfected with 
both FcyRITh2 and FcyRIII, but the other 7 epitopes were presented only when the 
B-cells expressed FcyRIII, but not FcyRIIb2. Therefore, the nature of the receptor 
that mediates Ag internalization determines the selection of epitopes presented 
on APC. Watts et al. addressed the role of mig in Ag processing by using EBV-
transformed B-cells with different specificity to tetanus toxin (TT) as APC 
(Simitsek et al., 1995; Watts and Lanzavecchia, 1993). They found that one of the 
Ig-expressing B-cells could simultaneously enhance the presentation of one 
epitope by more than 10-fold while strongly suppress the presentation of another 
epitope of TT. However, another IT-specific B-cell could present both T-cell 
epitopes efficiently. These studies strongly suggest that Ag processing in B-cells 
can be modulated with Ag-bound Ig, and presentation of T -cell epitopes can be 
either boosted or suppressed depending on the fine specificity of the Abs bound 
to the Ag molecules. Both studies were performed using B-cells as APC. It would 
be interesting to examine whether other APC such as macrophages and DC 
possess similar properties to selectively present T-cell epitopes following Ag 
internalization through their surface receptors such as FcyR. Manca et al. have 
shown that Abs facilitate Ag internalization and presentation in macrophages 
(Manca et al., 1991), but whether Abs can post-endocytically alter Ag processing 
in these macrophages is unclear. 
1.3.4. Ag modulation enhances generation of cryptic T -cell epitopes 
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1.3.4.1. Modifications within the T -cell determinants 
The immune system is programmed to attack foreign pathogens while it remains 
tolerant to self-proteins. However, post-translational modification of a self-Ag 
may cause abrogation of the established tolerance to this Ag and thus, trigger 
autoimmune disease (Mamula et al., 1999). The modification may occur inside or 
outside the dominant T-cell epitopes of the self-protein. As described above, a Tg 
peptide containing an iodine-modified structure, T4, has been identified as a 
pathogenic T-cell epitope, and also Tg-specific T-cell clones only recognize the 
iodine-modified Tg and T4(2553) peptide (Champion et al., 1991; Dawe et al., 
1996). Similarly, Skipper et al. identified a CTL clone that only recognized a 
modified tyrosinase produced from a melanoma cell (Skipper et al., 1996). The 
tyrosinase peptide recognized by the CTL clone contained a post-translational 
conversion of asparagine to aspartic acid, and the conversion had no impact on 
the capacity of the peptide to bind to the class I MHC molecule, suggesting that 
antigenic peptides can be derived from proteins following post-translational 
modification. Also, Meadows et al. found that two CTL clones specific for a H-Y 
Ag peptide only recognized the modified form of the peptide, which had an 
additional cysteine residue covalently bound to the cysteine residue at the 
seventh a.a. position of the peptide (Meadows et al., 1997). The study supported 
the importance of the post-translational modification in the generation of 
antigenic determinants. 
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Post-translational modifications of Ags such as iodination, glycosylation and 
cystylation have important implications in autoimmunity, since they may 
commonly occur to some self-Ags. For a given self-Ag, T-cells reactive to the 
dominant unmodified epitopes within the Ag may be eliminated due to the 
thymic selection and peripheral tolerance, butT-cells recognizing the modified 
APL (altered peptide ligand) of the dominant epitopes may escape the thymic 
selection and tolerance induction. It is unknown what ligands in the thymus 
mediate positive selection of those T -cells specific for the modified APL. 
1.3.4.2. Modifications outside the T-cell determinants 
Ag modifications may also occur outside the T -cell determinants within a protein 
Ag. Such modifications can affect Ag presentation by altering the Ag processing 
in APC, and thus, generate cryptic peptides. Wood et al. showed that some 
cryptic T -cell epitopes of an influenza A nucleoprotein could be generated after 
processing of the N-linked-glycosylated nucleoprotein, but not the non-
glycosylated nucleoprotein (Wood and Elliott, 1998). By monitoring the Ag 
presentation of gliadin, an auto-Ag in celiac disease, Molberg et al. demonstrated 
that an enzyme, transglutaminase, that catalyses cross-linking between Glu and 
Lys residues within the gliadin molecules could selectively modify peptide 
presentation (Molberg et al., 1998). They also found that pathogenic T-cells 
specific for gliadin reacted strongly to the modified gliadin, suggesting that 
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transglutaminase-mediated modification of gliadin might be an important 
trigger for development of autoimmune celiac disease. Griem et al. generated a 
T-cell clone specific for a cryptic epitope of RNase protein by immunization of 
animals with metal (Au) ion-modified RNase. The T -cell clone did not recognize 
native RNase but was reactive to the ion-modified RNase, suggesting that the 
modification by metal ion was critical for processing RNase to generate the 
cryptic peptide (Griem and Gleichmann, 1995; Griem et al., 1996). In addition, 
they found that the T-cell clone also recognized the denatured unmodified 
RNase, indicating that metal ions may not be required for TcR recognition. 
1.3.5. Factors that enhance generation of cryptic epitopes and trigger 
autoimmune diseases 
(summary of autoimmune triggers) 
The T-cell activation threshold is determined by the affinity between TcR and 
peptide-MHC, the avidity between the T-cell and the APC (numbers of TcR-
peptide-MHC complexes formed on a single T-cell-APC conjugate) and 
expression of co-stimulatory molecules (Healy and Goodnow, 1998). Factors 
affecting activation of auto-reactive T-cells can be divided into two categories. 
The factors that can enhance Ag internalization and alter Ag processing to 
generate cryptic epitopes in APC form the first category (Fig. 1.3, left). The other 
category (Fig. 1.3, right) includes factors, such as increased expression of TcR and 
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costimulatory molecules, that can lower the activation threshold of the auto-
reactive T-cells and cause recognition of those cryptic epitopes that are 
marginally presented on normal non-activated APC. Either increased 
presentation of cryptic epitopes on APC or lowered activation threshold of auto-
reactive T-cells may result in activation of auto-reactive T-cells specific for the 
cryptic epitopes. Synergistic effects between the APC and auto-reactive T-cells 
may occur in vivo to initiate autoimmune disease. 
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Fig. 1.3. Abrogation ofT -cell tolerance against cryptic self epitopes. On 
the left, the diagram shows factors that influence APC function. 
Inflammation may commonly induce an autoimmune response. In an 
inflammatory environment, chemokines recruit APC and lymphocytes, 
and the local accumulation of cytokines may activate the APC to increase 
expression ofMHC, costimulatory molecules and, more importantly, FeR, 
which, in turn, can facilitate Ag internalization by APC. Activation of 
APC at the inflammatory site may result in enhanced Ag internalization 
and presentation and subsequent generation of some cryptic epitopes. In 
addition, Ag modification can affect processing of auto-Ags in APC and 
result in a differential presentation ofT -cell epitopes. Ligands binding to 
auto-Ags may also affect Ag processing and selectively enhance or 
suppress generation of some cryptic epitopes. On the right, the diagram 
shows factors that can decrease the activation threshold of auto-reactive T-
cells. Such factors include molecular mimicry, which activates resting 
auto-reactive T -cells through bacterial and viral infections 
(microinfections), immunization with self-proteins, non-specific T-cell 
activation by super-Ags and bystander activation ofT-cells. Resting 
autoreactive T-cells cannot recognize cryptic peptides presented on normal 
APC in low amounts to become effector T-cells. Following activation, the 
T -cells express increased amounts of co-stimulatory molecules and high 
avidity TcR and circulate to the target tissues to initiate autoimmune 
responses. 
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1.4. Research rationale and hypotheses 
Most of the identified pathogenic Tg peptides have been characterized as non-
dominant epitopes due to their insufficient presentation following processing of 
Tg in vivo and in vitro. Table 1.2 demonstrates that immunization with Tg 
cannot activate T -cells recognizing T4(2553), Tg2495 and Tg2694 pep tides, and 
peptide-primed LNC cannot be stimulated by Tg in a recall proliferation assay. 
However, these non-dominant peptides, emulsified in adjuvant, efficiently 
activate specific T-cells and induce EAT in mice. The described work in this 
thesis aims to identify conditions or factors that promote the generation of 
cryptic T-cell epitopes during processing of Tg. 
Table 1.2. Cryptic T-cell epitopes of Tg 
In vitro LNC proliferation against 
In vivo 
immunization Tg 2495-2511 2549-2560 2695-2713 
Tg +++ + 
2495-2511 +++ 
2549-2560 +++ 
2695-2713 +++ 
Antigen-bound Abs may modulate antigen processing and facilitate generation 
of subdorninant or cryptic T -cell epitopes (Lanzavecchia 1993). A large 
percentage of patients with HT, and almost invariably all animals developing 
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EAT have circulating Tg-specific Abs (Weetman, 1994). It remains unclear, if 
such Abs play a role in promoting the generation of cryptic pathogenic Tg 
epitopes. We hypothesized that processing of Tg-Ab complexes generates 
pathogenic but non-dominant T-cell epitopes. The results of this work are 
presented in chapter 3. 
During the course of our experiments, we discovered that a Tg-specific mAb 
(55H8) was T4-specific and recognized an epitope containing iodine atoms. Also 
a T -cell hybridoma (3.47) was identified to recognize an iodine-modified epitope 
within the Tg peptide T4(2553). Based on these observations, we raised the 
question whether the mAb 55H8 might recognize the bulky iodine atoms of 
T4(2553) after the peptide was docked within the MHC molecule, leading to a 
blockade of the peptide-MHC recognition by the TCR of the 3.47 clone. This 
would provide evidence for an immunoregulatory role of thyroxine-specific 
mAbs on the development of AT. The results of this work are presented in 
chapter 4. 
Post-translational modification of Ag can trigger autoimmune responses to self-
proteins (recently reviewed by Doyle 2001). Metabolic iodination of Tg occurs 
after its translation and storage in the thyroid gland, and it has been suggested 
that iodine enrichment of Tg increases its immunogenicity, precipitating an 
autoimmune response (Rose 1997). We hypothesized that processing of highly 
iodinated Tg, but not normal Tg, may lead to generation of cryptic pathogenic 
determinants. The results of this work are presented in chapter 5. 
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CHAPTER2 
MATERIALS AND METHODS 
2.1. Antigens 
2.1.1. Purification of thyroglobulin (Tg) 
Tg purification was performed following a standard protocol as described before 
(Chronopoulou 1992). In details, frozen thyroid glands from outbred ICR mice 
(Bioproducts for Science, Indianapolis, IN) were homogenized in PBS buffer (pH 
7.2). The supernatant was centrifuged three times at 16,000g x 10 min. Separation 
of Tg was performed by passing the clear supernatant through a Sepharose CL-
4B column (2.5 x 55 em) (Pharmacia, Quebec, Canada). As shown in Fig. 2.1, the 
fractions of peak II representing Tg were pooled, concentrated to 3-5 mg /ml PBS 
with ultra-filtration cells (Amicon, Danvers, MA), and followed by filter-
sterilization. The purified Tg was stored at -2ooc until use. Tg concentrations 
were also expressed as molarity of the monomeric form (330 kD, 1 mg/ml = 3.03 
JLM). 
2.1.2. Peptides and synthesis 
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Thyroid hormone-containing Tg peptides were kind gifts from Dr. Y-C. Kong 
(Wayne State Univ., Detroit, MI). The preparation of F-moc-L-thyronine, F-moc-
L-thyroxine, and the synthesis of TO-or T4-containing peptides was previously 
described (Kong et al., 1995). The composition and relative purity of each peptide 
were verified by time-of-flight mass analysis on a Bio-Ion 20 Analyzer (Applied 
Biosystems Inc., Foster City, CA), and/ or by amino acid analysis of peptide 
hydrolysates (6N HCl, 22 h, 121 °C) on a Beckman 6300 amino acid analyzer 
(Beckman, Fullerton, CA). Purity was determined to be >90%. Non-hormone 
containing Tg peptides and mouse lysozyme peptide were synthesized at more 
than 80% purity on an Applied Biosystems (Foster city, CA) 430 A synthesizer at 
the Alberta Peptide Institute. Peptide purity was determined by HPLC and mass 
spectroscopic analysis. Peptides were blocked with an acetyl group at the N-
terminal end, and an amide group at the C-terminal end. The sequences of the 
pep tides used in the studies are listed in Table 2.1. 
2.2. Antibodies 
2.2.1. mAbs and purification 
Tg specific mAbs 5D2, 3B3, 2A4, and 3C4 were produced from hybridomas 
formed by fusing spleen cells from BALBI c mice immunized with human Tg 
with mouse myeloma NSI/I.Ag 4.1 cells. The binding sp ecificities were 
characterized previously (Chan et al., 1987). They were purified from culture 
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supernatants by affinity chromatography on protein G-Sepharose 4 Fast Flow 
columns (Pharmacia, Baie d'Urfe, Quebec, Canada). The purified mAbs were 
dialyzed in PBS, concentrated to 1-2 mg/mC filter-sterilized and stored in PBS at 
-20 oc. Tg-specific mAbs 55H8 and 91A1 were derived from human Tg-
immunized BALBI c splenic cells fused with the mouse myeloma NSO and was 
purified from ascites fluid by affinity chromatography. The purified material was 
concentrated to 1-2 mg/ml in PBS, filter-sterilized and stored in 50% glycerol at-
20 oc until use. Other rnAbs were either directly purchased from companies or 
purified from supernatants of the hybridomas by affinity chromatography on 
protein G-Sepharose 4 Fast Flow columns. Detailed information on all the rnAbs 
that were used in the studies is provided in Table 2.2. 
2.2.2. Isotyping of mAbs 
Isotyping of rnAbs was performed using the IS0-2 kit (Sigma). Briefly, a 96-well 
micro-titer plate was coated with 100 JLl/well of 1 JLg/ ml of testing mAb in PBS 
for 1 hour, followed by washing with PBST buffer. Isotype-specific goat anti-
mouse Igs provided in the kit were diluted 1:1000 in PBS, and 100 JLl of these 
isotype regents was incubated for 30 min in mAb-coated wells. The plate bound 
isotype specific goat Ab was detected by peroxidase-conjugated rabbit anti-goat 
IgG (Sigma A5420) and OPD substrate of peroxidase (Sigma). Development of a 
brown color in the well indicates positive for the isotype regent added. 
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2.2.3. Generation of F(ab)'2 fragment of mAbs 
Fragmentation of 3C4 to F(ab')2 was done using pre-activated papain as 
described (Andrew and Titus, 1997). Briefly, papain was pre-activated by cystine 
in acetate/EDT A buffer for 30 min. Excess cystine was removed by running the 
papain solution through a Sephadex G-25M PD-10 column (Pharmacia, Uppsala, 
Sweden). Digestion was performed by mixing 4 mg of 3C4 mAb dialyzed in 
acetate/EDTA buffer with 0.2 mg pre-activated papain enzyme (Ab : papain= 
20:1) in total3.5 ml of acetate/EDT A buffer. After incubation at 37 oc for 7h, the 
reaction was stopped by adding 0.3 ml of 0.3 M iodoacetamide. The Fe fraction of 
3C4 and/ or undigested intact 3C4 was removed by protein-G column. The 
concentration of F(ab')2 preparation of 3C4 mAb was determined by using 
Protein Assay Kit (Sigma Diagnostics). The purity of the F(ab')2 preparation was 
confirmed by SDS-P AGE and its binding to Tg was verified by ELISA. 
2.2.4. RIA 
Potential cross reactivity for pa1rs of Tg-specific mAbs was assessed by 
competitive RIA. Briefly, wells of microtiter PVC plates (Dynatech, Chantilly, 
VA) were coated by one of the Tg-specific mAbs (3 fA,g/well) and blocked with 
0.3% BSA. Competitive inhibition was performed in the first Tg-specific mAb 
coated wells by simultaneously adding serial dilutions of a second Tg-specific 
mAb and fixed amount of 125r-labeled Tg (240,000 cpm/ fA,g /well). After washing 
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and drying, Tg bound on the first mAb-coated wells was assessed by gamma 
counting (Wallac). 
2.3. Cells and tissue culture 
2.3.1. Cells and culture media 
The APC cell line TA3, produced by fusion of B cells from CAF1 mice with the 
M12.4.1 BALB/c B lymphoma (Allen et al., 1985), was kindly provided by L. 
Glimcher (Harvard Medical School) and was courteously provided by T. Watts 
(Univ. of Toronto). TA3 are known to express Akld, Ek/d, KdDd, IgG K-chain 
and FcyR molecules while they are negative for IgM, IgD, Thy-1.2 and Kk (Snider 
and Segal, 1987). The APC cell line LS 102.9 is a B-cell hybridoma (H-2Ad,s and 
H-2Ed) obtained from ATCC (Rockville, MD). T-cell hybridomas 5E8 and 6E10 
were generated by Dr. V. Rao, a previous student in the lab. The hybrid T-cells 
are IL-2 secreting, H-25 -restricted and Tg-peptide specific for TgP1 and TgP2 
respectively (Rao and Carayanniotis, 1997). 
Cell culture and assays were performed in DMEM medium (Gibco, Burlington, 
ON, Canada) supplemented with 10% fetal bovine serum (FBS) (Bioproducts for 
Science, Indianapolis, IN, USA}, 10 mM HEPES buffer, 2 mM L-glutamine, 100 
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U /ml penicillin, 100 ~-tg/ml streptomycin (all from Gibco) and 5 x 10-S M 2-ME 
(Sigma Chemical Co., St. Louis, MO, USA). 
2.3.2. Culturing CTLL-2 cells 
The IL-2-dependent CTLL-2line (Gillis and Smith, 1977) was purchased from the 
American Type Culture Collection (Rockville, MD, USA), and maintained in the 
above complete DMEM media supplied with 10% FBS and 10% of IL-2 
containing supernatant. The IL-2 containing supernatant was prepared by 
stimulating splenocytes (5x106 cells/ml) of female outbred rats with 5 ~-tg/ml of 
concanavalin A for 48h. The supernatant was centrifuged, filter-sterilized and 
stored at -70 oc until use. 
2.3.3. Generation peptide-specific T-cell hybridoma 
The T -cell hybridoma 3.47 clone was generated by Ms . K. Carayanniotis 
following a modified method of Perkins and co-workers (Perkins et al., 1991). 
Briefly, LNC from CBA/J mice, immunized with mouse Tg, w ere further 
stimulated in vitro with the same antigen and fused with an TcRa-(3- variant of 
the BW5147 thymoma (lymphocytes : tumor cells = 1:3) (White et al., 1989) (a 
kind gift of P. Marrack) using polyethylene glycol1500 (Boehringer Mannheim, 
Indianapolis, IN) . Selection of hybrid cells w ere p erform ed by gradually 
transferring the cells from Hypoxanthine-Aminopterin-Thymidine (HAT) to 
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Hypoxanthine-Aminopterin (Sigma) and finally to complete DMEM media. 
Peptide -specific hybridoma cells were cloned by limiting dilution at 0.3% 
cell/well in the presence of syngeneic RBC as filler cells. Specificity and 
sensitivity of cloned T-cell hybridoma cells were further tested by T-cell 
activation assay using TA3 cell line as APC. The 3.47 clone was further 
characterized to be CD4+, TcR+ and 1-Ak-restricted. They are able to release IL-2 
after stimulation with T4(2553) peptide in the presence of TA3 APC. 
The 8F9 T-cell hybrid clone was produced by fusing lymphocytes, which were 
collected from TgPl-immunized BlO.BR mice and further stimulated in vitro 
with the same peptide, with the BW5147 a-13- thymoma cells. Selecting, screening 
and cloning were performed similarly as above for generation of the 3.47 clone. 
The 8F9 T-cell hybridoma is CD4+, TcR+ and I-Ek-restricted. They release IL-2 
after stimulation with TgPl peptide in the presence of TA3 APC. 
2.3.4. Activation assay ofT -cell hybridomas 
Tg peptide-specific T-cell activation was performed by mixing 105 of both T-cell 
hybridoma and APC in total 200 JLl of media in triplicate wells of 96-well flat 
bottom culture plate. Following 24h culture, 100 t-~-1 of supernatant was removed 
and stored at -20 oc for assessment of IL-2, as measured by the proliferation of 
the CTLL line and expressed as 3H-thymidine incorporation during the last 6h of 
total 24h culture. 
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2.4. Antigen modulation 
2.4.1. Formation of Tg-mAb immune complexes (ICs) 
Tg-mAb ICs were formed by incubation of equal molar amount of Tg and mAbs 
for at least 1 hat room temperature. For preparing triplicate ICs mAb-Tg-mAb, 
equal molar amounts of each component were mixed and incubated for at least 1 
h at room temperature. The concentration of the ICs was expressed as molar 
concentration of Tg in the mixture. 
2.4.2. Iodination of Tg by non-radioactive iodine 
Iodination was performed in 12 x 75 mm glass tubes coated with 10 p,g of 
IODOGEN (Pierce, Rockford, Illinois). Tg (100 p,l of 1 mg/ml per tube) was 
incubated with 0.25 mM Nai in the IODOGEN-coated tubes at room temperature 
for 5-30 min. Free iodine was separated from Tg by dialysis in PBS. Iodinated Tg 
(1-Tg) was concentrated to 3-5 mg/ml by filtration with Centricon 30 micro-
concentrator (Ami con, Danvers, MA). The filter-sterilized I-Tg preparation was 
stored at -20 °C until u se. All the I-Tg used in this study was iodinated for 20 
min under the same condition and contained iodine ranging from 60 to 75 atoms 
per Tg molecule. 
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2.4.3. Determination of iodine content of Tg 
Determination of iodine in Tg samples (16 J.tg Tg in 0.4 mlSO% glacial acetic acid) 
was performed as previously described (Palumbo et al., 1982; Saboori et al., 
1993). Sodium arsenite was dissolved in 0.15 N sulfuric acid to give a final 
concentration of 10 mM. Ceric sulfate and ammonium sulfate were dissolved in 
2.8 N sulfuric acid resulting in final concentrations of 50 and 150 mM 
respectively. Bromine was dissolved in double-distilled water as 100 mM stock 
and diluted to a final concentration of 1 mM bromine prior to the assay. Thyroxin 
(T4) was dissolved in 99 vol of absolute methanol and 1 vol of 30% ammonium 
hydroxide up to a final concentration of 120 J.tM. For constructing the standard 
curve 0.4 ml of serial dilutions of T4 in 50% glacial acetic acid starting at 3840 
pmol iodine/ 400J.tl (1 M T4 equals 4 M iodine) was mixed with 0.16 ml of 
concentrated H2S04 in 3 ml cuvettes and incubated for 10 minutes at room 
temperature. Then, 0.08 ml of 1 mM bromine solution was added and, 15 
minutes later, 0.08 ml of eerie ammonium sulfate solution was mixed. Reduction 
of absorbance at 410 nm over 60 seconds was monitored immediately upon the 
addition of 0.8 ml of 10mM NaAs02 into the reaction solution. Iodine content of 
Tg was expressed as a monomeric Tg molecule. 
2.5. Ag processing and presentation 
2.5.1. Preparation of APC populations 
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Splenic B-cells: 
Splenic B-cells were enriched by complement-mediated cytolytic elimination of 
T -cells and accessory cells following a protocol described in Current Protocols in 
Immunology (Hathcock, 1997). Briefly, RBC lysed (using hypotonic NH4CL.Tris 
buffer) splenocyte suspensions (107 cells/ml) were incubated together with 20 
JLg/ml of each mAb: TIB 107 (anti-thy1.2), TIB128 (anti-Mac-1) and TIB227 (anti-
DC) for 30 min at 37oc, followed by washing with DMEM medium to remove 
unbound mAbs. The cytolytic depletion of T -cells and accessory cells was 
performed by incubating the mAb-coated cells (107 /ml) in 1:12 dilution of low 
toxic rabbit serum complement (Serotec, Oxford, UK) for 30 min at 370C. 
Surviving cells, mostly B-cells, were isolated with Ficoll-Paque (Pharmacia, 
Uppsala. Sweden). 
Splenic macrophages: 
Splenic macrophages were enriched by plastic adherence following a standard 
protocol (Guery and Adorini, 1995). Briefly, the RBC-depleted splenocytes 
suspended in DMEM medium (107 cells/ml) were incubated in plastic culture 
petri dishes for 90 min at 37°C with 5% C02• Non-adherent cells were discarded 
and the dishes were gently rinsed with medium. The dishes with adherent cells 
were subsequently replaced with complete media and incubated at 370C with 
10% C02 • After 18h culture, the released non-adherent cells mostly DC were 
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discarded, and adherent cells mostly macrophages were detached with 0.25% 
trypsin (Gibco) and used for continue study. 
Peritoneal macrophages: 
Peritoneal macrophages used for this study were thioglycollate stimulated 
activated macrophages. The mice were injected i.p. with 2.5 ml of 3% 
thioglycollate solution per mouse. The peritoneal macrophages were harvested 4 
days after stimulation. 
Dendritic cells: 
Dendritic cells were generated from bone marrow progenitor cells following 
stimulation with GM-CSF (Inaba et al., 1992). Briefly, the bone marrow was 
prepared from femurs and tibias, and RBC cells in the marrow were lysed with 
NH4CL. Fresh GM-CSF (~ 1000 U /ml) was added every other day to stimulate 
the adherent marrow cells (106 cells/ml/well) in 24-well plate. The proliferating 
immature DC were harvested by gentle dislodge on day 6, and plated on culture 
petri dish (107 cells/ml) in complete media with GM-CSF. The mature DC were 
present after 24h incubation and become non-adherent, after which they were 
collected for further study. 
2.5.2. F ACS analysis of APC 
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FACS analysis was performed by incubation of the enriched APC cells with 
either unlabeled or Biotin-labeled surface maker-specific rnAbs. Following rnAbs 
were used: TIB107 (anti-thy1.2), TIB 163 (anti-lyb.8.2), TIB 227 (anti-DC) (ATCC), 
Biotin-anti-Mac-1, Biotin-anti-B220 (Pharmingen) and Biotin-F4/80 (specific to 
macrophages) (Serotec, UK). FITC-labeled anti-Ig (Sigma) was used to detect 
those unlabeled first rnAbs, and Streptavidin-FITC (Sigma) was used for labeling 
the cells bound with Biotin-mAbs. Flow cytometry was performed with a Becton 
Dickinson F ACScan. 
2.5.3. Treatment of APC 
Fixation of TA3 was performed by suspending 4 x 106 cells I ml in 0.05% 
glutaraldehyde. After 30 sec the reaction was stopped by the addition of an equal 
volume of 0.2 M glycine. 
Mitomycin treatment of splenocytes was performed by incubating RBC-depleted 
cells (5x107 cells/ml) with 50 JLg/ml of mitomycin (Sigma) at 37°C for 15 min. 
The treated cells were washed with DMEM to remove the mytomycin 
completely. 
2.5.4. Ag internalization 
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To monitor uptake of Tg and ICs by TA3 APC, Tg was 1251-labelled using 
Iodogen (Pierce, Rockford, IL) and 1251-Na (DuPont Canada, Mississauga, ON) 
according to the manufacturer's protocol. All free 125J-Na was removed by 
extensive dialysis prior to IC formation and incubation with the APC. The 1251-
labeled Tg (170,000 com/ J,tg) was used to pulse the TA3 APC in the form of 
either ICs with mAbs or alone. The internalized Tg by TA3 cells was measured 
by counting radioactivity of the cell pellet, and expressed as cpm. 
2.6. Evaluation of immune responses against Tg and its peptides 
2.6.1. Animals and immunization 
Female SJL/J, C3H and CBA mice were purchased from the Jackson Laboratories 
(Bar Harbor, ME). Mice at 6-8wk age were immunized s.c. with 100 J,tg of Tg 
peptides, Tg or I-Tg emulsified 1:1 in CFA (with Mycobacterium butyricum, Difco, 
Detroit, Ml). After 9-12 days, the inguinal, brachial and axillary lymph nodes 
were collected for in vitro experiments. For induction of EAT, the mice were 
boosted after 2 wks of the first injection with the same Ag in IFA (Difco). The 
thyroidal lymphocytic infiltration was examined after 2wks of the second 
injection. 
2.6.2. ELISA 
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ELISA was performed by coating microtiter PVC plates (Dynatech, Chantilly, 
VA) with 1 JLg/well of Tg or Tg peptides and using an alkaline phosphatase-
conjugated goat anti-mouse IgG (Sigma, St. Louis, MO) as the second antibody. 
Absorbance at 405 nm was measured using a microplate reader (Vmax, 
Molecular Devices, U.S.A.). 
2.6.3. Cytokine analysis by ELISA 
LNCs from mice immunized with 100 11g of Tg or I-Tg in CFA emulsion for 9-12 
days were stimulated in vitro with Ags in 200 f.Ll microcultures (4-6 x 105 
cells/well). Culture supernatants were collected after 48h and stored at -20 °C. 
IL-2, and IFN-y released from culture LNCs were determined by Sandwich 
ELISA. In brief, 96-well microtiter polyvinyl chloride plates were coated 
overnight with primary capture rnAb (2 tLg/ml) specific for a particular cytokine 
and blocked with 0.5% BSA in PBS. Both cytokine standard and LNC culture 
supernatants were added (100 Ill/well). After overnight incubation at 4°C, the 
secondary biotinylated anti-cytokine mAb {1.0 /lg/ml) was used to detect the 
plate-bound cytokine. Alkaline phosphatase conjugated to Streptavidin and its 
substrate (Sigma) were used for color development. Absorbance at 405 nm was 
measured by using a microplate reader (Vmax, Molecular Devices. Menlo Park, 
CA). The amount of cytokine in each supernatant was extrapolated from the 
standard curve for the particular cytokine. The primary I secondary anti-cytokine 
rnAbs for IL-2, and IFN-y are as follow: IL-2: rat anti-mouse IL-2 (Pharrningen) I 
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Biotin anti-IL-2 (Pharmingen); IL-4: Purified anti-mouse IL-4 from HB188 
hybridoma (ATCC) I Biotin-labeled anti-IL-4 (Pharmingen); IFN-y: Purified anti-
mouse IFN-y mAb from HB170 cell line (ATCC) I Biotin anti-IFN-y 
(Pharmingen). Standard IL-2, IL-4 and IFN-y cytokines were purchased from 
Pharmingen. 
2.6.4. Lymphocyte proliferation assay 
Mice were immunized subcutaneously with Tg or I-Tg (100 11g) in complete 
Freund's adjuvant (CFA) emulsion. After 9-12 days, single cell mixture of 
inguinat brachia and axillary lymph nodes was allowed to proliferate for 96 
hours against the in vitro Ags in 200 111 microcultures (4-6 x 105 cells/well). 
During the last 24 h, 111Ci of 3H-thymidine (Dupont, Canada) was added to each 
culture well in 25 111 of medium. Cell harvesting and counting of the incorporated 
radioactivity was performed. Stimulation index is defined as: cpm in the 
presence of Ag I cpm in the absence of Ag. 
2.6.5. EAT induction and evaluation 
For direct induction of EAT, female 6-8 wk old mice were immunized s.c. with 
100 11g Tg or 1-Tg emulsified 1:1 in CFA (with Mycobacterium butyricum, Difco, 
Detroit, MI). Two weeks later, the mice were boosted with the same Ag in IFA 
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(Difco). EAT was assessed by histological examination of the thyroid glands 4wk 
after the initial immunization. 
For induction of EAT by adoptive transfer, donor mice were similarly 
immunized with Tg or I-Tg in CPA emulsion as direct induction of EAT. After 10 
days, the inguinal, brachia and axillary lymph node cells were collected and 
cultured with 80 J..tg/ml of respective immunization Ags or OVA for 72 h, 
followed by adoptive transfer of 107 living cells i.p. into each of the syngeneic 
recipients. Thyroid glands were removed from the recipients after 14 days of 
adoptive transfer, and fixed in formalin. Thyroid sections were stained with 
hematoxylin and eosin. 
Mononuclear cell infiltration was scored as following: 0.5 = interstitial 
accumulation of cells between two or three follicles; 1 =one or two foci of cells at 
least the size of one folicle; 2 = extensive infiltration, 10- 40% of the total area; 3 
=extensive infiltration, 40 - 80% of the total area; and 4 =extensive infiltration,> 
80% of the total area. 
2.7. TcR V-beta usage of peptide-specific T-cell hybridomas 
2.7.1. RNA isolation 
Total RNA of T -cell hyridoma 3.47 or 8F9 was extracted by using Trizol reagent 
(Gibco) according the manufacturer's instruction. Briefly, 5x106 of cells were 
lysed in 0.5 ml of Trizol reagent. Choloroform (100 J..tl) was added to separate the 
cell lysate. After centrifugation, the upper aqueous phase (-250 J..tl) was collected 
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for RNA precipitation using isopropanol (250 JLl). The isolated RNA was washed 
with ethanol, dried, dissolved in DEPC-treated ddH20 and stored at -70 oc. 
2.7.2. eDNA synthesis 
First strand eDNA synthesis was performed using a eDNA synthesis kit 
(Pharmacia, Sweden) according to the manufacturer's instruction. About 3-5 JLg 
of RNA was used for eDNA synthesis in a total 33 J.d of reaction volume. Not I-
d(T)18 primer was used for synthesizing eDNA only from the mRNA. The 
reaction was run at 37°C for 1 hand terminated by heating at 65 oc for 10 min. 
The eDNA product was stored at -70°C. 
2.7.3. PCR 
PCR reaction was performed in a total100 JLl reaction volume containing: 1x PCR 
buffer, 2 mM MgC12, 0.2 mM of each dNTP, 20 pmoles of each primer (forward 
and antisense primers), about 200 ng of eDNA temple, 2.5 Unit of Taq DNA 
polymerase and DEPC-H20. All reagents were from Gibco, and the primers for 
Vl3 (Forward) and Cl3 (Antisense) (Casanova et al., 1991; Waters et al., 1992) were 
synthesized in the GSD center for Biomaterials (Toronto, ON). Primer sequences 
are shown in Table 2.3. A 30-cycle amplification was conducted in a Perkin-
Elmer DNA Thermal Cycler (Cetus, Norwalk, CT) with 95°C x 1 min, 56°C x 1 
min and 72°C x 1 min. The PCR products were analyzed by running the samples 
on a 1.5% agarose gel containing ethidium bromide (0.5 /Lg/ ml). 
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Fig. 2.1. About 100 thyroid glands were homogenized in 2.5 ml ice 
cold PBS. The homogenate was centrifuged 3x at 16,000g x 10 min 
at 4°C, and the supernatant was loaded on Sepharose column. Tg 
was eluted with PBS. Fractions were collected after sample loading. 
Each fraction or tube contained 2.3 ml eluted solution. Fractions 
from 4 7 to 71 (1 08 to 163 ml of the elution) within peak II were 
collected as Tg preparation. 
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Table 2.1. List of peptide used in the studies 
Peptide name 
T4(5) 
T4(2553) 
T0(2553) 
T4(2567) 
TgP1 (17mer) 
TgP2 (18mer) 
ML (16mer) 
Location in Tg a.a. Sequence 
Hormone-containing Tg peptides (12mers) 
Tg 1-12 NH2-N I F E T4 Q V D A Q P L-NH2 
Tg 2549-2560 NH2-S T D D T4 A S F S R A L-NH2 
Tg 2549-2560 NH2-S T D D TO A S F S R A L-NH2 
Tg 2559-2570 NH2-A LE N AT R D T4 F I I -NH2 
Non-hormone containing Tg peptides 
Tg 2495-2511 Ac-G L I N R A K A V K Q F E E S Q G-NH2 
Tg 2695-2713 Ac-C S F W SKY I Q T L K D A D G A K-NH2 
Mouse lysozyme peptide 
ML 46-61 Ac-N R G D Q S T D Y G I F Q IN S-NH2 
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Table 2.2. List of mAbs used in the studies 
Name Hybridoma Animal Specificity Isotype Source 
5D2 5D2 mouse human Tg Ig02a Dr. Shepherd 
3C4 3C4 mouse human Tg lg01 Dr. Shepherd 
2A4 2A4 mouse human Tg lg01 Dr. Shepherd 
3B3 3B3 mouse human Tg Ig01 Dr. Shepherd 
55H8 55H8 mouse human Tg Ig01 Dr. Lymberi 
91A1 91A1 mouse human Tg Ig01 Dr. Lymberi 
T4 clone 5 HB8500 mouse Thyroxine IgG1 ATCC 
4C5 4C5 mouse TgP1 Our lab 
2.402 HB 197 rat mouseFcyR IgG2b ATCC 
10-3.6.2 TIB 92 mouse mouse 1-Ak IgG2a ATCC 
14-4-4S HB 32 mouse mouse I-Ek IgG2a ATCC 
Ml/70.15.11.5.HL TIB 128 rat mouse Mac-1 IgG2b ATCC 
33D1 TIB 227 rat mouse DC IgG2b ATCC 
30-H12 TIB 107 rat mouse Thy1.2 IgG2a ATCC 
RA3-3Al/6.1 TIB 146 rat mouseB220 IgM ATCC 
Cy34.1.2 TIB 163 mouse mouse Lyb.8.2 IgG1 ATCC 
M2-IC6-4R3 HB64 mouse Influenza A TgG1 ATCC 
H16-L10-4R5 HB65 mouse Influenza A IgG2a ATCC 
R4-6A2 HB 170 rat murine IFN-y IgGl ATCC 
llBll HB 188 rat murine IL-4 IgGl ATCC 
JES6-1A12 rat mouse IL-2 IgG2a PharMingen 
JES6-5H4-Biotin rat mouse IL-2 IgG2b PharMingen 
B VD6-2402-Biotin rat mouse IL-4 lgOl PharMingen 
XMG1.2-Biotin rat mouse IL-4 IgGl PharMingen 
75 
Table 2.3. Oligonucleotides for PCR amplification 
TcR VB primers* Sequences (5' - 3') 
Vf31 CCCAGTCGTTTTATACCTGAATGC 
VB2 TCACTGATACGGAGCTGAGGC 
VB3 CCTTGCAGCCTAGAAATTCAGTCC 
Vf34 GCCTCAAGTCGCTTCCAACCTC 
VB 5.1 GTCCAACAGTTTGATGACTATCAC 
Vf35.2 AAGGTGGAGAGAGACAAAGGATTC 
VB6 CTCTCACTGTGACATCTGCC 
Vf37 TACAGGGTCTCACGGAAGAAGC 
VB 8.1 CATTCTGGAGTTGGCTTCCC 
VB 8.2 CCTCATTCTGGAGTTGGCTACCC 
Vf38.3 ACGCAAGAAGACTTCTTCCTCCTGC 
VB9 TCTCTCTACATTGGCTCTGCAGGC 
Vf310 ATCAAGTCTGTAGAGCCGGAGGAC 
VB 11 GCACTCAACTCTGAAGATCCAGAGC 
Vf312 GAAGATGGTGGGGCTTTCAAGGATC 
VB 13 AGGCCTAAAGGAACTAACTCCAC 
VB 14 ACGACCAATTCATCCTAAGCAC 
VB 15 CCCATCAGTCATCCCAACTTATCC 
VB 16 CACTCTGAAAATCCAACCCAC 
VB17 GAGTAACCCAGACTCCACGA 
Vf318 CAGCCGGCCAAACCTAACATTCTC 
TcR Cf3 primer* Sequences (5' - 3') 
CB CCAGAAGGTAGCAGAGACCC 
*: TcR VB are sense primers. Cf3 is anti-sense primers and 
consensus for CBl and Cf32 sequences. 
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CHAPTER3 
ENHANCING AND SUPPRESSIVE EFFECTS OF ANTIBODIES 
ON PROCESSING OF A PATHOGENIC T-CELL EPITOPES IN 
THYROGLOBULIN 
(The work was published in J. Irnmunol., 162:6987, 1999. This is a modified version) 
Yang Dai"", Karen A. Carayanniotis*, Petros Eliades+, Peggy Lymberi+, Philip 
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*Faculty of Medicine, Memorial University of Newfoundland, St. John's, 
Newfoundland, Canada, +Dept. Immunology, Hellenic Pasteur Institute, Athens, 
Greece,# Dept. Immunobiology, Guy's, King's College and St. Thomas's 
Hospitals' Medical and Dental Schools, London, UK and tDept. Immunology 
and Microbiology, Wayne State University School of Medicine, Detroit, USA 
Yang Dai performed all the experimental work, data analysis and cloned 8F9 T-
cell hybridoma. Karen A. Carayanniotis generated T-cell hybidoma 3.47 and 
prepares culture media and some of experimental reagents. Petros Eliades and 
Peggy Lymberi provided mAb 55H8. Philip Shepherd provided mAbs 5D2, 2A4, 
3C4, 3B3. Yi-chi M. Kong provided T4(2553) peptide. 
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3.1. Abstract 
Thyroglobulin (Tg)- specific antibodies occur commonly in thyroid disease but it 
is not clear to what extent they affect Tg processing and presentation toT cells. 
Here we show that generation of the non dominant pathogenic Tg epitope (2549-
2560), containing thyroxine (T4) at position 2553 (T4(2553)), is augmented by Tg-
specific IgG mAbs which facilitated FeR-mediated internalization of Tg. 
However, other mAbs of the same (lgG1) subclass enhanced Tg uptake by APC, 
but had no effect on the generation of this peptide. Treatment of APC with 
chloroquine or glutaraldehyde abrogated enhanced generation of T4(2553). The 
boosting effect was selective since the enhancing mAbs did not facilitate 
generation of the neighboring cryptic (2495-2511) peptide which is also 
pathogenic in mice. When Tg was simultaneously complexed to a mAb reactive 
with T4(2553) and to a mixture of boosting mAbs, the presentation of this epitope 
was totally suppressed. These results suggest that Tg-specific antibodies alter Tg 
processing and may boost or suppress the presentation of non-dominant pathogenic 
determinants during the course of disease. 
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3.2. Introduction 
MHC class II-restricted T cells generally respond to a limited number of 
immunodominant epitopes in foreign or self antigenic proteins (Sercarz et al., 
1993). Antigen-bound Abs are known to influence this response pattern and 
facilitate generation of subdominant or cryptic T-cell epitopes (Lanzavecchia, 
1995) in several ways. First, Abs may increase the efficiency of Ag capture by 
FeR+ professional APC by 103-104-fold (Amigorena and Bonnerot, 1998), leading to 
increased Ag delivery to the processing compartment (Watts, 1997) and 
production of cryptic epitopes over a critical threshold level required for T -cell 
activation. Second, Abs may modulate antigen processing by preventing T-cell 
epitopes from loading onto MHC class II molecules regardless whether these 
epitopes overlap or not with peptides bound by the Ab combining site 
(Berzofsky, 1983; Watts and Lanzavecchia, 1993; Ozaki and Berzofsky, 1987). This 
may suppress the generation of dominant determinants while simultaneously 
augmenting the presentation of non-dominant epitopes. Third, internalization of 
immune complexes (ICs) may upregulate MHC class II synthesis or expression of 
adhesion and costimulatory molecules on APC, increasing their stimulatory 
capacity. These pleiotropic effects may act synergistically, mediating a 
spreading of the immune responses to epitopes distinct from those that initiated 
it. The above concepts are based on experimental evidence obtained mostly with 
bacterial antigens but they have profound implications in T cell-mediated 
79 
autoimmune diseases. Capture of autoantigen by slg on B cells, or autoantigen-
Ab complexes by FeR+ dendritic cells or macrophages, may activate autoreactive 
T cells (Lin et al., 1991; Mamula et al. , 1994) or mediate the spreading of the T-cell 
response from dominant to cryptic epitopes (Lehmann et al., 1992). 
In this study, we have used thyroglobulin (Tg) as a model antigen to examine 
whether processing of Tg-Ab complexes would generate pathogenic but non-
dominant T-cell epitopes. Tg is a 660 kDa homodimer- the largest autoantigen 
known - that causes experimental autoimmune thyroiditis (EAT), a T cell-
mediated disease that is considered as a model for Hashimoto's thyroiditis (HT) 
in humans (Weetman, 1992). Two observations render Tg an ideal choice for this 
study. First, none of the known pathogenic T-cell epitopes in Tg has been 
classified as dominant in EAT studies (Carayanniotis and Rao, 1997). Second, a 
large percentage of patients with HT, and almost invariably all animals 
developing EAT have circulating Tg-specific Abs. It remains unclear, if such Abs 
play a role in promoting the generation of cryptic pathogenic epitopes. 
We have developed T-cell hybridoma clones against two pathogenic MHC class 
11-binding peptides at the C-terminal end of Tg : the subdominant peptide (2549-
2560) which is derived following processing of Tg in vivo but not in vitro (Wan et 
al., 1997; Hutchings et al. , 1992); and the cryptic peptide (2495-2511), which is not 
generated following processing of intact Tg either in vivo or in vitro 
(Chronopoulou and Carayanniotis, 1992). The aim of the study was to examine if 
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mAbs bound to Tg would interfere with Tg uptake or processing by APC and 
promote the generation of these two peptides. 
3.3. Results 
3.3.1. Characterization of Tg-specific mAbs 
Tg-specific mAbs 5D2, 3C4, 3B3 and 2A4 were purified from culture 
supernatants from respective hybridoma cells. The supernatants were provided 
from Dr. P. Shepherd. Purification of the mAbs was performed as described in 
materials and methods by using protein-G-Sepharose column. The 55H8 mAb 
was provided from Dr. P. Lymberi, and similarly purified from ascites fluid. The 
binding activities of the rnAbs to Tg were confirmed by ELISA (Fig. 3.1). The 
results show that the mAbs raised against human Tg cross-reacted significantly 
with mouse Tg. Some differences in binding were, however, observed with 5D2 
and 55H8 mAbs exhibiting a 10-15-fold better binding to mouse Tg than the 
others. The subclasses of the mAbs were determined by using isotype-specific 
Abs. Except 5D2, which is IgG2b, all the other rnAbs belong to IgG1 subclass 
(Fig. 3.2). 
3.3.2. Uptake of Tg-mAb immune complexes by APC is blocked by an anti -
FcRmAb 
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To directly assess mAb-mediated uptake of Tg by APC, we pulsed TA3 cells for 6 
hr with 200 nM of 125r-Tg either in a free form or complexed to various mAbs, 
and the cell-bound radioactivity was subsequently measured. It was observed 
that all mAbs significantly enhanced Tg uptake by TA3 and that this effect was 
abolished in the presence of anti-FeR mAb (Fig. 3.3). In preliminary work, all 
mAbs were shown to exhibit similar binding to native or highly iodinated Tg in 
ELISA (Fig. 3.4). 
3.3.3. The 5D2 and 3C4 mAbs boost presentation of the T4(2553) but not the 
(2495-2511) determinant 
To follow the processing of Tg-mAb complexes, we monitored the generation of two 
neighboring pathogenic peptides T4(2553) and (2495-2511) using TA3 as APC. The first 
peptide was serendipitously found to activate 3.47, an Ak-restricted, T-cell hybridoma 
clone which was, nevertheless, unreactive to equimolar concentrations of intact Tg (Fig. 
3.5A). Processing of Tg bound to 5D2 and 3C4 boosted presentation of the T4(2553) 
epitope that was now detectable at 5-10 nM, (Fig. 3.5B), whereas the 2A4-Tg complex 
was 10-20-fold less efficient. On the other hand, binding of 3B3 and 55H8 mAbs to Tg 
had no augmenting effect on the generation of T4(2553), despite their enhancing of Tg 
uptake by TA3. The enhanced peptide presentation was not correlated with the Ab-
mediated Tg-uptake by TA3. For instance, 5D2 and 3C4 mAbs were the most efficient 
82 
mAbs that enhanced the peptide presentation, but they did not mediate the highest Tg-
uptake; 55H8 and 3B3 mAbs were able to mediate Tg-uptake at same level as the other 
mAbs, but had no effect on peptide presentation. Also, the boosting effect did not 
correlate either with the mAb lgG subclass (e.g. 3C4, 3B3 and 55H8 are all lgGl), or 
with the relative mAb binding to Tg (e.g. 5D2 and 3C4 mAbs showed different reactivity 
to Tg but augmented the generation of the T4(2553) peptide equally well). 
The second epitope (2495-2511) was recognized by 8F9, an Ek-restricted T-cell 
hybrid clone. 8F9 is similar to 3.47 in its sensitivity for free peptide detection (1-2 
nM range) and in its unresponsiveness to intact Tg (2-200 nM range) (Fig. 3.5C). 
However, unlike 3.47, 8F9 did not respond to TA3 co-cultured with any of the 
above Tg-mAb complexes (Fig. 3.50). Since 5D2 and 3C4lowered the threshold 
for presentation of the T4(2553) peptide without boosting the presentation of the 
second determinant localized 38 aa upstream in the Tg molecule, the boosting effect of 
these mAbs could not be attributed solely to enhanced Tg uptake by the 
complexes. These results suggested that 5D2 and 3C4 exerted a selective 
augmenting effect by interfering with the loading of the T4(2553) epitope on Ak 
molecules during Tg processing. 
3.3.4. 502 and 3C4 mAbs interfere with Tg processing 
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To exclude the possibility that the 5D2 and 3C4 mAbs exerted signaling effects 
on TA3 that would generally augment antigen presentation, we titrated Tg or 
T4(2553) in the presence or absence of a fixed amount of rnAb followed by the 
addition of TA3 and 3.47 T cells. 3.47 was again activated only after processing 
of Tg-rnAb complexes, not intact Tg (Fig. 3.6A). In contrast, 5D2 and 3C4 
showed no boosting effect on T4(2553) presentation when free peptide was used 
as antigen (Fig. 3.6B) arguing against non-antigen-specific signaling effects of 
these mAbs on TA3. Addition of chloroquine in the culture abrogated the 
enhancing effect of 5D2 or 3C4 on the presentation of the T4(2553) peptide 
following Tg processing, but did not influence the activation of 3.47 cells by TA3 
pulsed with free peptide (Fig. 3.7 A). Finally, glutaraldehyde-fixed TA3 cells 
pulsed with Tg-5D2 or Tg-3C4 complexes did not activate the 3.47 clone but 
retained the capacity to present free T4(2553) peptide to the same T cells (Fig. 
3.7B). These data indicated that 5D2 and 3C4 exert their effects on Tg processing 
either by facilitating the generation of the T4(2553) peptide or by augmenting the 
loading of this epitope on Ak molecules. 
3.3.5. FeR-mediated uptake of Tg-Ab complexes is necessary for the generation 
of T4(2553) peptide in TA3 cells 
Following digestion with preactivated papain, we obtained F(ab\ fragments 
from the 3C4 mAb. The concentration of the F(ab')2 was determined by Sigma 
protein determination kit. In ELISA, these F(ab\ fragments retained Tg-binding 
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activity similar to that of intact 3C4 (Fig. 3.8A&B), and could competitively 
inhibit 3C4 mAbs binding to Tg (Fig. 3.8C). It was subsequently observed, 
however, that TA3 pulsed with Tg bound to 3C4 F(ab')2 did not activate the 3.47 
clone (Fig. 3.9A). Also, addition of increasing amounts of FeR-specific rnAb in 
TA3 cultures completely blocked the activation of 3.47 mediated by 5D2-Tg or 
3C4-Tg complexes, whereas the same treatment had no effect on the stimulation 
of 3.47 by free T4(2553) peptide (Fig. 3.9B). These results demonstrated that the 
FeR-mediated uptake of Tg-Ab complexes by TA3 is a necessary step for the 
formation of the T4(2553) epitope. 
3.3.6. The 55H8 mAb suppresses T4(2553) generation during processing of Tg-
mAb complexes 
We subsequently screened by ELISA all rnAbs for potential reactivity against the 
two Tg peptides. The 55H8 mAb was reactive with the T4(2553) epitope (Fig. 
3.10A) whereas the 5D2 rnAb bound specifically to (2495-2511) (Fig. 3.10B). None 
of the other mAbs reacted with either of these two peptides. This observation 
explained the lack of augmenting function by 55H8 and further suggested that 
55H8 might prevent loading of T4(2553) on Ak molecules during Tg processing 
possibly due to peptide sequestration, as predicted by the T:B cell reciprocity 
hypothesis (Chronopoulou and Carayanniotis, 1992; Berzofsky, 1983; Ozaki and 
Berzofsky, 1987). To test this, equimolar amount of 55H8, Tg and a boosting 
rnAb (3C4 or 5D2) were mixed in wells of rnicrotiter plates in the presence of 
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TA3 and 3.47 T cells. The 3B3 mAb, which cannot augment presentation of 
T4(2553) (Figure 3.3.5.B) and does not bind to it (Figure 3.3.1l.A), was used as 
control. It was found that 55H8 abolished the augmenting effects of 3C4 or 502 
mAbs on the generation of this determinant, whereas the control 3B3 mAb was 
ineffective (Fig. 3.11A) . This dominant suppressive effect was also prevalent 
when all three potentiating mAbs 5D2, 3C4 and 2A4 were co-cultured with Tg 
and 55H8 (Fig. 3.11B). 55H8 did not interfere with the binding of the enhancing 
mAbs due to steric hindrance. As shown in Fig. 3.10C, none of the available 
mAbs could inhibit binding of Tg to 55H8 in a competitive inhibition RIA. 
Similarly, the lack of suppressive effects by 3B3 could not be explained by 
abrogation of binding due to interference: none of the mAbs inhibited binding of 
125!-labeled Tg to 3B3 (Fig. 3.100). 
3.4. Discussion 
This study demonstrates the presence of Tg-specific Abs that enhance or 
suppress the generation of a non dominant pathogenic T -cell epitope. 
Enhancement of peptide presentation results from a combined effect of Abs on 
increased Tg uptake and altered Tg processing. FeR-mediated endocytosis of IC by 
APC is a necessary step in this process because of the blocking effects of the FeR-
specific mAb and the failure of 3C4 F(ab')2 fragments to augment T4(2553) 
presentation. On the other hand, increased uptake of IC by APC is not sufficient 
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to allow generation of the same epitope because the 3B3 or 55H8 mAbs enhanced 
uptake of IC by TA3 cells but did not augment presentation of the T4(2553) 
peptide. Altered processing may occur if enhancing mAbs, such as 5D2 and 3C4, 
remain tightly bound to Tg at the endosomal acidic pH, stabilizing a domain that 
contains this epitope and facilitating the transport of this determinant in a 
peptide-loading compartment (Harding, 1996). 
The failure of 3C4 to boost generation of the cryptic (2495-2511) peptide provides 
a clear example of a qualitative effect on Tg processing. This soluble mAb, 
piggybacked on Tg, enhances Tg capture by TA3 but this does not lower the 
activation threshold for (2495-2511) to allow its detection by the 8F9 clone. How 
can the 3C4 mAb that binds to a monomeric Tg subunit of 2748 a.a. residues have 
such contrasting effects on the generation of two epitopes that are only 38 aa. 
apart? 3C4 does not bind to (2495-2511) and thus a plausible interpretation 
would be that endosomal proteases trim the 3C4-bound fragment of Tg and 
remove the (2495-2511) peptide because it is localized beyond the boundary of 
3C4 protection. Thus, it is conceivable that mAbs with different specificities from 
the ones used here will be found to promote presentation of (2495-2511). 
The TA3line has been produced after fusion of B cells with a B cell lymphoma 
and its inefficiency in the processing of intact Tg is paradoxical since the rate of 
fluid phase pinocytosis in B cell tumors is 10-60-fold higher than that of B cells 
(Chesnut et al., 1982). In earlier studies, Hutchings et al. (Hutchings et al., 1987) 
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demonstrated that B cells from Tg -primed mice present low amounts of Tg (1 
J.Lg/ml) to aT-cell hybridoma clone that was subsequently found to react with 
(2549-2560) (Champion et al., 1991). Our data and those findings demonstrate 
that Tg-reactive IgG either in soluble form or as sig on B cells can mediate 
enhanced Tg uptake by receptor-mediated endocytosis and modulate Tg 
processing to enhance the generation of this pathogenic epitope. Interestingly, 
the above data (Hutchings et al., 1987) also imply that B-cell clones bearing the 
55H8 specificity do not occur with high frequency in Tg-primed spleen cells1 but 
this interpretation requires caution since the 55H8 mAb was elicited after 
challenge with human Tg, whereas Hutchings et al. used a pool of mouse, dog 
and rat Tg for immunizations. 
Other investigators have similarly reported that Abs bound to foreign (Simitsek 
et al., 1995; Stockinger/ 1992; Liu et al., 1996) or self (Berg et al., 1997) antigens 
can modulate presentation ofT-cell determinants. In apparent contrast to our 
data, Fab fragments did mediate enhanced presentation of peptide antigen in 
some studies (Simitsek et al., 1995) but the APC were EBV-transformed, tetanus-
toxin- specific B cell clones which constitutively internalized IC via their slg. 
When B-cell lymphomas were used as APC, use of F(ab')2 fragments in IC did 
not improve antigen presentation (Stockinger, 1992) and FeR-specific Abs 
blocked T-cell activation (Stockinger, 1992; Berg et al., 1997), suggesting FeR-
mediated augmentation of antigen uptake and presentation. Other FeR-
expressing APC such as macrophages or dendritic cells might similarly process 
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Tg-Ab complexes to generate the peptides studied here but the outcome of the 
response is difficult to predict given that distinct sets of proteases may be active 
in different APC (Schneider and Sercarz, 1997). Assays based on adoptive 
transfer of antigen-specific LNC have clearly shown that the "non dominant" 
pathogenic (2495-2511) and/or T4(2553) peptides are generated within the mouse 
(Chronopoulou and Carayanniotis, 1992; Hutchings et al., 1992; Kong et al., 1995) 
or rat (Balasa and Carayanniotis, 1993) thyroid, possibly via processing of Tg or 
Tg fragments by intrathyroidal dendritic cells (Voorby et al., 1990). 
Antibody-mediated suppression of Tg peptide generation is exemplified by the 
55H8 mAb that binds to T4(2553) on Tg and may sequester this epitope from 
loading onto Ak molecules. This interpretation is in agreement with the T: B-cell 
reciprocity hypothesis (Berzofsky, 1983; Ozaki and Berzofsky, 1987), according to 
which, the slg on B cells, or soluble Ab bound on Ag, can at times negatively 
steer Ag processing because the part of the Ag within the Ab-combining site is 
protected from proteolysis and prevented from subsequent loading onto MHC 
class II molecules. A corollary of this hypothesis would be that soluble 55H8 
piggybacked on Tg would exert a dominant suppressive effect on the generation 
of this pathogenic epitope. This is fully supported by our data: when mixtures 
of potentiating mAbs and 55H8 were incubated with Tg, suppression was 
dominant. Suppression could not be attributed to 55H8 blockade of the T4(2553)-
Ak complex because the same 5D2-Tg-55H8 IC preparations did not affect 
presentation of free peptide on TA3 (unpublished data). A reciprocal 
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relationship is also highlighted by the 5D2 mAb and the (2495-2511)-specific 8F9 
clone which recognize overlapping determinants within (2495-2511) : this 
peptide cannot be generated during processing of 5D2-Tg complexes in TA3 
because the T- and B-cell epitopes physically overlap. To our knowledge, our 
findings provide the first examples that directly support the T: B cell reciprocity 
hypothesis in autoimmune disease. 
The present study reveals an immunoregulatory role for Tg-specific IgG Abs 
which are quite frequent in HT and include all four subclasses (Weetman and 
McGregor, 1994; Weetman et al., 1989; Tomer, 1997). The chronicity of the disease 
favors generation of high affinity IgG1 and IgG4 Abs and it has been suggested 
that rising titers of high affinity IgG1 anti-Tg may be indicative of impending 
hypothyroidism (Devey et al., 1989). As extrapolated from our data, such high-
affinity autoantibodies may have a neutral, suppressive, or augmenting effect on 
the generation of pathogenic Tg T-cell determinants, depending on the epitopes 
they recognize and the genetic background of the individual. In some cases, their 
net effect could be exacerbation of disease and the spreading of the autoimmune 
response to non dominant T-cell epitopes (Lehmann et al., 1993). At present, a 
more direct testing of this hypothesis with Tg-reactive, human CD4+ T-cell 
clones is not feasible because the epitopes they recognize remain unknown. In 
addition, we do not know whether Tg-specific, human autoantibodies in HT 
recognize linear or conformational determinants (Weetman and McGregor, 1994) 
and where these determinants are precisely localized. Several studies suggest, 
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however, that autoreactive IgG in the serum of HT patients bind to a limited 
number of Tg epitopes (Chan et al., 1987; Bresler et al., 1990; Kuppers et al., 1991; 
Nye et al., 1980; Tomer, 1997) including an immunodominant central region (aa. 
1149-1250) (Henry et al., 1992). Autoreactive, Tg-specific Abs may be induced by 
foreign antigens via molecular mimicry and gradually promote the generation of 
non dominant pathogenic T-cell epitopes, as suggested in other systems (Lin et 
al., 1991). Our data are not incompatible with this concept and support the notion 
that Tg-reactive Abs may play a much more complex role in the regulation of 
thyroid disease than previously anticipated. 
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Fig.3.1. Reactivity of Tg-specific mAbs. The 96-well plates 
were coated with 1 ~g/well of mouse Tg. Serial dilution of 
each mAb 55H8, 3B3, 2A4, 3C4 and 5D2 were added, 
followed with alkaline-phosphatase (AP) -conjugated anti-
mouse Ig and AP substrate. The absorbance was measured at 
405 nm. 
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Horseradish-peroxidase (HRP) conjugated isotype-specifi c Abs anti-IgG 1, 
anti-IgG2a, anti-IgG2b, anti-IgG3, anti-IgM and anti-IgA were added. The 
bound isotype-specific Ab was detected by adding OPD-peroxidase substrate. 
After the appearance of a brown color (about 30-60 min), the reaction was 
stopped by adding 50 ~-tl3N NaOH. The absorbance was read at O.D.405 run. 
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Figure 3.3. Tg-specific mAbs promote IC uptake by APC. 
Enhanced uptake ofTg-Ab complexes by TA3 is blocked by anti-
FeR mAb. 1251-labelled Tg (at a final cone. 200 nM, 170,000 
cpm /f.lg) either free or complexed with equimolar amounts of 
various mAbs was used to pulse 106 T A3 cells in 0.5 ml of 
culture medium for 6 hr at 37 oC. The anti- FeR mAb 2.4G2 was 
used at 10 f.lg/ml. Cell-bound radioactivity was measured after 
extensive washing. Each value is the mean of triplicate wells. 
Similar results were obtained in two independent experiments. 
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Figure 3.5. Selective generation of the pathogenic Tg epitope T4(2553) 
following processing of Tg-Ab complexes. IL-2 release following activation 
of 3.47 (A and B ) or 8F9 (C and D) T-cell hybrid clones by the antigens 
shown in the presence ofT A3 cells, as assessed by the proliferation of the IL-
2-dependent CTLL line. Each point represents the mean of triplicate wells. 
Similar data were obtained in three independent assays. Neither T-cell hybrid 
responded to equimolar concentrations of free mAbs (data not shown). 
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Fig.3.6. Enhanced presentation does not result from a non-specific 
effect ofmAbs on TA3. 3.47 T-cell activation following titration of Tg 
(A) or T4(2553) peptide (B) in the presence or absence of a fixed 
amount (200 nM) 5D2 or 3C4 mAbs and TA3. Each point represents 
the mean IL-2 release of triplicate wells. 
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Figure 3.7. Enhanced presentation of T4(2553), mediated by 3C4 and 502 
bound to Tg, requires an intracellular Tg processing step. Results show the 
activation of the T4(2553) -specific, IL-2 secreting 3.47 T-cell hybrid clone. A. 
Chloroquine (67 ~-tM) abrogates the enhanced generation ofT4(2553) following 
processing of Ab-bound Tg (50 nM) in TA3 cells, but has no effect on the 
presentation of equimolar amount of free peptide. B. Fixation of TA3 by 0.05% 
glutaraldehyde abrogates generation of T4(2553) from Tg-Ab complexes but 
has no effect on the presentation of free peptide. 
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Fig.3.8A&B. The F(ab')2 fragments of 3C4 mAb retained Tg-binding 
activity similar to that of intact 3C4. The microtiter plate was coated with 
lj.!g/well of Tg. Serial dilution of 3C4 mAb and its F(ab')2 fragments were 
added to allow binding with Tg. Plate bound mAb or F(ab')2 was detected 
by anti-Fab (A) or anti-Fc (B) conjugated with alkaline phosphatase (AP), 
followed by addition of the AP substrate. The plate was read at 405 run. 
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Figure 3.9. FeR-mediated uptake of Tg is necessary for the generation of 
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Figure 3.10. Reactivity of Tg-specitic mAbs against (A) T4(2553) or 
(B) (2495-25 11 ) peptides (1 llg/well) as assessed by ELISA. Each point 
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performed as described in Material and Methods, indicating the 
competitive inhibition of binding of radiolabelled Tg onto 55H8 (C) or 
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102 
40 
A 
30 
6. 383-Tg-3C4 
20 
.& 383-Tg-602 
o 55HI-Tg-3C4 
-c c • 551-e-Tg-602 c 10 ~ 
a. 
u 0 
-c 1 10 
0 
100 1000 
·- 30 ... 
ns B .. 
• ... 
·-
-0 
.. 20 0 55H8-Tg a. 
...I + 5D2/3C4/2A4 
...I 
1- A. 383-Tg 0 
10 + 5D2/3C4/2A4 
o-1---J~~~~~-J 
1 10 100 1000 
Ag concentration (nM) 
Figure 3.11. 55H8 suppresses generation of T4(2553) during 
processing ofiCs by TA3. A. IL-2 release was monitored following 
3.47 T-cell activation by Tg mixed at equimolar amounts with 
55H8 and either 3C4 or 5D2 mAbs in the presence ofTA3 as APC. 
B. 3.47 activation by Tg mixed at equimolar amounts with each of 
the mAbs shown. 
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THYROXINE-SPECIFIC ANTIBODIES BLOCK T-CELL 
RECOGNITION OF A PATHOGENIC THYROGLOBULIN 
EPITOPE 
(Modified manuscript for publication) 
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4.1. Abstract 
We have generated an Ak-restricted, IL-2-secreting, T cell hybridoma clone (3.47) 
specific for the pathogenic thyroglobulin (Tg) peptide (2549-2560) that contains 
thyroxine (T4) at position 2553 [T4(2553)]. The 3.47 clone did not recognize other 
T4-containing Tg peptides suggesting that presentation of T4 in the context of Ak 
molecules is not sufficient for activation. On the other hand, the non-iodinated 
analog peptide T0(2553), which binds to A k, did not stimulate the 3.47 cells 
indicating that I atoms within the peptide-MHC complex are necessary for 
triggering the 3.47 TcR. Following binding of T4(2553) to the Ak groove, T-cell 
activation was blocked by a Tg-reactive, T4-specific rnAb that recognizes the 5' I 
atom of the outer phenolic ring of T4. In addition, 55H8 inhibited the 
proliferation of T4(2553)-primed LNC against the peptide-pulsed APC and 
subsequently transferring of EAT to the recipient mice. This blockade implied 
sufficient projection of the bulky T4 moiety beyond the MHC groove to enable 
recognition by Abs. These data demonstrate that some T4-specific Abs can block 
T-cell recognition of pathogenic epitopes of thyroglobulin and, thus, may exert 
an immunoregulatory role during the course of thyroid disease. 
4.2. Introduction 
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Thyroglobulin (Tg), (660,000 Dalton), is the only protein known to be iodinated 
in vivo, and is unique in its ability to couple iodotyrosine residues to form 
thyroid hormones. Four major hormonogenic sites have been described, 
corresponding to four tyrosine residues in human Tg at positions 5, 2553, 2567 
and 2746 (Rawitch et al., 1983; Malthiery and Lissitzky, 1987). Other tyrosine 
residues such as Tyr1290 and Tyr685 are also considered as potential sites for 
thyroid hormonogenesis when the requirement for hormone synthesis increases 
(Lamas et al., 1989). 
Thyroxine (T4} and triiodothyronine (T3) behave as strong haptens, because, in a 
free form, they do not elicit an anti-hormone response, but become 
immunogenic only when conjugated with a carrier protein. It is suggested that 
Tg is the carrier protein for induction of thyroid hormone autoantibodies 
(THAA) (Benvenga et al., 1987). THAA have had diagnostic use in thyroid 
diseases (Sakata, 1994), but their pathogenic roles have been rarely discussed. 
THAA are the most frequently detected auto-Abs in patients with thyroid 
abnormalities (Erregragui et al., 1996), but they are also prevalent in the normal 
population (Sakata et al., 1994). 
Research on the pathogenic role of the hormonogenic sites within Tg was 
boosted when a Tg peptide containing a thyroxine (T4) molecule at position of 
2553 (T4(2553)) was identified as a thyroiditogenic epitope (Champion et al., 
1991; Hutchings et al., 1992). A non-iodinated analog of this T4(2553) peptide 
could not stimulate a T4(2553)-specific T-cell hybridoma (Dawe et al., 1996). These 
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studies provided a first direct evidence for the role of iodine in activation of T-
cells. However, other studies showed that T-cells recognize T4 and the peptide 
backbone chain encompassing this hormonogenic site (Kong et al., 1995). Non-
iodinated Tg is not immunogenic and cannot induce experimental autoimmune 
thyroiditis (EAT) (Champion et al., 1987)(Rose et al., 1997). The enhancement of 
Tg immunogenicity by iodine indicates a potential pathogenic role for 
hormonogenic sites, since most of iodine incorporated into Tg molecule is 
utilized for hormone synthesis, albeit other tyrosine residues may also act as 
iodination sites to form monoiodotyrosine (MIT) and diiodotyrosine (DIT) 
residues. Formation of T4 and T3 within the Tg may create some new hormone-
containing B-andT- cell epitopes and trigger immune responses against Tg. 
T -cells recognize pep tides presented in the MHC groove, whereas Abs bind their 
ligands directly. T and B cell epitopes do not usually overlap, but in some cases a 
BcR may share a similar binding specificity as a TcR. It has been reported that 
peptide-MHC complexes can be recognized by both TcR and Ab (Stryhn et al., 
1996; Aharoni et al., 1991). An Ab binding to the peptide loaded in a class I MHC 
groove was recently described (Apostolopoulos et al., 1998). Apparently, the 
bulged middle position of the peptide beyond the class I MHC ~-sheet of the 
binding groove provided enough surface area for recognition by the peptide-
specific Ab. However, Abs recognizing peptides lying on the MHC class II 
binding groove have not been reported. As mentioned above, both T-cells 
recognizing T4-containing peptide and THAA Abs specific for T4 have been 
detected in AT. In this study, we examined whether T4-specific Abs can bind T4-
107 
containing peptides presented on class II MHC groove, and thus, block the 
recognition of the peptide-MHC complex by T-cells. 
4.3. Results 
4.3.1. Characterization of T4(2553)-specific T-cell hybridoma 3.47 
4.3.1.1. The 3.47 T-cell clone is reactive to T4(2553) peptide 
T-cell hybridomas were produced following fusion of the LNC from Tg-primed 
CBA/J mice (H-2k) with tumor cells BW5147 (TcR a-~-) as described in Materials 
and Methods. The 3.47 clone was initially selected for its reactivity to mTg-pulsed 
TA3 cells, but upon continuous culture it lost responsiveness to mTg or intact Tg 
from human, bovine, porcine or rat origin (Fig. 4.1A). However, it was 
serendipitously found that 3.47 was strongly activated by the conserved Tg 
peptide (2549-2560) which contains T4 at position 2553 [T4(2553)], while it 
remained unreactive to two other Tg peptides, (2495-2511) and (2695-2713) (Fig. 
4.1B). 
4.3.1.2. The 3.47 clone is A k-restricted, CD4+ 
1 08 
To examine the MHC restriction of the 3.47 T-cell clone, anti-Ak and anti-Ek mAbs 
were used to block the activation of 3.47 T -cells. The A k_ and Ek- expressing TA3 
cells were used as APC to present T4(2553) peptide to 3.47 T-cells. As shown in 
Fig. 4.2A, as the concentration of anti- Ak mAb increases, the activation of 3.47 
clone is significantly inhibited, but the anti-Ek mAb at 100 J.tg/ ml had no effect on 
3.47 activation, suggesting the 3.47 T-cell clone is Ak-restricted. Activation of a 
control T-cell hybridoma 8F9, which is Tg2495-2511 peptide-specific, was blocked 
by anti-Ek but not anti- Ak mAb (Fig. 4.2B), indicating the blocking of the T-cell 
activation was not due to a non-specific effect. Expression of TcR and CD4 
molecules on the 3.47 and 8F9 cells was verified by direct F ACS analysis (Fig. 
4.3). 
4.3.1.3. The TcR f3-chain sequence of the 3.47 T-cell clone 
To identify the Vf3 family of the 3.47 TcR, the mRNA was isolated from a fresh 
culture of 3.47 T-cells, followed by first-strand eDNA synthesis. Primers specific 
for different Vf3 families and Cf3 were used for PCR amplification of the unique 
VDJ region of the 3.47 TcR f3-chain. The PCR products were visualized by 
agarose-gel electrophoresis. A band was obtained when Vf31 and Cf32 -specific 
primers were used in PCR amplification of the 3.47 eDNA, suggesting that the 
3.47 TcR uses Vf31 for f3-chain (Fig. 4.4). Similarly, the TcR of the Tg2495-2511 
peptide-specific T-cell clone 8F9 was identified as using Vf314. To sequence the 
VDJ region of the TcR f3-chain of the 3.47 clone, the PCR product was extracted 
109 
from the agarose-gel and subjected for DNA sequencing with ABI method (Fig. 
4.5). The sequencing data of the VDJ region of the 3.47 TcR ~-chain partially or 
fully match the mRNA sequences of the mouse TcR V~1 gene (Hedrick et al., 
1984; Morinaga et al., 1985), the mouse J2.6 gene (Smith et al., 1991) and the 
mouse TcR C~2 gene (Chien et al., 1984; Saito et al., 1984). For the 8F9 T-cell 
clone, the sequencing data for the VDJ region show that the TcR [3-chain uses 
Vb14 (Malissen et al., 1986; Behlke et al., 1986), J~2.5 (Horwitz et al., 1994) and 
Cf32. According to the GenBank sequences of the above mouse TcR ~-chain 
genes, the full mRNA sequences for 3.47 and 8F9 TcR [3-chains are predicted and 
shown in Fig. 4.6A &B. 
4.3.2. The 3.47 clone does not recognize peptides from other hormonogenic sites 
To test whether the presence of T4 within any peptide backbone is sufficient to 
activate the 3.47 clone, we examined the activation properties of two additional 
T4-containing 12mer peptides of Tg: the T4(5) (a.a. 1-12) and T4(2567) (a.a. 2559-
2570). As shown in Fig. 4.7 A, TA3 APC pulsed with those peptides or free T4 
could not stimulate 3.47 to secrete IL-2. Lack of activation was not due to lack of 
peptide binding to Ak because the T4(2567) peptide inhibited 3.47 activation by 
the T4(2553) peptide in a competitive inhibition assay to the same extent as the 
mouse lysozyme peptide (46-62) which is known (Moudgil et al., 1996) to bind 
strongly to Ak (Fig. 4.7B). The T4(5) peptide and free T4 were not inhibitory 
suggesting very weak or no binding to Ak. The pathogenic 9mer Tg peptide 
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(2496-2504) that binds to Ek (Rao et al., 1994) also showed no inhibitory effect. 
These results confirmed that the backbone amino acid residues within T4-
containing peptides were essential for Ak- binding and/ or optimal TCR contact 
that would lead to the activation of the 3.47 clone. 
4.3.3. The 3.47 T -cell done recognizes an iodinated determinant. 
Previous observations by Roitt's group had suggested that the (2549-2559) 
peptide containing de-iodinated thyroxine (thyronine) at position 2553 [T0(2553)] 
was non stimulatory for a T-cell hybridoma that recognizes the T4-containing 
analog (Dawe et al., 1996). This was confirmed in the present study since the 
T0(2553) peptide pulsed on TA3 could not stimulate the 3.47 clone (Fig. 4.8A). In 
contrast to the findings of that study, however, the T0(2553) peptide could 
almost completely block the activation of 3.47 by T4(2553) (Fig. 4.8B) suggesting 
strong binding of the thyronine-containing analog to the Ak molecule. The 
above results clearly demonstrate that the 3.47 clone recognizes a determinant 
modified by I atoms within the two phenolic-ring structure of T4, and also 
suggest that the I atoms may not contribute to binding of T4(2553) peptide to the 
Ak molecule. 
4.3.4. I atoms on the phenolic ring of T4 are recognized by T4-specific mAbs 
1 1 1 
We have previously reported the generation of a Tg-specific mAb (55H8) that 
binds to the T4(2553) peptide (Dai et al., 1999). We proceeded to examine 
whether 55H8 is T4-specific by monitoring its reactivity against other T4-
containing peptides. It was found that 55H8 reacted similarly against T4(5) and 
T4(2567) whereas it did not bind to the T0(2553) analog (Fig. 4.9A). These data 
suggested that the 55H8 mAb is T4-specific and the I atoms on the phenolic ring 
of T4 are essential for such recognition. This was further confirmed by a 
competitive inhibition ELISA in which free T4, or T4-containing peptides but not 
T0(2553) completely inhibited the binding of 55H8 to mouse Tg (Fig. 4.9B). 
When we compared the reactivity profile of 55H8 with that of a second T4-
specific mAb 91Al, we obtained an overall similar pattern of response with some 
slight differences. As shown in Fig. 4.9C, mAb 91Al reacted with all the three T4-
containing peptides but not T0(2553) peptide on a solid phase despite evidence of 
a weaker binding to peptides T4(5) and T4(2553). Similarly, in competitive 
inhibition, all of the T4-containing peptides and free T4 molecule could inhibit 
binding of 91Al to mouse Tg (Fig. 4.9D) although such inhibition was detectable 
at higher concentrations of peptides and T4 molecule than those for 55H8. Thus, 
the two T4-specific mAbs 55H8 and 91Al possess an overall similar reactive 
profile to T4-containing peptides. 
4.3.5. Different fine specificity of the two T4-specific mAbs 
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The bulky T4 molecule (763 Dalton) contains 4 iodine atoms, two at positions 3 
and 5 of the inner phenolic ring and another two at positions 3' and 5' of the 
outer ring. To examine whether iodine atoms contribute to the recognition sites 
of T4-specific mAbs, we conjugated rabbit serum albumin (RSA) with T4 (3', 5', 3 
and 5) or T3 (3', 3 and 5) and allowed binding of T 4-specific mAbs 55H8 and 91Al 
to T4-RSA or T3-RSA on ELISA plate. Interestingly, unlike 91Al mAb, which 
bound equally well to T4-RSA and T3-RSA, mAb 55H8 bound strongly to T4-
RSA but not to T3-RSA (Fig. 4.10) indicating that the I atom at the 5' position of 
the outer ring is an integral component of the determinant recognized by 55H8, 
but is not recognized by 91Al mAb. Nevertheless, both mAbs equally bound to 
mouse Tg. 
4.3.6. TcR recognition of the T4(2553) - Ak complex is blocked by the SSHB 
mAb 
It is well known that peptide-specific Abs do not common! y recognize their 
ligand within peptide-MHC complexes due to sequestration of the peptide within 
the MHC groove. Due to the bulkiness of the T4 moiety within T4(2553), and the 
requirement for T4 in the TCR triggering of the 3.47 clone, we envisaged that the 
T4-reactive mAbs might bind to the peptide-MHC complex and block peptide 
recognition by this T-cell clone. To test this, TA3 cells (Fig. 4.11A) or peritoneal 
thioglycollate-stimulated macrophages (Fig. 4.11B) were pulsed with 2 JLg/ml 
T4(2553) for 6 hr and were subsequently washed. These peptide-pulsed APC 
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were subsequently cultured with 3.47 T cells in the presence of increasing 
amounts of 55H8 and 91Al mAbs or a control Tg-specific mAb of the same IgG 
subclass (3B3). Surprisingly, activation of the T-cell hybridoma 3.47 was strongly 
inhibited by 55H8, whereas the 91Al and the control mAb 3B3, used at 
equimolar amounts, had no effect. The blocking effect of 55H8 could not be 
explained by removal of T4(2553) peptide from the MHC molecule due to a high 
dissociation rate, because fixation of T4(2553)-pulsed TA3 APC with 
glutaraldehyde did not affect the blockade of 55H8 on the activation of 3.47 cells 
(Fig.4.12A). The result suggests that some T4-specific Abs exemplified by 55H8 
can block recognition of this pathogenic epitope by T cells. An immune complex 
made by mixing equimolar amounts of Tg and 55H8 could not block activation 
of 3.47 cells by T4(2553)-pulsed APC, suggesting that free 55H8 is required to 
block the activation of the 3.47 cells (Fig.4.12B). 
4.3.7. 55H8 blocks activation of T4(2553)-primed LNC and transfer of EAT 
We then proceeded to examine whether the 55H8 mAb could block proliferation 
of T4(2553)-primed LNC. Since 55H8 binds to free T4(2553) peptide in solution, 
we could not directly add both peptide and mAb together in LNC cultures. Thus, 
we first pulsed syngeneic splenic lymphocytes with T4(2553) and cultured the 
peptide-pulsed splenocytes with 55H8 or 91Al mAb before mixing them with 
T4(2553)-primed LNC in a proliferation assay. As shown in Fig. 4.13, T4(2553)-
pulsed splenocytes could activate T4(2553)-primed LNC with a simulation index 
of 5.5. When the pulsed splenocytes were treated with 55H8, but not the control 
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mAb 91Al, prior to mixing with T4(2553)-primed LNC, the proliferation of the 
T4(2553)-primed LNC was significantly inhibited with a S.L of 2.1. Furthermore, 
subsequent adoptive transfer of these in vitro stimulated T4(2553)-primed LNC 
into syngeneic CBA mice demonstrated that the T4(2553)-primed LNC cultured 
with the 55H8-treated T4(2553)-pulsed splenocytes could not induce severe EAT 
in recipient mice showing an average thyroidal lymphocyte infiltration index of 
1.42 ± 0.58 (Fig. 4.14). In contrast, the T4(2553)-primed LNC cultured with the 
non-treated or the 91Al-treated, T4(2553)-pulsed, splenocytes induced 
significantly higher lymphocyte infiltration in the recipient's thyroid glands with 
an average infiltration index of 2.42 ± 0.58 (p < 0.05). The result suggests that 
55H8, but not 91Al, could block the activation of T4(2553)-specific T-cells and 
their differentiation into EAT effector cells. 
4.4. Discussion 
The capacity of the T4-specific mAb 55H8, but not 91Al, to block stimulation of 
peptide-specific T-cells by T4(2553)-pulsed APC can be explained by proposing 
that the bulky T4 molecule projects sufficiently beyond the groove to allow 
recognition by either T4-specific Ab or specific TcR. In the presence of T4-specific 
mAb, the activation of peptide-specific T-cells is significantly suppressed due to a 
steric hindrance. 
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The T4(2553)-specific T-cell hybridoma 3.47 was generated by fusing BW5147 a-~­
thymoma cells with the Tg-specific lymphocytes from CBA/J mice. The 
serendipitous finding that 3.47 cells recognize the T4(2553) peptide suggests that 
the immune response to the T4(2553) epitope may be dominant in CBA/J mouse 
strain. Other T4-containing Tg peptides, such as T4(5) and T4(2567) , could not 
activate 3.47 T-cells indicating that presence of T4 in a peptide is not sufficient for 
3.47 activation. The amino acid sequence is also essential for the recognition of 
the T4(2553) peptide by 3.47 cells. The peptide analog T0(2553) containing 
thyronine instead of T4 at position 2553 did not activate 3.47 T-cells suggesting 
that the I atoms form part of the epitope recognized by 3.47 TcR. Thus, the T4 
molecule in the T4(2553) peptide is necessary, but not sufficient for activation of 
the 3.47 T-cells. Previous work proposed that the iodine atoms in T4(2553) 
peptide were essential for loading the peptide into class II MHC molecule (Dawe 
et al., 1996), because the T0(2553) peptide could not competitively inhibit the 
activation of the T4(2553)-specific T-cells by T4(2553) peptide. In contrast, we 
have demonstrated that the T0(2553) peptide can inhibit the activation of 3.47 T-
cells suggesting the T0(2553) peptide is able to bind to Ak molecule and I atoms 
are thus not required for efficient binding of the peptide to MHC. Our data agree 
with the previous suggestions that T-cell recognition of T4(2553) requires 
presence of the backbone amino acid residues (Kong et al., 1995). Normal Tg 
purified from outbred mice may contain T4 at position 2553, since position 2553 
is the second important hormonogenic site after the position 5 and accounts for 
25 % of hormone synthesis (Dunn and Dunn, 1999). It has been reported that 
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circulating Tg in healthy individuals is poorly iodinated, but the iodine content of 
Tg increases in patients with thyroid disorders (Schneider et al., 1983). It is 
possible that self tolerance is established by Tg with low iodine content. 
Enhanced iodination and hormone synthesis may break tolerance against Tg and 
induce autoimmune responses. 
The mAb 55H8 and 91A1 were derived from human Tg-immunized BALB/c 
splenic cells fused with the mouse myeloma NSO. The T4-specificity of the mAbs 
was examined with various T4-containing peptides and T4(2553) analogs. The 
difference in the fine-specificity between the 55H8 and 91A1 mAbs was identified 
using T4- and T3- conjugated RSA. The mAb 91A1 bound to both T4- and T3-
RSA, but 55H8 recognized only T4-RSA. The 55H8, but not 91A1 inhibited the 
activation of 3.47 cells by T4(2553)-pulsed APC indicating binding of 55H8 to 
T4(2553) presented on Ak MHC. Abs reacting to peptide-MHC complexes have 
been frequently reported (Stryhn et al., 1996; Murphy et al., 1992; Aharoni et al., 
1991; Nygard et al., 1991). Furthermore, an Ab recognizing its specific peptide 
ligand presented in the MHC groove has been described indicating that some 
peptides buried in MHC groove may still present sufficient contact surface for 
Ab binding (Apostolopoulos et al., 1998). T4(2553) is unique in its structure. The 
bulky T4 molecule accounts for nearly 50% of the total molecular weight of the 
peptide. The peptide does not fit into all the restricting pockets of the binding 
motif of Ak molecule (Fremont et al., 1998; Weber et al., 1998), but the presence 
of aspartic acid at the N-terminal of T4(2553) is the most stringent requirement 
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for binding to Ak molecule. The amino acid following the aspartic acid (normally 
tyrosine) is not part of the agretope that binds to Ak molecule implying that it 
may project out of the groove and participate in TcR recognition. Our results 
suggest that the T4 molecule within T4(2553) is part of the epitopic moiety for 
3.47 T-cell recognition. The bulky T4 molecule is large enough to occupy the 
paratope of Ab which can accommodate 15-22 amino acid residues with a 
contacting surface of 650-900 angstroms (Garcia et al., 1992; Harris et al., 1992). 
Given the structural similarity of the complementarity-determining regions 
(CDR) between TcR and Ig (Bentley et al., 1995; Fields et al., 1995), the 3.47 TcR, 
like some anti-T4 mAbs, may not recognize all the iodine atoms present on the 
T4-phenolic-ring. T4(2553) analogs containing mono-, di- and tri- iodothyronine 
may address the fine specificity of 3.47 TcR. 
Thyroid hormones are haptens. They do not induce immune response unless 
they are coupled to a carrier protein. It is widely accepted that Tg is the carrier 
molecule of T4 and T3 for generation of THAA (Erregragui et al., 1996; Sakata et 
al., 1990). Most of the THAA specifically recognize T3, but other specificities such 
as T4, T3+ T4, reverse T3 + T4 and T3 + reverse T3+ T4 are also frequently 
observed (Benvenga et al., 1987; Sakata, 1994). As shown in this study, 55H8 Ab 
binds to T4-RSA, but not to T3-RSA. On the other hand, 91Al Ab cross-reacts 
with T3 or T4 -RSA. Whether these different types of THAA play a different role 
in hormone metabolism or pathogenesis of thyroid diseases is not clear. The 
occurrence of THAA in patients with thyroid disease and healthy individuals 
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(Sakata et al., 1994; Bryhni et al., 1996) suggests that some THAA may be 
harmless, or maybe even protective. The relationship between different types of 
THAA and thyroid disease should be addressed in future studies. The 
pathogenetic role of THAA may also be due to an effect on the metabolism of 
thyroid hormones. It has been suggested, however, most THAA do not affect 
peripheral T4 and T3 levels due to their lower affinity than thyroxine-binding-
globulin (TGB) for thyroid hormones. The existence of THAA mostly reduces 
hormone disposal (Costante et al., 1990), but extremely high affinity THAA may 
cause hypothyroidism by competitive binding to peripheral T4 and T3. The 
importance of THAA affinity in regulating the T4 and T3 level in blood raises the 
question whether blocking effect of THAA on the activation of T-cells specific for 
hormonogenic sites is a matter of affinity competition between TcR and Ab as 
described in this study. Abs such as 55H8 may bind to hormone presented on 
MHC and thus block TcR recognition. Abs such as 91A1, with lower affinity for 
T4, may not be able to block the T-cell activation. The peptide binding assay 
showed that 55H8 bound to T4(2553) better than 91Al. If the affinity of THAA is 
the key for blocking T-cell activation, generation of Abs with extremely high 
affinity for 1'4 may help in suppressing EAT induced by T4-containing peptides. 
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Fig. 4.1. The 3.47 T cell hybridoma clone specifically recognizes the Tg 
peptide T4(2553). Activation of the 3.47 clone was performed by 
culturing the 3.4 7 cells (1 05 /well) with an equal number of T A3 APC in 
the presence of serial dilutions of Tg preparations from various species 
(A) and Tg peptides (B) as shown. IL-2 secretion of 3.47 T-cells was 
monitored by CTLL proliferation. Points are means of triplicate wells. 
Standard deviations were less than 10% of the means. 
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Fig. 4.2. MHC class II restriction of 3.47 and 8F9 T-cell hybridomas. T-cell 
activation was performed by culturing 3.4 7 (A) and 8F9 (B) 105 cells I well 
with an equal number ofT A3 APC and a fixed concentration (0.2 IJ.g/ml) of 
the respective stimulating peptide: T4(2553) (A) or Tg2495-2511 (B). Serial 
dilutions of anti-MHC mAbs were added in the culture for blocking. CTLL 
cell proliferation was followed over 24h culture to monitor the IL-2 secretion 
in the culture supernatants. Without blocking mAbs, the CTLL proliferation 
for the stimulated T-cells was: 3.47 = 13,120 cpm; 8F9 = 14,568 cpm. 
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Fig.4.3. TcR and CD4 expression on 3.47 T-cells. 2.5 x 105 3.47 
cells were directly stained with FITC-labeled anti-mouse TcR or 
CD4 for 30 min. The results are shown as non-filled curves. As a 
control, the 3.4 7 cells were similarly stained with FITC-labeled 
anti-mouse IgG (Fe) (Filled). 
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Fig. 4.5. The VDJ region sequences of3.47 and 8F9 TcR J3-chains 
Sequencing results for the VDJ region of the 3.47 TcR beta-chain 
1 aagctacttt tacatatatc tgccgtggat ccagaagact cagctgtcta 5e 
51 tttttgtgcc agcagccatg atcgggacag ggactatgaa cagtacttcg 1ee 
lel gtcccggcac caggctcacg gttttagagg atctgagaaa tg t gactcca 15e 
151 cccaaggtct ccttgtttga gccatcaaaa gcagagattg caaacaaaca 2ee 
2el aaaggctacc ctcgtgtgct tggccagggg cttcttccct gaccacgtgg 25e 
251 agctgagctg gtgggtgaat gg 272 
Sequencing results for the VDJ region of the 8F9 TcR beta-chain 
1 ccactctggc ttctacctct gtgcctggag ttggcaagac acccagtact 5e 
51 ttgggccagg cactcggctc ctcgtgttag aggatctgag aaatgtgact 1ee 
lel ccacccaagg tctccttgtt tgagccatca aaagcagaga ttgcaaacaa 15e 
151 acaaaaggct accctcgtgt gcttggccag gggcttcttc cctgaccacg 2ee 
2e1 tggagctgag ctggtgggtg aatgg 225 
1 2 4 
Fig.4.6.A. The full TcR P-chain sequence ofthe 3.47 T-cell clone* 
1 atgagctgca 
51 actcatgaac 
1e1 gagcaaataa 
1S1 tactggtata 
2e1 caatcttaaa 
2S1 ctgaatgccc 
3el ccagaagact 
351 ggactatgaa 
4e1 atctgagaaa 
4S1 gcagagattg 
Se1 cttcttccct 
5S1 tccacagtgg 
6e1 agctactgcc 
6S1 tcctcgaaac 
7e1 aggacaagtg 
751 gcagaggcct 
8e1 tcagggggtt 
8S1 ccaccctata 
9e1 aagaaaaaaa 
ggcttctcct gtatgtttcc ctatgtcttg tggaaacagc 
actaaaatta ctcagtcacc aagatatcta atcctgggaa 
gtctttggaa tgtgagcaac atctgggaca taatgctatg 
aacagagcgc tgagaagccg ccagagctca tgtttctcta 
cagttgattc gaaatgagac ggtgcccagt cgttttatac 
agacagctcc aagctacttt tacatatatc tgccgtggat 
cagctgtcta tttttgtgcc agcagccatg atcgggacag 
cagtacttcg gtcccggcac caggctcacg gttttagagg 
tgtgactcca cccaaggtct ccttgtttga gccatcaaaa 
caaacaaaca aaaggctacc ctcgtgtgct tggccagggg 
gaccacgtgg agctgagctg gtgggtgaat ggcagggagg 
ggtcagcacg gaccctcagg cctacaagga gagcaattat 
tgagcagccg cctgagggtc tctgctacct tctggcacaa 
cacttccgct gccaagtgca gttccatggg ctttcagagg 
gccagagggc tcacccaaac ctgtcacaca gaacatcagt 
ggggccgagc agactgtgga atcacttcag catcctatca 
ctgtctgcaa ccatcctcta tgagatccta ctggggaagg 
tgctgtgctg gtcagtggcc tagtgctgat ggccatggtc 
attcctga 
*Leader sequence: 1 -54 
V-region: 55- 339 
D-region: 340- 354 
J-region: 355 - 396 
C-region: 397 - 918 
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Fig.4.6.B. The full T cR ~-chain sequence of the 8F9 T -cell clone* 
1 atgctgtact 
51 tgctcagact 
lel gcccactgtc 
151 tactggtact 
2el tattactgtt 
251 ccaggccgaa 
3e1 agccactctg 
351 ctttgggcca 
4e1 ctccacccaa 
451 aaacaaaagg 
Sel cgtggagctg 
551 gcacggaccc 
6e1 agccgcctga 
651 ccgctgccaa 
7e1 agggctcacc 
751 cgagcagact 
Bel tgcaaccatc 
851 tgctggtcag 
9e1 tga 
ctctccttgc ctttctcctg 
atccatcaat ggccagttgc 
tctggggtgt accataaagg 
ggcaggccac aggaggcacc 
ggccaggtag agtcggtggt 
ggacgaccaa ttcatcctaa 
gcttctacct ctgtgcctgg 
ggcactcggc tcctcgtgtt 
ggtctccttg tttgagccat 
ctaccctcgt gtgcttggcc 
agctggtggg tgaatggcag 
tcaggcctac aaggagagca 
gggtctctgc taccttctgg 
gtgcagttcc atgggctttc 
caaacctgtc acacagaaca 
gtggaatcac ttcagcatcc 
ctctatgaga tcctactggg 
tggcctagtg ctgatggcca 
*Leader sequence: 1 - 45 
V -region: 46- 330 
D-region: 331 - 336 
J-region: 337- 381 
C-region: 382 - 903 
ggcatgttct 
cgagatcaag 
ggaaatcaag 
ctccagcaac 
gcaactgaac 
gcacggagaa 
agttggcaag 
agaggatctg 
caaaagcaga 
aggggcttct 
ggaggtccac 
attatagcta 
cacaatcctc 
agaggaggac 
tcagtgcaga 
tatcatcagg 
gaaggccacc 
tggtcaagaa 
tgggtgttag se 
gctgtgggca 1ee 
ccctaacctc 15e 
tcttctactc 2ee 
ctctcagctt 25e 
gctgcttctc 3ee 
acacccagta 3Se 
agaaatgtga 4ee 
gattgcaaac 45e 
tccctgacca see 
agtggggtca sse 
ctgcctgagc 6ee 
gaaaccactt 65e 
aagtggccag 1ee 
ggcctggggc 75e 
gggttctgtc see 
ctatatgctg sse 
aaaaaattcc 9ee 
9e3 
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Figure 4.7. The presence of T4 within a Tg peptide is not sufficient to 
activate the 3.47 clone. A, The 3.47 clone does not recognize other T4-
containing peptides ofTg. B, Competitive inhibition of 3.47 T-cell activation 
in the presence of 37.5 nM of T4(2553), TA3 APC and increasing amounts 
of inhibitor peptides. Control without inhibitory peptide is 14,830 cpm. 
Points indicate means of triplicate wells and denote the thymidine uptake 
(cpm) by the IL-2-dependent CTLL cells. 
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Figure 4.8. The 3.47 clone recognizes a Tg determinant modified by 
iodine atoms. A, Lack of 3.47 T-cell activation by the thyronine-
containing analog peptide T0(2553); B, Competitive inhibition of 
3.47 activation in the presence of25 nM ofT4(2553), TA3 APC and 
increasing amounts of the competitor analog peptide T0(2553). Data 
represent one of three separate experiments. 
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Figure 4.9. A and C, Reactivity of mAbs to Tg peptides. ELISA was 
performed using 1 J..lg peptide/well and serial dilution of 55H8 (A) and 91Al (C) 
as shown. Band D, Competitive inhibition ofmAbs binding to mouse Tg in the 
presence of T4 or Tg peptide. ELISA plates were coated with 1 J..lg Tg/well. 
Competitive inhibition was performed by usingl .O jlg/ml of 55H8 (B) or 5.0 
J..lg/ml of 91Al (D) in the presence of serial dilution of peptides or T4 
molecules. Points indicate means of triplicate wells and standard deviations are 
less than 10% of the means. 
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Figure 4.10. Fine specificity of the two T4-specific mAbs. 
Recognition of Tg and T4 or T3 carried by rabbit serum albumin 
(RSA) by mAb 55H8 (A) and 91Al (B). ELISA was performed using 
1 IJ.g ofTg or RSA conjugates per well and serial dilution of mAbs as 
shown. 
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Figure 4.11. The T4-specific mAb 55H8 blocks recognition of the 
T4(2553) peptide by the 3.47 clone. The APC line TA3 (A) or 
thioglycollate-stimulated peritoneal macrophages from CBA mouse 
(B) were pulsed with T4(2553) (3 Jlg/ml) for 4 hr, washed and 
cultured with 3.4 7 cells in the presence of increasing amounts of the 
mAbs shown. Points indicate means of triplicate wells and reflect the 
relative amounts ofiL-2 released in the culture supernatants following 
activation of the 3.47 cells. Data represent one of three separate 
experiments. 
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Fig.4.12. A. 55H8 blocks activation of3.47 T-cells by the fixed, T4(2553)-pulsed 
APC.TA3 cells (5x106 cells I ml) were pulsed with 3 ~g/ml of T4(2553) peptide 
for 2h followed with fixation by 0.05% glutaraldehyde for 30 seconds. The fixed, 
T4(2553)-pulsed TA3 cells (5x105 /well) were cultured with same number of 3.47 
T -cells in the presence of serial dilution of blocking mAbs shown. CTLL 
proliferation assay was performed to compare IL-2-secretion by the 3.47 T-cells 
under different conditions. B. The 55H8-Tg immune complex did not block the 
activation of 3.47 T-cells by T4(2553) peptide. The 55H8-Tg immune complex 
was preformed by mixing equimolar amount of 55H8 and Tg for 1 h before the 
assay. The concentration ofiC was expressed as 55H8 concentration. To perform 
the activation assay, the TA3 cells (5x106/ml) were pulsed with 2 Jlg/ml of 
T4(2553) peptide for 6 h followed by washing. The pulsed TA3 cells were 
cultured with same number of 3.47 T-cells (5x105/well) in the presence of serial 
dilutions of either 55H8 mAb or the 55H8-Tg immune complex. The IL-2 content 
of the 24h-culture supernatants was assessed by CTLL proliferation. The control 
without blocking mAbs was 14,097 cpm. 
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Figure 4.13. Blockade of activation of T4(2553)-primed LNC by T4(2553)-
specific mAb 55H8. Mitomycin-treated normal CBA splenocytes were 
pulsed with or without 10 J.Lg/ml of T4(2553) peptide for 6 hr. After washing, 
some of the T4(2553)-pulsed splenocytes were treated with 60 IJ.g/ml of mAb 
55H8, 91Al or 3B3 for 1 hr, followed by complete washing. LNC from CBA 
mice immunized 9 days earlier with 100 IJ.g T4(2553) peptide in CFA were 
cultured with T4(2553)-pulsed (Black bar), T4(2553)-pulsed and mAb-treated 
(Hatched bars), or non-pulsed (Empty bar) syngeneic splenocytes for 
proliferation assay as described in Materials and Methods. 
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Fig. 4.14. 55H8 mAb ameliorates EAT transferred by T4(2553)-primed LNC. 
RBC-lysed and mitomycin-treated splenocytes (2xl 07 cells/ml) from CBA mice 
were pulsed with 30 J..tg/ml of T4(2553) peptide for 4h, followed with complete 
wash. The T4(2553)-pulsed splenocytes (2x107 cells/ml) were incubated with 
100 j..tg/ml ofmAb 55H8 or 91Al or with media only for 2h (Variants are shown 
on the X-axis). After washing, the different groups of splenocytes (2x107 
cells/ml) were mixed with T4(2553)-primed LNC (4x107 cells/ml) from CBA 
mice immunized with 100 J..tg of T4(2553) peptide emulsified in CFA for 10 
days, and the mixture was cultured in 6-well plate in complete DMEM media 
for 4 days. Then, dead cells in the mixture were removed with Ficoll 
centrifugation, and living cells were collected. For adoptive transfer, 107 of living 
cells suspended in 1 ml of DMEM were injected i.p. into female CBA mice (6 
mice per group). On day 13 after the transfer, the thyroid glands of the recipient 
mice were collected for scoring EAT severity. The lymphocyte infiltration 
indexes were scored blind as described in Materials and Methods. Horizontal 
bars represent the means of the infiltration indexes, and the vertical bars 
represent the standard deviations. 
134 
CHAPTERS 
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5.1. Abstract 
Increased iodine intake has been associated with the development of 
experimental autoimmune thyroiditis (EAT), a T -cell mediated disease. The 
biological basis for this association remains poorly understood but an attractive 
postulate has been that enhanced incorporation of iodine in thyroglobulin (Tg), 
promotes generation of pathogenic T-cell determinants. Since most of the known 
pathogenic Tg T-cell epitopes are cryptic and do not contain iodine atoms, we 
sought in this study to directly test this hypothesis by using the pathogenic non 
dominant A5-binding Tg peptides p2495 and p2694 as model antigens. SJL mice 
challenged with highly iodinated Tg (I-Tg) developed EAT of higher severity 
than Tg-challenged controls and LNC from I-Tg primed hosts showed a higher 
proliferation and IL-2 or IFN-y release in response to 1-Tg in vitro than Tg-
primed LNC reacting to Tg. Interestingly, 1-Tg-primed LNC proliferated 
strongly in vitro against p2495 but not p2694 indicating efficient and selective 
generation of p2495 following processing of I-Tg in vivo. Tg-primed LNC did not 
respond to either peptide. Similarly, the p2495-specific, IL-2 secreting T-cell 
hybridoma clone 5E8 was activated when cultured with I-Tg, but not Tg -pulsed 
splenocytes. Whereas, the p2694-specific T cell h ybridoma clone 6E10 remained 
unresponsive to splenic APC pulsed with either Tg or 1-Tg. The selective in vitro 
generation of p2495 was demonstrable in macrophages or dendritic cells but not 
B cells suggesting heterogeneity in the capacity of various APC sets to process 1-
Tg. These data demonstrate that enhanced iodination of Tg facilitates selective 
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processing and presentation of a cryptic pathogenic peptide in vivo or in vitro 
and suggest a mechanism that can account for the association of high iodine 
intake and development of EAT. 
5.2. Introduction 
Increased iodine (I) ingestion has been shown to promote induction of 
autoimmune thyroiditis in humans (Beierwaltes, 1969; Boyages et al., 1989; 
Braverman et al., 1971; Kahaly et al., 1998; Tajiri et al., 1986), and experimental 
animals such as chicken (Bagchi et al., 1985), rats (Allen et al., 1986; Mooij et al., 
1993), hamsters (Follis, 1959) and mice (Rasooly et al., 1996). The mechanisms 
underlying this association remain poorly understood. One attractive theory has 
been that enhanced I intake increases the immunogenicity of thyroglobulin (Tg), 
precipitating an autoimmune response. This is a plausible explanation given that 
a) the main metabolic role of Tg is the organification of I and the formation of the 
hormones thyroxine (T4) and triiodothyronine (T3) via intramolecular coupling 
of specific iodotyrosyls (Dunn, 1995), b) Tg is the largest autoantigen known, 
inducing experimental autoimmune thyroiditis (EAT) in several species 
(Weetman and McGregor, 1994) and c) highly iodinated Tg (1-Tg) demonstrates 
enhanced immunogenicity (Sundick et al., 1987) or altered antigenicity (Saboori 
et al., 1998) at the serological level. 
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Tg-induced EAT, which serves as a model for Hashimoto's thyroiditis in 
humans, is nevertheless, considered to beaT-cell mediated disease (Weetman 
and McGregor, 1994) and the question whether or how incorporation of I into Tg 
promotes generation of Tg-specific autoreactive T cells has not been adequately 
investigated. Four out of the five known pathogenic Tg peptides do not contain I 
atoms or T4 residues (Carayanniotis and Kong, 2000; Carayanniotis and Rao, 
1997). Furthermore, studies using peptide analogues that encompass 
hormonogenic - i.e. T4-containing sites of Tg have clearly shown that these 
epitopes are generated even after processing of normal Tg and that the presence 
of I atoms per se does not render a peptide immunogenic (Champion et al., 1991; 
Dawe et al., 1996; Kong et al., 1995). On the other hand, processing of non-
iodinated Tg does not generate the pathogenic peptide (2549- 2560) in vitro 
(Champion et al., 1987), suggesting that a minimal amount of Tg iodination is 
required for the generation of some Tg T-cell epitopes. 
In this study, we have examined whether transition of normal Tg to a highly 
iodinated form (I-Tg) - i.e. a shift from 15-20 I atoms to 55-70 I atoms per 
monomeric subunit- would enhance its immunopathogenicity in mouse EAT. 
The availability and prior characterization of two non dominant, A5-binding, 
pathogenic Tg peptides (2495-2511) (p2495) and (2694-2711) (p2694) in our 
laboratory (Carayanniotis et al., 1994; Chronopoulou and Carayanniotis, 1992) 
has further allowed us to test the hypothesis that processing of I-Tg, but not Tg, 
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leads to generation of cryptic pathogenic determinants. Such a mechanism might 
partly account for the association of high I intake and autoimmune thyroiditis. 
5.3. Results 
5.3.1. Preparation of highly iodinated Tg (1-Tg) 
The iodine content in the I-Tg preparations was assessed by a modified (Saboori 
et al., 1993), non-incinerative, colorimetric method (Palumbo et al., 1982) that is 
based on the catalytic function of iodine in the reduction of the yellow eerie ion 
Ce(IV) to the colorless cerious ion Ce(III) by arsenite As(III). Using thyroxine 
(T4) as a standard in the assay it was confirmed that the initial change in 
absorbance was proportional to the concentration of T4 over the range of 120 to 
960 pmol (Fig. 5.1A). By extrapolation, normal mouse Tg was shown to contain 
15-20 I atoms and this content increased to a plateau of 70 I atoms per molecule 
over a 20 min incubation period with IODOGEN (Fig. 5.1B). Maximally 
iodinated Tg (55-75 I atoms per monomer) was used in all subsequent work. 
5.3.2. Iodination enhances the immunogenicity and pathogenicity of Tg 
To compare the immunogenicity of I-Tg vs. Tg, SJL/J mice were challenged s.c. 
with 100 JJ.g Tg or I-Tg emulsified in CFA, and the antigen-specific in vitro 
139 
responses of primed LNC were determined 9-11 days later. It was observed that, 
upon in vitro stimulation with Tg, LNC from Tg-primed mice did not proliferate 
significantly (S.I. <3) and did not secrete detectable levels of IL-2 (<52 pg/ml) or 
IFN-y ( < 366 pg/ml) in the culture supernatant (Table 5.1). In contrast, LNC 
from I-Tg-primed mice, proliferated strongly (S.I.= 12-15) against I-Tg in vitro, 
while secreting significant amounts of IL-2 (785-805 pg/ml) and IFN-y (787-3654 
pg/ml). Interestingly, I-Tg-primed LNC responded only weakly to Tg in vitro 
(Table 5.1) while no responses were detected against highly iodinated OVA(= 10 
I atoms/molecule, data not shown), indicating recognition of determinants 
restricted mainly to I-Tg. These data suggested that modification of Tg by I 
rendered this molecule highly immunogenic at the T cell level. 
To examine whether the increased imunogenicity of I-Tg correlates with its 
thyroiditogenicity, we immunized SJL/J mice (6 mice/group) with Tg or I-Tg in 
CFA on day 0, and boosted them with the respective Ag in IFA on day 14. 
Thyroids were collected on day 28 for histological examination of EAT 
development. Five out of six I-Tg-challenged mice developed severe EAT 
(infiltration index (1.1.);::: 3) and the group exhibited a mean 1.1.= 2.83 ± 0.98 (Fig. 
5.2). In contrast, all Tg-challenged mice developed mild EAT (1.1. ~ 2.0) and a 
significantly lower group 1.1. mean (=1.33 ± 0.75, p< 0.01). These results 
demonstrated the increased pathogenicity of the 1-Tg preparation. 
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5.3.3. Enhanced iodination of Tg promotes generation of the cryptic pathogenic 
peptide p2495 
The enhanced immunopathogenicity of I-Tg vs Tg could be explained via at least 
two distinct mechanisms that are not mutually exclusive. First, iodination might 
facilitate generation of cryptic T-cell epitopes that are shared with normal Tg but 
are formed only after processing of 1-Tg in APC. Second, iodination might lead 
to formation of new !-modified T-cell epitopes that do not exist in normal Tg. We 
proceeded to seek evidence for the first mechanism because of the availability 
and prior characterization of the cryptic Tg peptides (2495-2511) (p2495) and 
(2694-2711) (p2694) in our laboratory (Carayanniotis et al., 1994; Carayanniotis 
and Rao, 1997; Chronopoulou and Carayanniotis, 1992). These peptides are 
immunogenic and cause EAT but are not generated following processing of Tg in 
vivo or in vitro. 
SJL/J mice were again immunized with Tg or I-Tg in CFA, and 9 days later, the 
draining LNC were tested in recall proliferative assays against p2495 or p2694 in 
vitro. Neither peptide could stimulate the Tg-primed LNC to proliferate, in 
accordance with their cryptic nature (Fig. 5.3). Surprisingly, however, p2495 but 
not p2694 induced significant proliferation of I-Tg-primed LNC. This finding 
supported the view that iodination of Tg promotes selective generation of 
pathogenic peptides such as p2495. To confirm this at the clonal T-celllevel we 
used the CD4+, A5-restricted 5E8 and 6E10 T-cell hybridoma clones that secrete 
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IL-2 upon recognition of p2495 and p2694, respectively (Fig. 5.4A and B). Freshly 
isolated SJL spleen cells, used as APC, were incubated with 5E8 or 6E10 T cells 
and varying concentrations of Tg, I-Tg or I-OVA. It was observed that I-Tg 
activated strongly the p2495-specific SE8 clone within the 0.1-1 J.!.M range (Fig. 
5.4C), whereas equimolar amounts of normal Tg were not stimulatory. Similarly, 
I-OVA did not elicit a response up to 3.5 J.!.M excluding the possibility that the 
high I content in the antigenic preparation mediated a non-specific activation of 
the T cells. On the other hand, the p2694-specific 6E10 clone was not activated 
with either Tg or I-Tg, (Fig. 5.4D) while it responded strongly to equimolar 
amounts of free p2694 (data not shown). These data confirmed that enhanced 
iodination of Tg promoted the selective processing and presentation of the 
cryptic pathogenic peptide p2495 in APC. 
5.3.4. Generation of p2495 following processing of I-Tg in macrophages and 
DC 
We next examined whether the selective generation of p2495 could be observed 
only after processing of I-Tg in certain APC subsets. Splenic resting B-cells were 
isolated by complement-mediated depletion ofT-cells and accessory cells using 
anti-Thyl.1, anti-MAC-1 and anti-DC mAbs. Splenic macrophages were enriched 
by plastic adherence. Mature dendritic cells (DC) were obtained by culturing 
bone marrow progenitors in the presence of GM-CSF. The various APC 
populations were mixed at 1:1 ratio with 5E8 or 6E10 T cells in the presence of 1 
J.!.M Tg and I-Tg, using equimolar amounts of free p2495, p2694 and I-OVA as 
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controls. As shown in Fig. 5.5, none of the APC populations could generate 
p2495 or p2694 following processing of normal Tg, as indicated by the lack of 
activation of the peptide-specific T-cell clones. In contrast, processing of 1-Tg in 
macrophages or dendritic cells but not B cells allowed the generation of p2495 
and the activation of the 5E8 clone (Fig. 5.5, A, C, E). This was a selective process 
because p2694 was not generated in any APC under identical conditions of 
culture (Fig, 5 B, D, F). These findings demonstrated that enhanced iodination of 
Tg promotes selective generation of p2495 in specific APC subsets such as 
macrophages and DC which are potent stimulators of naive T cells. 
5.4. Discussion 
Tg plays a central role in thyroid function and pathology because of its capacity 
a) to store available iodine, b) to act as a matrix for the formation and storage of 
thyroid hormones, and c) to encompass epitopes that activate infiltrating T cells 
that destroy the thyroid gland (Weetman and McGregor, 1994). In this study, we 
provide evidence that increased iodination of normal Tg renders the molecule 
highly immunogenic via at least one distinct mechanism: the enhanced 
generation of non-iodinated, cryptic, pathogenic T -cell determinants, such as 
p2495, in APC. Since the structure (Edelhoch et al., 1969), and proteolytic 
degradation (Pouchier et al., 1983; Lamas and Ingbar, 1978) of Tg are known to 
be affected by its iodine content, the present findings can be best explained by an 
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iodine-mediated modification of Tg substrate sites resulting in altered I-Tg 
processing in APC as compared to that of normal Tg. This hypothesis can 
account for the observed selective changes in the hierarchy (Sercarz et al., 1993) 
ofT-cell epitopes in 1-Tg, manifested by the generation of p2495 which changes 
from cryptic (Chronopoulou and Carayanniotis, 1992) to dominant and by the 
apparent lack of effect on the formation of p2694 which remains nondominant 
(Carayanniotis et al., 1994). The same hypothesis can also account for the 
differential capacity of various APC (macrophages and dendritic cells vs B cells) 
to process a given peptide, due to their diverse protease contents (Vidard et al., 
1992). Because circulating Tg is poorly iodinated (Ikekubo et al., 1981; Schneider 
et al., 1983), peptides such as p2495 would not be normally generated in 
extrathyroidal sites, but once formed, they could elicit strong autoreactive T cell 
responses, as it is unlikely that immune mechanisms of peripheral tolerance 
would be pre-established against cryptic epitopes. This consideration deserves 
further merit in view of the fact that, so far, all known pathogenic T-cell epitopes 
in Tg have been characterized as nondominant (Carayanniotis and Rao, 1997). 
Our results are analogous to those of Griem et al. (Griem et al., 1996) who 
showed that alteration of bovine ribonuclease A by the metal ion Au(III) leads to 
sensitization ofT cells specific for cryptic peptides. 
Processing of I-T g could also generate novel, iodine-modified T -cell determinants 
containing iodotyrosyls, or enhance the production of T -cell epitopes that 
encompass hormonogenic sites. While there is no evidence yet for the former 
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mechanism, the peptide (2549-2560) containing T4 at position 2553 (T4(2553) is 
known to activate pathogenic CD4+ T cells that recognize I atoms since they 
cannot be activated by a thyronine-containing (T0(2553)) analog that lacks 
iodine (Champion et al., 1991; Dawe et al., 1996; Hutchings et al., 1992; Kong et 
al., 1995). If there is increased production of T4(2553) during the processing of I-
Tg vs Tg, it could potentiate generation of Tg-reactive, EAT-inducing T cells. 
However, the contribution of hormonogenic regions to the enhanced 
immunopathogenicity of I-Tg is likely to be minimal since most T4-containing 
peptides are weakly antigenic or devoid of immunogenicity (Carayanniotis and 
Kong, 2000). 
High iodine intake may promote the iodination of Tg but it can also precipitate a 
number of other pathogenetic cascades related to iodine toxicity. High doses of 
iodine can cause necrosis of hyperplastic thyroid glands of normal animals 
(Bagchi et al., 1995; Follis, 1959) or human thyroid follicles in vitro (Many et al., 
1992). This initial thyroid cell injury may be an important prerequisite for the 
subsequent development of autoimmune thyroiditis in goitrous NOD mice 
(Many et al., 1995), Obese Strain chickens (Bagchi et al., 1995) or humans with 
pre-existing goiters (Kahaly et al., 1998; Mizukami et al., 1993; Tajiri et al., 1986). 
In addition, iodine can exhibit pleiotropic effects by influencing processes that 
interfere with immune function. These include inhibition of IFN-y-induced class 
II expression on rat (FRLT-5), but not human, thyroid cells (Davies et al., 1989), 
increase in the inducibility of the 72-kDa heat shock protein in cultured human 
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thyrocytes (Sztankay et al., 1994) and enhancement of IgG production in PWM-
stimulated human peripheral blood lymphocytes in vitro (Weetrnan et al., 1983). 
Our findings are in agreement with studies reporting an essential role of iodine 
for Tg recognition by human (Rasooly et al., 1998) T cells. Presentation of cryptic 
I-Tg peptides on professional APC such as dendritic cells would lead to 
activation of resting autoreactive T-cells that can subsequently act as effector cells 
in autoimmune thyroiditis and/ or as T helper cells in the concomitant antibody 
response against thyroid antigens. In conjunction with the available TcR 
repertoire, the host MHC haplotype would dictate, via determinant selection, the 
relative contribution of each peptide in the disease process. This hypothesis 
would explain why only certain individuals develop autoimmune thyroiditis 
after high iodine intake (Weetrnan and McGregor, 1994) or why they occasionally 
present with enhanced B-cell autoreactivity to Tg without overt symptoms of 
thyroiditis (Boukis et al., 1983). The validity of this hypothesis will be further 
tested following the discovery of additional pathogenic T-cell epitopes in Tg. 
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Fig. 5.1. Iodine determination for Tg and I-Tgs. A, T4 standard curve. The 
reduction of absorbance at 410 nm in the first 60 seconds of iodine-catalyzed Ceric-
Arsenite reaction is shown for various amounts of T4 added in the reaction. B, 
Iodination increases the iodine contents in Tg. Tg was iodinated by IODOGEN 
method for various periods as shown, and 16 f..lg of the Tg or I-Tg samples was 
used for iodine determination. Iodine content ofTg was extrapolated from A (one 
mole ofT4 equals 4 moles of iodine). 
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Table 5.1. Iodination of Tg enhances its immunogenicity 
Ags in vitro 
Exp. Ag Tg 1-Tg No. in vivo 
SI ll..-2* IFN-y* SI ll..-2 IFN-y 
Exp.l Tg 2.9±0.3 52±8.8 <278 5.7±0.7 119±5.3 <278 
1-Tg 5.8±1.5 133±3.5 325±47 14.9±1.7 785±14 786.9±38 
Exp.2 Tg 2.1±0.4 46±9 <366 3.3±0.2 87±8 <366 
1-Tg 2.9±0.6 131±15 <366 12.4±0.5 805±23 3654±62 
* ll..-2 & IFN-y: pg/ml 
Background cpm (cultures with no Ag) were: Tg-primed LNCs = 614 (740), 1-Tg-primed 
LNCs = 1208 (1355); Detection limit for IL-2 was 52 (46) pg/ml; IFN-gamma was 278 
(366) pg/ml. [ Exp.l (Exp. 2)]. IL-4 in all culture supernatants was undetectable. 
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Fig. 5.2. Direct induction of EAT by immunization with Tg or 1-
Tg. Six female 6-8wk SJL mice per group were immunized with 
100 J.l.g of either Tg or I-Tg emulsified in CFA. After 2wk, the 
mice were boosted with 50 Jlg of the same Ags emulsified in 
IF A. The thyroid glands were collected at 4wk for histology 
examination. Scoring the slides for lymphocyte infi ltration 
indexes was performed blind as described in Materials and 
Methods. (p < 0.01) 
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Fig. 5.3. Generation of the cryptic peptide, p2495, following immunization 
with I-Tg. Two female SJL mice per group were immunized with 100 J.lg of 
either Tg or 1-Tg emulsified in CFA. After 10 days, the draining LNC 
(5x105 cells/well) were cultured with of each ofTg peptides (20 J.lg/ml) or 
media in total 200 Ill/well of complete media. Proliferation of the LNC was 
expressed as the 3H-thymidine incorporation in last 24 h of total 96 h 
culture. Each value represents average of triplicate wells. 
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Fig. 5.4. Enhanced presentation of p2495 following processing of I-Tg. A&B, 
Specificity of Tg peptide-reactive T-cell hybridomas. H-25-restricted T-cell 
hybridomas 5E8 (A&C, p2495-specific) and 6E10 (B&D, p2694-specific) cells 
(1 05 /well) were cultured in 1 :5 ratio with syngeneic splenocytes in the 
presence of serial dilutions of Ags as shown. IL-2-release from the T-cells was 
determined by CTLL proliferation assay. 
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Fig. 5.5. Macrophages and DC are efficient in generation of p2495 following 
processing of 1-Tg. Splenic macrophages, B-cells and bone-marrow-derived DC 
were isolated from SJLI J mice as described in Materials and Methods. Activation of 
T-cell hybridomas 5E8 (A, C and E, p2495-specific) and 6E10 (B, D and F, p2694-
specific) was performed by culturing the hybridoma cells (1 05 cells/well) at a 1:1 
ratio with the various APC in the presence or absence of 1 11M Ag as shown (* : not 
done). IL-·2-release from the T -cells in the 24h-culture supernatants was assessed by 
CTLL proliferation assay. Each value represents average of triplicate wells, and 
figures shown are one of 3 experiments with similar results. 
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CHAPTER6 
FUTURE DIRECTIONS 
The present study was initiated following the observation that none of the three 
pathogenic T-cell epitopes in Tg, Tg(2495-2511), Tg(2694-2711) and T4(2553), 
were immunodominant. All three peptides can directly induce EAT in mice 
following immunization with the peptides emulsified in CFA, but LNC primed 
with these peptides cannot recognize intact Tg in in vitro recall assays. The 
question raised at the beginning of the study was whether alterations of Tg 
processing in APC could facilitate generation of these cryptic or non-dominant 
epitopes. The data obtained demonstrate that processing of Tg-mAb ICs or 
iodinated Tg by certain APC populations can generate some of these non-
dominant Tg epitopes. The study provides insights into mechanisms, such as 
post-translational modification of auto-Ag and epitope spreading, operating in T-
cell-mediated organ-specific autoimmune diseases. This work has also raised 
new questions. 
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6.1. Regulation of T -cell response to Tg peptides using Tg-specific mAbs 
Auto-Abs against Tg are commonly present in HT patients (Nordyke et al., 1993). 
The results in Chapter 3 clearly demonstrate that Tg-specific Abs can influence 
the processing and presentation ofT-cell epitopes of Tg in vitro, suggesting that 
they may have an important immunoregulatory role during the course of HI. 
Tg-specific B-cells may play a central role in T -cell epitope spreading, a 
phenomenon commonly observed in T-cell-mediated autoimmune diseases such 
as EAE (Lehmann et al., 1992; Mamula et al., 1994). Tg-specific B-cells carry slgs 
that recognize various binding sites on Tg, and following Tg internalization and 
processing, different B-cell clones may present different epitopes to Tg-specific T-
cells through a mechanism proposed in our study. Therefore, the T-cell response 
against Tg can be diversified due to the activation of different Tg-specific B-cells. 
One objective in future studies will be to examine whether Tg-specific B-cells can 
selectively present T-cell epitopes of Tg and regulate the development of EAT. 
6.1.1. Generation of T4(2553) peptide following processing of Tg by Tg-specific 
B-cells 
Hypothesis: Tg-specific B-cells can efficiently internalize Tg and generate T4(2553) 
peptide. 
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Rationale: LNC primed in vivo with the T4(2553) peptide cannot proliferate in 
vitro in the presence of Tg but can be activated strongly by the priming peptide 
in culture (Champion et al., 1991). These data suggest that generation of T4(2553) 
peptide is not efficient following processing of Tg by APC in vitro. However, 
immunization of CBA/J mice with Tg emulsified in CFA can activate T-cells 
reactive to the T4(2553) peptide (Hutchings et al., 1992; Kong et al., 1995). 
Processing of Tg in vivo may generate sufficient T4(2553) to activate peptide-
specific T -cells. Based on our observations in Chapter 3 that Tg-specific mAbs 
can enhance generation of T4(2553) following processing of Tg-Ab ICs in APC 
(Dai et al., 1999), we propose that Tg-primed B-cells are efficient in processing Tg 
to generate T4(2553) peptide. 
Experimental design 1: To examine the efficiency of Ag processing and 
presentation in Tg-primed B-cells, the T-cell hybridoma 3.47 specific for T4(2553) 
will be used to monitor the generation of T4(2553). Tg-primed B-cells will be 
collected from the spleen of CBA/J mice previously challenged with Tg and LPS. 
B-cells will be purified by positive selection with anti-B220-coated magnetic 
beads. A control Ag such as OVA will be used to generate OVA-specific B-cells. 
Tg internalization in B-cells will be monitored directly using 1251-labeled Tg. The 
activation assay will be performed by co-culturing 3.47 T-cells with Tg or OVA 
-specific B-cells in the presence of Tg. 
Interpretation of results: If B-cells primed only with Tg but not OVA can activate 
the 3.47 T-cells in the presence of Tg in culture, we will conclude that Tg-primed 
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polyclonal B-cells can selectively enhance generation of T4(2553) during 
processing of Tg, perhaps due to their capacity to internalize large quantities of 
Tg. This finding will also support the hypothesis that Tg-primed B-cells may 
generate T4(2553) in vivo. 
Experimental design 2: The hypothesis can be further addressed by examining 
whether Tg-primed B-cells have the capacity to activate T4(2553)-specific effector 
T-cells. T-cells collected from the draining LN of CBA/J mice immunized with 
T4(2553) will be used as responder cells. T-cells will be isolated by positive 
selection with anti-Thy-1-coated magnetic beads. Tg- or OVA-specific B-cells can 
be obtained from Ag-primed splenocytes following purification with anti-B220-
coated magnetic beads. Activation of T4(2553)-primed T-cells will be done by 
culturing the enriched T4(2553)-primed T-cells with B-cells primed with Tg or 
OVA in the presence of Tg in culture. Generation of T4(2553)-primed effector T-
cells will be demonstrated by adoptive transfer of the cultured T -cells into 
syngeneic na1ve recipient mice. 
Interpretation of results: Development of EAT in mice receiving T4(2553)-primed 
T -cells will confirm the generation of pathogenic effector T -cells in culture. If 
mice receiving T4(2553)-primed T-cells cultured with Tg and Tg-primed B-cells 
but not OVA-primed B-cells develop EAT, it will further support that generation 
of T4(2553) by Tg-primed B-cells are sufficient to activate T4(2553)-specific 
effector T -cells. 
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6.1.2. In vivo effects of 502 and 3C4 mAbs on activation ofT-cells specific for 
T4(2553) 
Hypothesis: 5D2 and 3C4 mAbs have an immunofocusing effect on activation of 
T4(2553)-reactive T-cells in vivo. 
Rationale: In Chapter 3, it was shown that processing of 5D2-Tg and 3C4-Tg ICs 
in the B-cellline, TA3, enhances the generation of T4(2553). Whether this in vitro 
phenomenon represents a physiological mechanism, i.e. it can be mediated by 
normal B-cells, remains unkown. 
Experiment design 1: To examine whether normal B-cells can process Tg-5D2 and 
Tg-3C4 ICs efficiently to generate T4(2553) peptide, resting B-cells from the 
spleens of normal CBA/J mice will be used as APC. Purification will be 
performed as above using anti-B220 coated magnetic beads. Tg-Ab ICs will be 
formed as described in Chapter 2. ICs, formed with the Tg-specific mAb 3B3 that 
is unable to enhance generation of T4(2553) shown in Chapter 3, will be used as 
controls. The rate of internalization of Tg-Ab ICs by normal B-cells will be 
directly measured by pulsing the B-cells with ICs of 1251-labelled Tg with mAbs. 
The 3.47 T-cell hybridoma will be used to monitor the presentation of T4(2553) 
following processing of Tg or Tg-Ab ICs, and activation of the T-cells will be 
examined by measuring the IL-2 concentration in the culture supernatant. 
Interpretation of results: If B-cells cultured with Tg-5D2 and Tg-3C4 but not Tg-3B3 
activate the 3.47 T -cells, supportive evidence will be provided that normal B-cells 
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may process Tg-5D2 and Tg-3e4 ICs efficiently and amplify the T4(2553)-specific 
T -cell response. 
Experiment design 2: Tg-Ab res will be used for immunization and induction of 
EAT in CBA/J mice. Tg-3B3 res will be again used as a control. On day 9 to 12 
after immunization, draining LN will be collected for proliferation assay against 
T4(2553) in vitro. For induction of EAT, eBA/J mice will be s.c. immunized with 
Tg-Ab ICs emulsified in CFA, and boosted with same Ag in IFA after 2 weeks. 
Development of EAT will be examined by scoring the lymphocytic infiltration of 
thyroid glands in the second week after the boosting. 
Interpretation of results: If LNe primed with Tg-5D2 and Tg-3C4 proliferate more 
strongly than Tg-3B3 -primed LNC against T4(2553) in vitro, this will support 
the view for an enhancing effect of 5D2 and 3C4 on generation of T4(2553) 
peptide following processing of Tg-Ab res in vivo. Increased EAT severity in 
mice immunized with Tg-5D2 and Tg-3C4, vs Tg-383-primed mice, will further 
confirm the immunofocusing effect of 5D2 and 3C4 on activation of T4(2553)-
reactive T-cells. 
6.1.3. Tg processing in B~cells with same specificity as 502 and 3C4 mAbs 
Hypothesis: B-cells carrying slg of the same specificity as 5D2 and 3e4 mAbs are 
efficient in processing of Tg and generation of T4(2553). 
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Rationale: It was shown in Chapter 3 that the B-cell hybridoma TA3 cannot 
process Tg to generate T4(2553). However, this peptide was generated efficiently 
in the same APC following processing of Tg complexed to 5D2 and 3C4 but not 
3B3 mAbs. This enhanced presentation of T4(2553) requires FeR-mediated Ag 
internalization. It is not clear whether Tg internalized through BcR will be 
processed similarly as that through FeR. In other words, can different Tg-specific 
B-cell clones selectively generate different T-cell epitopes during Tg processing? 
Experimental design: To construct B-cells with the same specificity as 5D2, 3C4 and 
3B3 mAbs, the variable regions of the H- and L- chains of each mAb will be 
cloned from the respective mAb-secreting B-cell hybridoma. Then, the variable 
region eDNA will be subcloned into vectors containing the H- or L- chain 
constant regions of slg to form chimeric Ig genes (Goodnow et al., 1988). TA3 B-
cell hybridoma will be transfected with each of the chimeric slg eDNA. Stable 
T A3 transfectants expressing the chimeric slg of 5D2, 3C4 and 3B3 will be 
selected for Ag processing. To examine whether these transfected B-cell clones 
carrying the different chimeric slgs can selective present T4(2553) peptide 
following processing of Tg, activation assay will be performed by co-culturing 
the 3.47 T-cells with the B-cell clones in the presence of Tg. Since the slg 
expression level on the transfected B-cells may affect the rate of Tg 
internalization and, subsequently, the generation of T4(2553), expression of slg 
on these B-cell clones will be examined using fluorescence-labeled anti-IgG. B-
cell clones expressing similar levels of slg will be u sed as APC. Tg binding and 
internalization in these B-cells will be directly measured with 1251-labeled Tg. 
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Interpretation of results: If the B-cells of the same specificity as 5D2 and 3C4 but 
not 3B3 activate the 3.47 T-cells in the presence of Tg, we will obtain evidence 
that diverse Tg-specific B-cell clones may vary in their capacity to generate 
T4(2553). That is, generation of T4(2553) will not be simply a result of enhanced 
Tg uptake by Tg-specific B-cells. 
6.2. Regulation of autoreactive T-cells: using TcR transgenic mice 
expressing a TcR specific for T4(2553) 
EAT is T-cell-mediated autoimmune disease, and it is still unclear how auto-
reactive T -cells escape from thymic selection and become activated in periphery. 
Since autoreactive T-cells causing autoimmune diseases are commonly 
polyclonal and recognize unknown epitopes, it is difficult to examine their 
development and fate during the onset of the disease. TcR transgenic mice 
provide a unique tool to overcome this difficulty. In these mice, most of 
circulating T -cells express a single TcR reactive with a known epitope of a self-
Ag. TcR transgenic mice have been used with success in several autoimmune 
disease models, such as IDDM and EAE (Goverman et al., 1993; Katz et al., 1993), 
and have aided in the elucidation of mechanisms of T-cell maturation and 
regulation of autoimmune responses. However, so far, TcR-transgenic mice have 
not been established in EAT. The T-cell hybridoma 3.47 that has been 
characterized in Chapter 4 is an excellent material for the construction of a TcR-
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transgenic mouse model, since it carries a TcR specific only for the T4-containing 
Tg peptide T4(2553) but not for the tyrosine-containing analog (Dawe et al., 
1996). Such a TcR transgenic mouse model will be extremely valuable in EAT 
studies, concerning the maintenance of peripheral T-cell tolerance and 
recognition of post-translationally modified T-cell antigens. 
6.2.1. Generation of transgenic mice expressing the TcR of the 3.47 clone 
The TcR ~-chain of the 3.47 clone consists of V~1, J~2.6. The VDJ sequence was 
shown in Fig. 4.5. TcR Va and Ja usage by the 3.47 clone will be identified using 
the "anchored PeR" method. 
Construction of a- and ~- chain vectors: 
Forward and reverse primers flanked with restriction sites will be designed to 
amplify the complete VJ region of a-chain or VDJ region of ~-chain from the 3.47 
genomic DNA sample. The PCR fragments will be ligated into pTacass and 
pTpcass vectors that direct expression of TcR a-chain and ~-chain genes, 
respectively, in transgenic mice (Kouskoff et al., 1995). Several clones will be 
sequenced to ensure that proper ligation of VJ or VDJ sequence into the vectors 
has been achieved. The functionality of the a- and ~-chain constructs will be 
examined by transfection of the pTacass and pTpcass vectors containing 3.47 a-
and ~-chain genes into the BW5147 a-~- thymoma or into aT-cell hybridoma with 
different specificity from 3.47 such as 8F9. Activation of the TcR-transfectants by 
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T4(2553) in the presence of Ak-expressing APC such as TA3 will provide 
evidence for the functionality of 3.47 a- and ~- chain vectors. 
Generation of founder mice: 
Linearized TcR dsDNA from both the pTacass and pT~cass vectors will be co-
injected into fertilized B6 oocytes to generate TcR transgenic founders with the 
EAT resistant B6 background as described by Kuchroo's group (Waldner et al., 
2000). The TcR transgenes will be introduced into the EAT-susceptible strain 
CBA/J mice by backcrossing for at least 5 generations. Genotyping of the TcR 
transgenes will be done by Southern analysis using probes specific for the VJ of 
a-chain and the VDJ of ~-chain genes of 3.47 clones. DNA from 3.47 and 8F9 T-
cell clones will be used as positive and negative controls, respectively. The 
phenotype of the TcR-transgenic mice will be examined by proliferation assay of 
the peripheral lymphocytes against T4(2553) peptide. 
6.2.2. The role of iodine in the development of spontaneous autoimmune 
thyroiditis (SAT) in the TcR transgenic mice 
Hypothesis: Development of SAT in the T4(2553)-TcR transgenic CBA/J mice is 
iodine-dependent. 
Rationale: It has been well-documented that post-translational modification of 
auto-Ags can increase their immunogenicity leading to autoimmune disease 
(Mamula et al., 1999; Molberg et al., 1998). Iodination of Tg molecules is an 
important post-translational modification that takes place in thyrocytes. Excess 
iodine intake has long been considered as a causative environmental factor of HT 
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(Rose et al., 1997). Roitt et al. proposed that Tg iodination facilitates the 
generation of new iodine-containing T-cell epitopes. We plan to examine the role 
of iodine in SAT development in TcR-transgenic mice enriched with T4(2553)-
specific T -cells. This study will generate valuable data for understanding the role 
of iodine on development of HT. 
Experiment design 1: The anti-Tg titer in the sera of the T4(2553)-TcR transgenic 
CBA/J mice will be tested by ELISA at different ages of the mice raised on 
normal diet. Mice of different ages will be sacrificed for histological examination 
of thyroid lymphocytic infiltration. The 5th generation of the backcrossing 
littermates expressing either TcR a-chain or TcR J3-chain single transgene will be 
used as control for development of SAT. The incidence and severity of SAT will 
be used as indexes for comparing the development of SAT between the T cR 
transgenic mice and their normallittermates. 
Interpretation of results: If T 4(2553)-TcR transgenic mice develop SAT early in their 
life when they are raised on normal diet, then this result will support the view 
that generation of T4(2553) peptide following Tg processing in vivo is sufficient 
to activate the transgenic T -cells. 
Experiment design 2: To examine whether iodine plays a role in the development 
of SAT in the TcR-transgenic mice, mice will be divided into 3 groups as follows: 
Mice in Group 1 will be fed with drinking water containing TPO inhibitor 3-
amino-1,2A-triazole (ATA), which blocks iodination of Tg and hormonogenesis 
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in thyroid glands; Mice in group 2 will be treated with normal diet and water; 
Mice in Group 3 will be treated with iodine-enriched diet by adding 0.05% iodide 
in the drinking water. Development of SAT will be assessed by the serum Tg-
specific IgG level and thyroid lymphocyte infiltration. Initiation of treatment and 
examination of SAT may differ depending on the age and severity of SAT in mice 
raised on normal diet. 
Interpretation of results: Mice treated with ATA cannot synthesize T4 at position 
2553. Therefore, decreased iodine uptake will prevent the development of SAT in 
the TcR-transgenic mice. If excess iodine intake exacerbates the development of 
SAT in the TcR-transgenic mice, then this result will support the concept that 
increased iodination of Tg can facilitate the generation of T4(2553) either by 
enhanced presentation of the peptide during Tg processing or by generation of 
more T4(2553)-containing Tg during hormonogenesis in thyrocytes. 
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